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Abstract 
The work in this thesis considers the development and optimisation of methods with regards to 
the synthesis and formation of polymeric nanomaterials. A particular focus is placed on 
synthesising polymers based on N-2-hydroxypropyl methacrylamide (HPMA) and ε-
caprolactone (PCL) with regards to drug delivery applications. Polyethylene glycol (PEG) and 
PEG-based materials were intentionally avoided due to the growing body of research 
surrounding the accelerated blood clearance phenomenon. 
 
Reversible addition-fragmentation chain transfer (RAFT) polymerisation was employed in the 
synthesis of linear, block and branched forms of poly(N-(2-hydroxypropyl)methacrylamide) 
(PHPMA). Linear PHPMA was synthesised according to established synthetic methods and 
found to yield well defined materials (12 – 17 kg mol-1; Ð 1.02 – 1.08). Homotelechelic PCL 
with terminal RAFT functionalities was employed as a macro-CTA in the synthesis of 
PHPMA-b-PCL-b-PHPMA triblock copolymers. After optimisation of the reaction conditions 
a reasonably well-defined amphiphilic polymer was obtained (Mn 29 kg mol-1; Ð 1.41) which 
was observed to undergo spontaneous self-assembly in water (average particle diameter 44 
nm). Alternative synthetic routes utilising click methodologies (thiol-ene, hetero-Diels-Alder 
and copper azide-alkyne cycloaddition) were investigated but ultimately did not yield any 
improvements when compared to the macro-CTA grafting-from approach. Hyperbranched 
PHPMA was synthesised by a free-radical crosslinking copolymerisation method which 
utilised ethylene glycol dimethacrylate (EGDMA) as a divinyl crosslinking agent. Extensive 
characterisation of branching parameters was performed using a combination of triple detection 
size-exclusion chromatography (SEC) and 1H NMR. After optimising the reaction conditions, 
three hyperbranched copolymers of HPMA and acetylated-HPMA (APMA) were synthesised; 
surface RAFT moieties underwent additional polymerisation with HPMA to ultimately yield 
novel PHPMA-star-(hb-PHPMA-co-PAPMA) core-crosslinked amphiphilic star copolymers 
(Mn 139 – 243 kg mol-1, Ð 1.07 – 1.27). 
 
Additionally, charge controlled nanoprecipitation of homotelechelic carboxyl terminated PCLs 
in a range of alkaline pH buffered solutions was performed according to a literature procedure. 
The lowest diameter particles were observed to form when precipitation was performed in a 
pH 9 aqueous phase (14 ± 1 nm), as determined by dynamic light scattering (DLS).  
iii 
 
Overall, synthesis of PHPMA-b-PCL-b-PHPMA block copolymer at higher molecular weight 
and lower dispersity than previously reported materials from a homotelechelic dithiobenzoate 
macro-CTA was achieved. Furthermore, three novel PHPMA-star-(hb-(PHPMA-co-
PAPMA)) copolymers were synthesised and the branching parameters of the hydrophobic core 
characterised by 1H NMR spectroscopy. Preliminary work into developing a scalable synthetic 
procedure for producing PCL nanoparticles was undertaken. Under optimal conditions PCL-
oTHPA nanoparticles were produced with a number-average particle diameter of 14 ± 1 nm 
(error is ± 1 S.D.).  
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1 Introduction 
The aim of the research described herein was to develop facile methodologies for synthesising 
amphiphilic block copolymers capable of delivering therapeutic agents. Amphiphilic block 
copolymers are any polymers which exhibit amphiphilic properties due to the combination of 
hydrophobic and hydrophilic monomers. Arrangement of the monomers is in blocks (i.e. 
AAAAA-BBBBB or (A)x-(B)y) however the arrangement and number of the blocks may vary 
(though typically A-B; A-B-A; B-A-B etc.). In this context, a therapeutic agent is any 
molecular entity that has a mostly beneficial effect on a given disease state. Such a broad 
definition necessarily encompasses traditional pharmaceuticals (typically hydrophobic 
molecules of < 1,000 g mol-1) but also includes polypeptides, proteins, polynucleotides, metals 
and metal-complexes. Polymeric carriers are an important and growing class of therapeutic 
materials, the context for which is outlined in greater detail below and are typically synthesised 
via reversible-deactivation radical polymerisation (RDRP) techniques. The major RDRP 
techniques have been discussed in the context of their application to modern polymer synthesis. 
 
While many amphiphilic block copolymers are based on polyethylene glycol (PEG) the status 
of PEG as the “gold standard” for non-immunogenic materials has been called into question. 
The identification of an enhanced bio-clearance effect upon subsequent injection of PEGbased 
therapeutics[1] has drawn attention to the issue up to the time of writing.[2,3] As a result there 
has been a growing desire to find alternatives to PEG as it has commonly been employed as 
both the hydrophilic and hydrophobic block in many amphiphilic copolymers and to impart 
“stealth” properties on a range of biologically active materials. A number of alternatives have 
been identified, in particular poly(N-(2-hydroxypropyl) methacrylamide) (PHPMA)[4] and 
poly(ε-caprolactone) (PCL)[5] which are hydrophilic and hydrophobic polymers respectively. 
A discussion of their individual properties can be found below but broadly they are non-toxic, 
non-immunogenic FDA approved polymers with a history of use in polymeric carriers. A 
discussion of the methodologies to generate novel biocompatible polymeric carrier systems has 
been undertaken, with particular emphasis on these materials. 
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1.1 Drug Discovery in the 21st Century 
 
The discovery and approval of effective therapeutic agents is difficult and expensive. It is 
estimated that it takes around 8-12 years and $1.6 - $4 billion to go from drug concept to market 
and many of these molecules fail during the final hurdle of clinical trials.[6] Rising R&D costs, 
exhausting more easily-drugged targets, restricted healthcare spending, the rise in antibiotic 
resistance and the growing desire to treat both rare (≤5 cases per 10,000 people) and complex 
diseases, e.g., Alzheimer's disease and cancer, all combine to compound the issue.[7,8] A key 
measure of drug development is the number of new molecular entities (NMEs) approved each 
year. Despite significant improvements in knowledge, technology and funding, the number of 
NMEs which have achieved approval over the past 35 years has remained relatively stable with 
occasional deviation from the norm (Figure 1.1). The recent 2012 and 2014 uptick in NMEs 
has been attributed to a shift in focus towards diseases with a strong genetic signature.[9]  
 
 
Figure 1.1 – Graph showing the number of globally approved therapeutic agents between 1981 – 2014 
(reproduced from ref [10]). Data for 2015 – 2016 is number of NMEs approved by the U.S. FDA [11] 
 
The development of new drugs with a significant increase in therapeutic effect, compared to 
current treatments, is becoming increasingly difficult. As a result, there has been a growing 
interest in systems capable of masking the undesirable traits of a drug while simultaneously 
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improving efficacy by targeting them to the specific diseased tissue which will be discussed 
further below.  
 
1.2 Polymer Nanotherapeutics and Improving Drug Delivery 
 
The majority of new drugs are small molecules (typically <500 g mol-1) with a short biological 
half-life, often low solubility, low oral bioavailability and poor targeting in vivo.[12] These 
factors mean only a small amount of the drug actually reaches the desired target. The rest may 
become evenly distributed, binding to other biomacromolecules and causing side effects, or 
quickly eliminated. In 1975, Helmut Ringsdorf developed a model for the design of polymer-
drug conjugates (Figure 1.2) which would be able to mitigate many of these problems.[13] 
 
 
 
Figure 1.2 – Ringsdorf’s model for the design of therapeutically active polymers reproduced from R. 
Haag and F. Kratz [14] 
 
His model contained four major components: 
1. A polymer backbone that would ideally be water-soluble, non-toxic and able to be 
eliminated from the body (often by degradation). In order to avoid rapid clearance by 
the body, the final macromolecule should be above the renal clearance threshold 
(typically >30-40 kg mol-1).[15] By satisfying this parameter the polymer can achieve 
extended circulation time thereby promoting its therapeutic effect. 
 
2. The conjugate should contain cleavable spacers which attach the therapeutic agent and 
permit later release. For example, Etrych et al. showed the use of a pH sensitive 
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hydrazone spacer (Figure 1.3) that released doxorubicin under site-specific conditions 
such as low pH in tumour cells.[16] At pH 7.4 they found minimal doxorubicin release 
(< 10%) but up to 80% release at pH 5. Their work highlights the strength of pH 
sensitive linkers in controlling selective release of a drug at the target site. 
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Figure 1.3 – Poly(N-2-(hydroxypropyl)methacrylamide) (PHPMA) copolymer synthesised by Etrych 
et al. showing pirarubicin bound by the pH sensitive hydrazone moiety [17] 
 
3. Solubilising groups to improve dissolution of the polymer-drug conjugate within the 
body. Such groups can be particularly important when attaching hydrophobic drugs that 
may significantly reduce the solubility of the conjugate. 
 
4. A targeting moiety (antibodies, peptides and sugars have all been used previously[18–
20]) to promote binding of the polymer-drug conjugate to the cells of interest. For 
example, the Ghandehari group has shown that the cyclic Arg-Gly-Asp (RGD) peptide 
can be used for active targeting of the αvβ3 receptor in order to deliver the anti-cancer 
drug glendanamycin.[21] Interestingly, they note that the RGD sequence may have some 
cytotoxic effect as polymer conjugates bearing no glendanamycin reduced cell viability 
by 40-50% at high concentrations (1.2 mg mL-1). This highlights an important point 
that as various groups are added for enhancement of a therapeutic effect (e.g. targeting), 
there is the potential for beneficial and/or negative secondary effects. 
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1.2.1 Enhanced Permeability and Retention Effect 
 
While active targeting of polymer therapeutics has clear benefits, it is not always possible to 
utilise specific binding sites or incorporate targeting moieties in the polymer backbone. 
Additionally, these moieties add to the complexity of the synthesis and the number of 
interactions within the host. However, even in the absence of a targeting group, polymer-drug 
conjugates can localise to target sites by virtue of their size. In 1986, Matsumura and Maeda 
were the first to report the enhanced permeability and retention effect (EPR effect).[22] They 
noted the retention of macromolecules within tumour tissues and related this to the enhanced 
permeability of the vascular structure and poor lymphatic drainage (Figure 1.4). 
 
 
 
Figure 1.4 – Schematic drawing highlighting the salient features of the EPR effect (reproduced from 
R. Haag and F. Kratz [14]) 
 
In general, small molecules are evenly distributed between normal and tumour tissues while 
macromolecules are unable to penetrate the endothelial layer of normal tissue. Tumour tissues, 
however, exhibit a fenestrated endothelial layer which allows uptake of macromolecules. They 
are then retained as a result of poor drainage by an underdeveloped lymphatic system. By 
looking at the effects of permeability enhancers (such as nitric oxide) on macromolecular 
uptake, Maeda et al. verified the link between the permeability of the vascular structure and 
the uptake and retention of macromolecules.[23,24] Identification of the EPR effect was an 
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important milestone in the development of polymer therapeutics, particularly in the field of 
cancer research, as it showed that all macromolecules are capable of passive targeting of solid 
tumours.  
 
Since the Ringsdorf model, many other forms of polymer nanotherapeutics have come to light. 
The term “polymer nanotherapeutics” is a catch-all term to describe any polymer system that 
is or can be used to increase the efficacy of a therapeutic agent. The Ringsdorf model relates 
specifically to polymer-drug conjugates, though other types of polymer nanotherapeutics exist 
such as polymer-protein conjugates, polymer-nucleotide conjugates (polyplexes) and bioactive 
polymers. Before discussing the current state of polymer therapeutics it is first useful to 
consider the methods by which these materials are synthesised. 
 
1.3 Synthesis of Polymers for use in Therapeutics 
 
Free radical polymerisation is the method of choice for synthesising polymers from vinyl 
containing monomers. Tolerance of functional groups and the availability of a diverse range of 
monomers enables the synthesis of polymers with structural and functional group variety. 
However, there are limitations over the control of the macromolecular structure, particularly 
with regards to molar mass distribution and chain architecture. The development of reversible- 
deactivation radical polymerisation (RDRP) techniques has provided a set of new tools for 
regulating these parameters. The preferred IUPAC terminology is RDRP, though many 
publications still used the abbreviated term “controlled radical polymerisation” (CRP). RDRP 
is defined as “chain polymerisation, propagated by radicals that are deactivated reversibly, 
bringing them into active-dormant equilibria of which there might be more than one”.[25] These 
techniques are of particular importance in a biomedical context as reproducibility and narrowly 
defined parameters make structure-function relationships easier to identify. Additionally, the 
incorporation of ‘click’ chemistries (reactions which are synthetically simple, high-yielding 
and purifiable without chromatography) has provided access to more complex and 
multifunctional materials.  These will be discussed in greater detail in the sections that follow. 
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1.3.1 Reversible-Deactivation  Radical Polymerisation 
 
The foundations for “living” polymerisation techniques were originally set by Szwarc[26,27] in 
his study of the anionic polymerisation of styrene initiated by sodium naphthalene. The group 
reported styrene chains continued to grow, as measured by an increase in solution viscosity, 
upon addition of further monomer after the initial monomer had been completely consumed. 
These results were rationalised by the absence of any termination reactions meaning chains 
could potentially remain active indefinitely. The application of this principle to free radical 
polymerisation (FRP) lead to the development of RDRP. While termination reactions are not 
absent in RDRP, their occurrence is significantly suppressed thereby preserving end-
functionalities for future activation. A general scheme for RDRP processes is outlined in 
Scheme 1.1, below.  
 
(Pn
Monomer
X)
ka
kda
Pn + X
dormant
active
kp
 
 
Scheme 1.1 – General principle for controlled radical polymerisation (adapted from [28]) 
 
The basic principle is that the active growing species (Pn·) is in equilibrium with the dormant 
species (Pn-X) and this equilibrium favours formation of the dormant species i.e. kda >> ka. As 
a result the number of active species is kept low, which reduces the probability of interaction 
between active chains thereby suppressing termination events. If the rate of propagation is 
sufficiently slower than the rate of formation of active species then approximately all chains 
can be initiated at the same time, before propagation begins. This allows the growing species 
to add monomer at similar rates thus chains have an equal chance to grow. Consequently, if 
termination is suppressed and all chains grow at a similar rate then dispersity is kept low (<1.5), 
giving rise to the controlled nature of RDRP. The degree of polymerisation (Xn) can be 
predetermined by the initial concentration of monomer ([M]0) and initiator ([I]0) according to 
equation (1.1) below:  
 Xn = [M]o[I]o  × conversion (1.1) 
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As such, the degree of polymerisation, thus also molecular weight, would be expected to 
increase linearly with conversion. This is in contrast to FRP where high molecular weight 
material is formed quickly at the start of the reaction but molecular weight does not increase 
significantly as a function of monomer conversion.  
 
 The three major branches of RDRP are atom-transfer radical polymerisation (ATRP), 
nitroxide-mediated radical polymerisation (NMRP) and reversible addition-fragmentation 
chain transfer polymerisation (RAFT).While these processes  are based on the general scheme 
outlined above (Scheme 1.1) they differ in how equilibrium control is achieved, end-group 
functionality, tolerance of monomer functionality, and the reaction environment. 
 
ATRP[29] is a highly versatile technique with excellent functional group tolerance however it 
utilises transition metals, typically copper, in order to achieve equilibrium control. The general 
scheme is outlined in Scheme 1.2. 
 
Pn
Monomer
X
ka
kda
Pn + X-Mtm+1/L
kp
Mtm/L+
kt
Pn Pn  
 
Scheme 1.2 – Propagation equilibrium in ATRP (adapted from [29]) 
Dynamic equilibrium is achieved by halide abstraction from the dormant alkyl halide (Pn – X)  
by the transition metal catalyst (Mtm/L) to form the active radical (Pn·). This species can 
subsequently react with the oxidised catalyst (X-Mtm+1/L), thereby reforming the dormant alkyl 
halide, undergo propagation with monomer to grow the polymer chain or terminate. Methods 
for removing and reducing the amount of potentially toxic transition metals have been 
developed.[30,31] Over the past two decades the number of ATRP citations have been 
consistently higher than citations for both RAFT and NMP (Figure 1.5). 
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Figure 1.5 – Published items per year for search terms “atom transfer radical polymerization”, 
“nitroxide mediated radical polymerization” and “reversible addition fragmentation chain transfer 
polymerization” (Web of Science, May 2019) 
NMP[32] is the simplest of the three techniques, requiring only an initiator, monomer and a 
source of nitroxide radicals to mediate the propagating species. The reagents have been 
simplified further by combining the initiator and nitroxide species into a single "universal 
initiator" first described by Hawker.[33] However, the high temperatures required for forming 
the initiating radicals constrain the functional groups that can be tolerated. Additionally, the 
difficulty of converting alkoxyamine end groups into more useful functionalities limit the 
application of NMRP. A general scheme for NMRP has been shown in Scheme 1.3 below.  
 
Pn
   +   X
Pn
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X
ka
kda
kp
 
 
Scheme 1.3 – Propagation equilibrium in NMRP (adapted from [32]) 
 
RAFT[34] polymerisation avoids two of the major problems with NMRP and ATRP techniques, 
having excellent functional group tolerance and not requiring the use of potentially toxic 
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transition metals. Controlled polymerisation is achieved through the use of a chain transfer 
agent (CTA) referred to as the 'RAFT agent'. The major types of RAFT agent structures are 
shown in Figure 1.6 and consist of a thiocarbonyl moiety flanked by the 'R' and 'Z' groups. 
 
Z
S
S
R
Dithiocarbamate TrithiocarbonateXanthate
Z =
XO N
X'
X
XS
Dithiobenzoate  
Figure 1.6 – Major classes of RAFT agents 
 
By convention, the R group is the polymer’s α-terminus while the Z group is the ω-terminus. 
Unlike ATRP, the adaptive nature of the R and Z groups allows for functionalisation of both 
the polymer ends through selection of the RAFT agent. By selecting a Z group that activates 
the thiocarbonyl bond to radical addition and an R group that is both a good homolytic leaving 
group and efficient radical reinitiator the reactivity of the RAFT agent can be tailored to the 
reactivity of the monomer. A good homolytic leaving group can be defined in terms of a 
partition coefficient (ϕ)  (Equation (1.2)), which relates the rates of radical addition to the 
RAFT agent during pre-equilibrium (Scheme 1.4), where ϕ ≥ 0.5.[35] 
 
 
∅ = 
kβ
k-add+ kβ
 
(1.2) 
 
With these criteria met, molecular weight ideally increases linearly with monomer conversion. 
These characteristics allow for the synthesis of a wide range of well-defined polymeric 
materials; these are discussed further throughout sections 1.5 – 1.9 of this review. It is for these 
reasons that RAFT was selected as the RDRP technique for the work in this thesis. 
 
There is still some debate over the exact mechanism of RAFT polymerisation, in particular 
with regards to dithiobenzoate RAFT agents[36–38], however there is a generally accepted 
scheme which is able to rationalise the vast majority of experimental data. 
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Scheme 1.4 – Mechanism of RAFT polymerisation (adapted from [34]) 
 
As with all radical polymerisation methods, the first step is initiation. Typically thermal 
initiators such as 2,2'-azobis(2-methylpropionitrile) (AIBN) provide the initial radical species 
(I·), however novel initiator methods have recently been the subject of review.[39] The 
concentration of these initiating species is typically kept low, such that the majority of chains 
are terminated by the RAFT end groups however there are always a small number of initiator-
terminated chains present. Similar to FRP the rate of initiation for RAFT polymerisation can 
be given by the equation: 
 
 𝑅𝑅𝑖𝑖 = 2𝑘𝑘𝑑𝑑𝑓𝑓[𝐼𝐼] (1.3) 
 
 
where Ri is the rate of initiation, kd is the initiator decomposition rate coefficient, f is the 
initiator efficiency and [I] is the concentration of initiator. Formation of I· leads to production 
of the propagating species (Pn·).  
 
During pre-equilibrium, Pn· combines with the RAFT agent to form the intermediate radical 2. 
Decomposition of 2 via kβ generates the R· radical and the dormant polymeric thiocarbonyl 
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compound 3. Reaction of R· with monomer forms a new propagating radical (Pm·) in the 
reinitiation step. 
 
The newly formed Pm· is then available to react with 3 and in doing so enters into the main 
equilibrium stage. Here, rapid equilibrium between Pn· and Pm· provides equal opportunity for 
reaction with monomer and leads to near-equal growth of all propagating chains. It should be 
noted that the growing chains spend most of their time in the dormant form of intermediates 3 
and 5 and as such, this is the main form during the reaction. The rate of RAFT polymerisation 
follows that of a conventional FRP and as such equation (1.4) can be used to determine the 
polymerisation rate. 
 
𝑅𝑅𝑝𝑝 = 𝑘𝑘𝑝𝑝[𝑀𝑀]�𝑓𝑓𝑘𝑘𝑑𝑑[𝐼𝐼]0𝑒𝑒−𝑘𝑘𝑑𝑑𝑡𝑡𝑘𝑘𝑡𝑡  (1.4)  
 
Here, Rp is the polymerisation rate, kp is the propagation rate constant, [M] is the monomer 
concentration and kt is the termination rate coefficient. 
 
Unlike the previously discussed RDRP techniques, RAFT does not directly suppress the rate 
of chain termination reactions. As the propagating species spend the majority of time in the 
form of 3/5, the concentration of Pm· and Pn· is low. This reduces the probability of combination 
and disproportionation reactions occurring and so RAFT is often described as a pseudo-living 
technique. 
 
Critical to synthesising low dispersity materials via RAFT is selecting the correct RAFT agent 
for the monomer of interest. Broadly, monomers can be classified as "more-activated" 
(MAMs), where the vinyl group is conjugated to another vinyl, aromatic or carbonyl group, or 
as "less-activated" (LAMs), where the vinyl group is adjacent to an oxygen or nitrogen atom.[34] 
The Z-group of the RAFT agent modifies the rate of addition and fragmentation and if not 
properly controlled can lead to poor homolytic fission of RAFT end group 3 and low reactivity 
of propagating radicals. This can retard polymerisation and inhibit the formation of controlled 
materials. General guidelines for matching RAFT Z-groups to various monomers has been 
outlined in Figure 1.7. 
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Figure 1.7 – Guidelines for matching RAFT Z-groups to various monomers (adapted from [34,35]) 
 
Recent developments have allowed for the control of both MAM and LAM type monomers 
with a single, "switchable" RAFT agent (Scheme 1.5) controllable by pH.[40] 
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Scheme 1.5 – Mechanism for controlling the "switchable" RAFT agent, reproduced from [40] 
 
Dithiocarbamates have a reduced double bond character in the thiocarbonyl moiety due to the 
zwitterionic resonance form. Protonation of the pyridine ring disfavours the zwitterionic form 
and promotes controlled polymerisation of MAMs by lowering the energy of the RAFT agent’s 
lowest-unoccupied molecular orbital (LUMO) to more closely match the singularly-occupied 
molecular orbital (SOMO) of the propagating species.  
 
As alluded to at the start of section 1.3.1, for RAFT polymerisation the theoretical number 
average molecular weight (Mn,theo) can be calculated from the initial monomer concentration 
according to (1.5).[34] 
 
Mn, theo= 
[M]0𝑝𝑝Mm
[RAFT]0
 + MCTA (1.5) 
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Where [M]0 is the initial monomer concentration, [RAFT]0 is the initial RAFT agent 
concentration, p is the monomer conversion, and Mm and MCTA are the molecular weight of the 
monomer and CTA respectively. By varying the initial monomer-RAFT agent ratio polymers 
can be synthesised across a range of molecular weights. 
 
1.3.2 Click Chemistry 
 
The concept of “click” chemistry was first proposed in 2001 by Sharpless[41] as highly efficient 
reactions for the rapid synthesis of compounds. To be classed as a click reaction the method 
should be (i) high yielding, (ii) wide in scope, (iii) produce inoffensive by-products that can be 
removed non-chromatographic methods, (iv) stereospecific (but not necessarily 
enantioselective), (v) simple to perform and (vi) in benign or easily removed solvents. Barner-
Kowollik et al. proposed additional criteria before reactions could be considered “click” in a 
polymer chemistry context.[42] In addition to the definition provided by Sharpless and co-
workers, polymeric click reactions should be equimolar, though exception could be made in 
situations where simple large-scale purification is feasible. Efficient click reactions have been 
postulated to facilitate easier synthesis of macromolecules while providing access to ever more 
complex materials and architectures. The combination of click methodologies and controlled 
polymerisation techniques has been shown to create well defined materials with novel 
functionalities. Key areas in the study of polymeric click reactions are cycloaddition reactions 
(such as the Huisgen 1,3-dipolar and Diels-Alder cycloadditions) and addition to carbon-
carbon double or triple bonds. 
 
1.3.2.1 Application of Cycloadditions in Polymer Chemistry 
 
Cycloadditions can be broadly summarised as the combination of two or more π-systems to 
form a stable cyclic molecule with newly conceived covalent sigma bonds. This definition can 
be exemplified through the Huisgen 1,3-cycloaddition[43,44] (Scheme 1.6) and is typified by the 
reaction of an azide and alkyne to form a 1,2,3-triazole.[45,46] 
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Scheme 1.6 – Comparison of (a) Huisgen 1,3-dipolar and (b) copper catalysed azide-alkyne 
cycloadditions (adapted from [47]) 
 
Azide-alkyne cycloadditions of this type typically require elevated temperatures to be 
successful. Addition of a CuI catalyst enables the reaction to be performed over broad 
temperature ranges, provides a marked increase in rate and exclusively yields the 1,4-
disubstituted product.[45,46,48] The combination of these effects allows the reaction to be 
considered a true click reaction. Copper-catalysed azide-alkyne cycloadditions (CuAAC) are 
by far the most common type of azide-alkyne cycloadditions, however the use of other catalysts 
such as Ru has also been explored.[49] Introduction of the CuI catalyst is typically achieved by 
direct addition of a CuI salt (e.g. CuBr[50]) or formation in situ by reduction of a CuII salt with 
a suitable agent. The Kopeček group utilised CuSO4 and sodium ascorbate to generate CuI ions 
in an aqueous environment in their synthesis of biodegradable multiblock PHPMA.[51] 
Nitrogenous chelating ligands are also employed to maintain the concentration of catalytically 
active species by preventing oxidation of CuI as well as acting as accelerating ligands.[52] 
Significant increases in rate have been observed when aliphatic tridentate amine ligands are 
employed compared to aliphatic tetradentate ligands or tri/tetra-dentate pyridine based 
ligands.[53] 
 
Post-polymerisation introduction of terminal azide and alkyne functionalities has been 
regularly employed in the synthesis of block copolymers. While the methods discussed below 
are by no means an exhaustive list for the introduction of azide/alkyne functionality, it does 
reflect some of the most common strategies employed to date.  
 
Tosylation of hydroxyl functionalities and subsequent nucleophilic substitution with NaN3 has 
been shown to impart azide functionality and this has been used for the attachment of PEG 
blocks.[53–55] Alkyne functionality has been introduced by Steglich esterification of hydroxyl 
moieties with pentyonic acid[56] while carboxyl moieties have been modified via reaction with 
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propargyl amine.[57] Similar methods have been employed in the synthesis of azide/alkyne 
terminated RAFT agents.[58] Mužíková et al. utilised a combination of these strategies for the 
synthesis of a novel, high molecular weight PHPMA capable of thermal degradation at 37 °C 
(Scheme 1.7).[59] 
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Scheme 1.7 – Synthesis of thermally degradable multiblock PHPMA[59] 
 
The modified RAFT agent 7 was used in the polymerisation of HPMA to yield the azide 
terminated polymer 8. Post polymerisation modification of the thiocarbonyl moiety was 
achieved by heating in the presence of a large excess of the alkyne terminated azo compound 
9. The resulting α-azido-ω-alkyne heterotelechelic PHPMA underwent CuAAC coupling to 
yield multiblock PHPMA 12. GPC was used to show degradation of the multiblock polymer 
after incubation in phosphate buffer at pH 5 or in the presence of the lysosomal enzyme 
cathepsin B. 
 
Alternative architectures to multiblock and block copolymers can also be readily achieved 
through CuAAC mediated polymer-polymer coupling. Acik and co-workers introduced 
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backbone azide functionality to polypropylene chloride by post polymerisation nucleophilic 
substitution with NaN3.[60] Subsequent CuAAC conjugation with alkyne terminated PCL or 
PEG yielded a series of PP-g-(PCL/PEG) copolymers in a “grafting to” strategy. Their work 
exemplified the easy way by which graft copolymers can be synthesised, however the method 
required multiple preparative and purification steps. Gungor and Kiskan developed a novel 
one-pot strategy for the synthesis of graft copolymers (Scheme 1.8).[61] Epoxide opening of 12 
yielded the inimer (initiator-monomer) 13, capable of initiating ROP of ε-caprolactone while 
simultaneously acting as a monomer in a CuAAC mediated polymerisation which yielded the 
final poly(triazole-g-caprolactone) polymer 14. While novel, application of this strategy is 
limited to systems where a central polytriazole backbone is acceptable.  
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Scheme 1.8 – Method for synthesising poly(triazole-g-caprolactone) via a combined one-pot ROP of 
ε-caprolactone and CuAAC coupling 
 
Introduction of alkyne functionalities to monomers pre-polymerisation was recently 
highlighted by Darcos et al. by deprotonation of ε-caprolactone with LDA and quenching of 
the ionic intermediate with propargyl bromide (Scheme 1.9).[62] Polymerisation of the modified 
monomer with ε-caprolactone yielded a statistical copolymer with pendent alkyne 
functionality. Further modification of these materials via CuAAC coupling with diazido 
functionalized diethylenetriaminepentaacetic acid and complexation of gadolinium (III) ions 
provided a series of MRI-active nanoparticles.[63,64] 
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Scheme 1.9 – Synthesis of MRI-active PCL nanoparticles via CuAAC coupling with azido 
functionalised Gd3+ complexing ligand 
 
While CuAAC reactions have had an important role in shaping polymer synthesis it is not 
without problems. Chief among them is the lingering presence of residual copper ions. Efforts 
have been made to minimise the concentration of copper ions required for successful 
coupling.[65] Other groups have attempted to remove the copper catalyst altogether by 
developing alternative coupling pathways. Agard et al. utilised fluorescent labelled 
cycloalkynes for the detection of azide modified glycoproteins without apparent physiological 
harm.[66] The authors attribute the driving force for the reaction to the release of ring-strain, 
allowing the reaction to proceed in the absence of a copper catalyst. While the strain promoted 
azide-alkyne cycloaddition (SPAAC) eliminated the requirement for toxic copper catalysts it 
suffered from slow reaction kinetics and required an excess of reagents. Development of the 
next generation of SPAAC cycloalkynes was undertaken by several groups and brought about 
cyclooctyne derivatives with superior rate constants, such as DBCO (Figure 1.8).[67] 
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Figure 1.8 – (a) Structure of cycloalkyne originally reported by Agard et al. and (b) the commercially 
available DBCO 
 
The improved rate constants of newer cycloalkyne reagents makes SPAAC an attractive 
alternative to traditional CuAAC chemistries. Beck et al. recently formed a DNA polyplex and 
promoted targeting by utilising SPAAC coupling to attach DEC205 targeting antibodies.[68] 
While the authors report successful coupling between DBCO modified antibodies and pendent 
azide moieties, coupling to polymers with only terminal azide functionality was unsuccessful. 
This was attributed to the low effective concentration of the terminal azides and limited 
accessibility. Reduced efficiency in sterically demanding environments has also been reported 
independently elsewhere in the literature.[69] Despite its advantages, SPAAC receives 
significantly less attention than CuAAC coupling, though it is understandable why. As of 
writing, commercial DBCO remains an expensive reagent in part due to the 6 – 9 step syntheses 
involved.[70,71] The high associated costs, hydrophobicity of reagents and previously discussed 
steric issues prevent SPAAC from being a complete replacement for CuAAC chemistries. The 
desire for efficient, metal-free cycloadditions has bought the Diels-Alder (DA) reaction to the 
forefront of many synthetic strategies. 
 
DA reactions share desirable characteristics with SPAAC, notably 100% atom efficiency and 
lack of toxic metal catalysts. Unlike SPAAC, DA reactions utilise inexpensive and readily 
available dienes and dienophiles. Anthracene-maleimide DA reactions have found utility in the 
synthesis of block copolymers.[72–74] However, the high temperatures (> 100 °C) and long 
reaction times (typically > 24 h) are undesirable and limit the application of these methods to 
thermally stable materials. Furan-maleimide DA coupling are more common and have been 
utilised in direct polymer-polymer conjugation, for example in the synthesis of AB-type block 
dendrimers[75] and PCL-(poly-L-lactide) conetworks.[76] In addition, the furan-maleimide 
adducts have been used to introduce terminal[77] and backbone maleimide[78] functionality to 
polymers. However, the major interest in furan-maleimide click reactions stems from the 
relatively low temperatures (ca. 100 °C) required to induce the retro-Diels-Alder (rDA) 
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reaction of the resulting adduct.[79] The utility of this functionality has been reviewed with 
regards to self-healing polymers[80] however it also has applications in biomedicine. Ninh and 
Bettinger synthesised shape-memory elastomers by furan-maleimide coupling of 
poly(glycerol-co-sebacate) with bifunctional maleimide cross-linking agents.[81] The material 
could be manipulated into a temporary planar shape which reverted to the pre-programmed 
helix shape when heated above the material’s Tg. These materials have potential applications 
in biomedicine however the rDA processing temperature is significantly higher than 
physiological temperatures, limiting in vivo shape re-configuration. 
 
Increasing interest in RAFT polymerisation has resulted in an abundance of thiocarbonyl 
terminated materials. Electron deficient dithioesters have been shown to be excellent 
dienophiles for hetero-Diels-Alder (HDA) reactions,[82,83] however the Barner-Kowollik group 
were the first to utilise these moieties for controlled polymerisation of polystyrene (PS) and 
subsequent HDA conjugation to trans,trans-2,4-hexadiene terminated PCL to yield PS-PCL 
block copolymers (Scheme 1.10).[84] 
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Scheme 1.10 – Synthesis of PS-b-PCL copolymer via HDA coupling of pre-formed macromolecules 
 
Complete coupling of PS 15a to PCL 16 was achieved by reaction for 24 h at 50 °C in the 
presence of a ZnCl2 catalyst. The reaction time was improved by using PS 15b which achieved 
complete coupling in 2 h at 50 °C with TFA as a catalyst, suggesting the pyridinyl dithioester 
is a more efficient heterodienophile. Comparable results are seen when the authors synthesised 
a series of star multi-arm polymers by a similar method.[56,85] Further increases to the reaction 
rate were achieved when the rotationally restricted diene, cyclopentadiene replaced trans,trans-
2,4-hexadiene as the terminal functionality. Coupling low molecular weight (5 – 30 kg mol-1) 
polymers was achieved in 10 min by shaking at ambient temperature, still with TFA as a 
40 
 
catalyst.[86] Ultra-fast HDA reactions present a significant improvement in Diels-Alder 
conjugation methods particularly in comparison to previously discussed anthracene-maleimide 
and furan-maleimide strategies. However, this method relies upon electron-poor dienophiles 
which have been shown to afford poorer control in the RAFT-mediated polymerisation of 
styrene.[87,88] 
 
1.3.2.2 Application of Thiol-Ene reactions in Polymer Chemistry 
 
RAFT end groups are easily cleaved to yield thiol-terminated polymers, typically by adding an 
excess of a suitable nitrogenous base[89,90] however reductive cleavage has also been 
explored.[91] Reducing agents (e.g. TCEP,[92] DMPP[93] or acetic acid and zinc[94]) are typically 
added to prevent disulphide coupling of newly generated thiols. Additional consideration 
should be given when generating thiols in polymethacrylates due to potential intramolecular 
thiolactone formation from “backbiting” reactions.[95] If the concentration of thiols are ‘dilute’ 
relative to the macromolecule concentration or a suitably fast thiol-ene mechanism is available, 
disulphide coupling in the absence of a reducing agent may not be observed.[96] While 
disulphide coupling of RAFT generated thiols is generally considered undesirable, their 
formation has been successfully applied to the synthesis of core-crosslinked[97], monocyclic[98] 
and multiblock[99] polymers. 
 
Any reaction of suitable thiol containing and vinylic compounds could be classified as a ‘thiol-
ene’ reaction however this broad definition omits clear mechanistic differences in many 
reactions (Scheme 1.11). Thiols can be deprotonated by weak bases, either directly added 
(Scheme 1.11 (a)) or formed in situ by an added nucleophile adding to the Michael acceptor to 
give an enolate (Scheme 1.11 (b)), and the resulting thiolate anion reacts via a nucleophilic 
Michael-type addition (herein referred to as ‘thiol-Michael’ addition). Whereas hydrogen 
abstraction by a suitable radical initiator or intermediate alkyl radical generates thiyl radicals 
which subsequently add to the alkene (herein referred to as ‘thiol-ene’ addition, Scheme 1.11 
(c)). 
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Scheme 1.11 – General mechanisms for (a + b) thiol-Michael and (c) thiol-ene addition reactions 
 
Thiol-Michael addition favours addition to low electron density alkenes. Maleimides have 
often been selected due to the presence of two electron withdrawing carbonyl groups and the 
release of ring strain energy upon C-S bond formation.[100] However, careful selection of 
reaction parameters should be employed to prevent unwanted side reactions in “one-pot” 
reactions.[101] Pan et al. utilised thiol-Michael coupling with maleimides to synthesise Dox 
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loaded PHPMA multiblock polymers. While an effective conjugation strategy, initial analysis 
by GPC showed the material was comprised of a series of multiblock polymers from di- to 
octa-block materials.[102] Further work showed fractionation to be suitable for isolating well 
defined multiblock polymers of a single type (Ð = ~ 1.1).[103] 
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Figure 1.9 – Acrylates used by Spruell et al.  in the post-polymerisation thiol-Michael modification of 
PMMA-b-PS copolymers [91] 
 
Acrylates were shown to be versatile reagents for introducing a range of terminal functionalities 
(Figure 1.9). Additionally, the authors extended their work to synthesise a well-defined (Ð = 
1.16) PMMA-b-PS-b-PEG triblock copolymer.[91] However, successful coupling required a 
large excess of reagents (10 eq. of acrylate terminated PEG; 50 – 100 eq. of non-polymeric 
acrylates) to achieve high percentage functionalisation (86 – 95%). Recently, Holley et al. 
introduced a terminal amine moiety via “one-pot” trithiocarbonate cleavage and subsequent 
thiol-Michael addition of N-(3-aminopropyl)methacrylamide (Scheme 1.12). The resulting 
macroinitiator ultimately yielded a series of PHPMA-b-(benzyl-L-glutamate) diblock 
copolymers.[104] 
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Scheme 1.12 – One-pot introduction of terminal amine moiety[104] 
 
Unlike most radical-mediated processes, thiol-ene reactions are generally insensitive to the 
presence of oxygen and have been applied in a range of syntheses.[105] Thermal and photo- 
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initiated generation of thiyl radicals has been explored[106,107] as well as direct irradiation in the 
absence of an initiating species.[108–110] Skinner, Whiffin and Price explored sonochemical 
initiation but did not find significant advantages, in terms of reaction efficiency or time, 
compared to more conventional thermally initiated methods.[111] However, the method was 
effective within aqueous systems in the presence of air and the authors highlight its potential 
for crosslinking in biomedical applications. 
 
Valade et al. exploited thiol-ene addition to modify poly(allyl methacrylate)-b-PHPMA 
copolymers with cysteamine hydrochloride to yield cationic block copolymers for 
complexation with siRNA.[112] The authors reported 100% addition efficiency when using 10 
eq. of cysteamine hydrochloride. Francini et al. modified PHPMA homopolymers with allyl 
isocyanate to introduce N-allyl carbamate pendent moieties (46% conversion).[113] Complete 
conversion of pendent alkenes was reported using between 2 – 10 eq. for a range of thiols. Both 
papers highlight the ease of thiol-ene modification of pendent moieties and these have been 
achieved with fewer equivalents of thiol than previously discussed thiol-Michael strategies. 
This is not to suggest thiol-ene addition is inherently superior to thiol-Michael addition. Cakir 
et al. demonstrated the utility in combining orthogonal thiol substitution mechanisms (Scheme 
1.13).[114] 
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Scheme 1.13 – Orthogonal thiol-ene / thiol-Michael addition to multiarm star PS[114] 
 
Complete modification of multiarm star PS was reported by sequential aromatic substitution 
with 1-propanethiol (10 eq., 4 h) and thiol-ene addition of N-acetyl-L-cysteine methyl ester (10 
eq., 2 h). Model reactions were undertaken and showed pentafluorophenyl moieties underwent 
no detectable thiol-ene addition with N-acetyl-L-cysteine methyl ester. Similarly, no detectable 
changes were reported for allyl ether terminated PS homopolymers undergoing addition of 1-
propanethiol, highlighting the orthogonality of the method. 
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1.4 Biocompatible Polymers 
 
For any successful application of polymers as a delivery system, the polymers should 
simultaneously increase the efficacy of the therapeutic agent while also being non-toxic, non-
immunogenic and excretable in a timely manner. Polyethylene glycol (PEG) is often 
considered the gold standard for biocompatible polymers as it was the first material to 
successfully gain U.S. FDA approval as the polymer-protein conjugate Adagen® in 1990.[115] 
 
The use of proteins, such as antibodies or enzymes, as therapeutic agents is often impeded by 
their poor stability, short shelf-lives, low bioavailability, rapid degradation by proteases and 
the possibility of immunogenic response. In the late 1960s, Professor Frank Davis began laying 
the foundations for PEG-protein conjugates, such as Adagen®, and in 1973 filed his first patent 
on the subject.[116,117] Since then PEG has been a prominent feature of the literature and its 
synthetic strategies the subject of multiple reviews.[118,119] It is so prolific that attachment of 
PEG to another material gained its own moniker: ‘PEGylation’. 
 
The beneficial features of PEGylation have been related to an increase in steric factors. This 
steric barrier is thought to reduce the capacity of opsonins to bind with the material and thus 
reduce the effectiveness of the mononuclear phagocytic system (MPS).[120] This leads to 
increased circulation times and bioavailability. PEG is particularly effective at increasing steric 
effects as it has been estimated that each repeat unit in the PEG chain coordinates three water 
molecules[121] and this dramatically increases its hydrodynamic volume in vivo. Two papers by 
Nakaoka et al. and Sherman et al. describe the difference in hydrodynamic volume observed 
when proteins and PEG chains of comparable molecular weight were analysed by GPC. Their 
data shows co-elution of PEG chains with proteins roughly one third their molecular weight 
and this discrepancy can increase to a 9-fold difference for particularly large proteins.[122,123] 
As PEG is a non-biodegradable polymer, selecting chain lengths sufficient to provide the 
desired effect but not so large as to prevent timely excretion, which could otherwise cause toxic 
bioaccumulation, is a critical parameter in designing PEGylated materials. 
 
If the beneficial effects of PEG are related to increasing steric effects then it is clear that total 
molecular weight, chain length and density of surface coverage will also be critical parameters. 
While considering the effects of these parameters, it is important to note the difficulty in 
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affecting only a single factor at a time. For example; changing molecular weight will inevitably 
affect the size of the material and altering surface density can modify the zeta-potential. Despite 
this, clear efforts have been made to minimise the effect of, or acknowledge, these difficulties 
within the literature. 
 
Increasing the molecular weight of PEG has been shown to correlate with an increase in 
circulation time in mice. Miteva et al. observed that the blood circulation half-lives of PEG 
copolymer micelles increased from 4.6 to 17.7 min as the molecular weight of PEG increased 
from 5 to 20 kg mol-1.[124] Additionally, when Dos Santos et al. tested the effect of PEG in the 
range of 350 – 750 g mol-1 on plasma clearance they observed no significant difference between 
samples.[125] Only by increasing to 2 kg mol-1 PEG were they able to significantly affect plasma 
clearance. The implication of these results is that there may be a minimum molecular weight 
of PEG required before significant changes to circulation will be observed. However, Yang et 
al. showed that grafting density also plays an important role. They report that polystyrene 
nanoparticles coated in 559 g mol-1 PEG chains exceeding surface densities of 1.2 PEG nm-2 
were able to achieve circulatory half-lives ≥ 14 h while particles with lower grafting densities 
were eliminated within 2 h.[124] This is a comparable half-life to that reported previously by 
Dos Santos et al.. The comparison of this work clearly highlights the need for assessing grafting 
density when producing novel materials through surface modification. 
 
The first generation of PEG-protein conjugates utilised single attachment of high molecular 
weight PEG or multiple attachments of low molecular weight PEG chains via conjugation of 
activated carboxylic acid moieties (e.g. succinimide esters) to the amine of lysine residues.[126] 
While various other conjugation chemistries have been explored[127] one of the most interesting 
developments is the use of the CuAAC reaction. Plaks et al. reported a method for highly site 
specific attachment of alkyne-modified PEG to azide modified proteins (Scheme 1.14).[128] 
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Scheme 1.14 – Azide modification of a protein and subsequent click reaction with an alkyne 
terminated molecule (reproduced from [128]) 
 
By inserting the 13-amino acid LAP sequence (GFEIDKVWYDLDA) into Green Fluorescent 
Protein (GFP), the group were able to use the lipoic acid ligase enzyme to incorporate 
azidodecanoic acid at the LAP site - thereby introducing an azide moiety. Lipoic acid ligase is 
utilised by some organisms for covalent attachment of free lipoic acid to enzymes at the LAP 
sequence; the modified enzymes are key cofactors in aerobic metabolism.[129] A subsequent 
click reaction, in this case an azide-alkyne cycloaddition, with an alkyne terminated PEG chain 
yielded GFP modified at only the desired site. The work presents a novel strategy for highly 
specific PEGylation that can yield homogeneous polymer-protein conjugates. However, the 
strategy’s limitation is that it requires significant pre-modification of the protein in the form of 
insertion of the LAP sequence with no detrimental effect on protein function. 
 
Although generally considered safe, recent research has called into questions the non-
immunogenic nature of PEG. Originally highlighted by Dams et al.[1], a number of papers have 
observed accelerated blood clearance (ABC) of PEGylated materials upon injections 
subsequent to the first encounter in a range of organisms including: guinea pigs, mice, rabbits, 
rats, and rhesus monkeys.[1,130–132] Ishida et al. later showed this ABC phenomenon to be 
mediated by M-isotype anti-PEG immunoglobulins (anti-PEG IgM).[133] Earlier work by Cheng 
et al. indicated these immunoglobulins recognised the oxyethylene moieties of PEG[134,135], 
however more recent work suggests the problem is more nuanced. Shiraishi et al. suggested it 
is the interface of PEG-hydrophobic conjugates that is being recognised[136] while Kierstead et 
al. correlated intrinsic viscosity and circulatory half-life.[4] Production of anti-PEG IgMs has 
been shown to centre on the spleen, however even after splenectomy there was still evidence 
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of the ABC phenomenon, suggesting a more complicated immunological response is at 
work.[132,137] 
 
Although a lot of the literature has focused on the immunogenic effects of PEG there is also 
evidence that under the correct circumstances it can induce a toxicological response.[138] Such 
studies are however in the minority and most literature finds there is no significant risk 
associated with exposure to PEG, leading to endorsement by many regulatory bodies. It has 
therefore found widespread use in many sectors including food, cosmetics, and 
pharmaceuticals (as a drug excipient and laxative). Expanded usage has greatly increased 
passive public exposure to PEG. As such there has been an increase in the number of people 
with pre-existing anti-PEG IgMs, from 0.2%[139] to 22-25%[140], over the past two decades. 
These patients are less likely to benefit from treatment with PEGylated materials. 
 
Identification of the ABC phenomenon has altered the landscape of PEG research. Some 
groups have attempted to avoid anti-PEG IgMs by focusing on non-systemic administration 
such as via mucosal membranes[141], ocular administration[142] and convection enhanced 
delivery to the brain[143]. Others have begun screening for alternative polymeric materials to 
PEG that do not induce the ABC phenomenon.  
 
Kierstead et al. looked for evidence of the ABC phenomenon in mice and rats with a variety 
of lysosomes modified with polymers including: poly(N-(2-hydroxypropyl) methacrylamide 
(PHPMA); poly(vinylpyrrolidone) (PVP); poly(2-methyl-2-oxazoline) (PMOX); poly(N,N-
dimethyl acrylamide) (PDMA) and poly(N-acryloylmorpholine) (PAcM) and PEG.[4] All of the 
polymer-modified lysosomes showed increased circulation times and decreased uptake by 
organs compared to free lysosomes. It was found that PMOX exhibited the ABC phenomenon 
alongside PEG but interestingly there was no observed cross-reactivity between anti-PEG IgMs 
and PMOX in vitro or in vivo. This suggests that IgMs are polymer specific and the existence 
of pre-existing anti-PEG IgMs is unlikely to affect therapeutics containing polymeric 
alternatives to PEG. Additionally, this is the first report that PHPMA does not induce an 
observable ABC effect, alongside PVP, PDMA and PAcM. As such these polymers deserve 
further consideration when designing new polymeric therapeutic materials to avoid repeating 
the current predicament with PEG. 
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1.5 Development and Current Uses of N-(2-Hydroxypropyl) Methacrylamide 
 
N-2-Hydroxypropylmethacrylamide (HPMA) was originally developed by Jindřich Kopeček 
in 1973 when his group began researching biocompatible polymers based on hydrophilic N-
substituted amides of methacrylic acid.[144] 
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Figure 1.10 – Structure of N-2-hydroxypropyl methacrylamide (HPMA) and poly(N-2-hydroxypropyl 
methacrylamide) (PHPMA) 
 
The Kopeček group chose HPMA for further development as it was a crystalline monomer 
with simple purification and reproducible synthesis. The monomer exhibits good 
polymerisation kinetics and the presence of a pendent hydroxyl group provides a readily 
functionalisable moiety in every repeat unit of the polymer. The resulting linear polymer, 
PHPMA, has been shown to be non-toxic in rats up to 30 g/kg and exhibits no identifiable 
binding to plasma proteins.[145] The α-substituted carbon and N-substituted amide provide 
excellent hydrolytic stability, however this functionality also significantly hinders enzymatic 
degradation. To prevent potentially toxic bioaccumulation the molecular weight of linear 
PHPMA should be kept below ~45 kg mol-1 in order to allow for renal glomerular filtration 
and clearance.[146] 
 
Tao et al. have shown how PHPMA can be used in a strategy analogous to PEGylation. They 
synthesised a thiazolidine-2-thione modified RAFT agent and used it to produce a range of 
well-defined PHPMA chains (Ð ≤1.10).[147] These were subsequently conjugated to free 
surface amines of a lysozyme under mild conditions. Additionally the authors showed how the 
degree of conjugation can be partially controlled by the pH of the reaction, however as a bulk 
attachment method conjugation per protein cannot be controlled. The work does highlight two 
key factors: firstly, the ability to use RAFT polymerisation to produce PHPMA at a range of 
50 
 
molecular weights with low dispersity and secondly, conjugation of a polymer to a protein with 
little loss in functionality. 
 
Circulation time of PHPMA polymers has been shown to correlate with increasing molecular 
weight.[146,148] As previously mentioned however, molecular weight should be kept below ~45 
kg mol-1to allow for renal glomerular filtration. In order to reconcile these opposing factors, 
much work has concentrated on introducing degradable linkers to the PHPMA backbone. The 
Kopeček group highlighted the use of peptide linker sequences to combine short PHPMA 
chains into a larger multiblock structure.[149] 
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Scheme 1.15 – Synthetic procedure for the formation of H≡C-PHPMA-N3 and subsequent Cu(I) 
catalysed azide-alkyne cycloaddition to form high molecular weight multiblock PHPMA 
 
A tetrapeptide macro-CTA with a terminal alkyne group was first synthesised and then used to 
polymerise HPMA to give 18 (Scheme 1.15). The azide-terminated PHPMA was subjected to 
post-polymerisation modification, by heating in the presence of 20, to yield the heterotelechelic 
polymer 21. Utilising CuSO4/sodium ascorbate as a low-toxicity source of the Cu(I) catalyst, 
the group successfully joined the PHPMA chains to form a mixture of high molecular weight 
multiblock PHPMA. Approximately 60% of the heterotelechelic polymer underwent coupling, 
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37% of which was reported as the dimer and the remainder as higher weight oligomers. 
Fractionation of the oligomers, on a Superose 6 preparative column, led to the isolation of a 
well-defined fraction (Mw = 290.6 kg mol-1, Ð = 1.06). Incubating this fraction of 22 with the 
protease papain yielded smaller PHPMA fragments (Mw = 49 kg mol-1, Ð = 1.04) with similar 
properties to the starting heterotelechelic PHPMA. As well as degradability to fragments below 
the renal clearance threshold, this work presents a novel method for synthesising high 
molecular weight (>50 kg mol-1) polymers while maintaining very low dispersity, a difficult 
feat for traditional controlled radical polymerisations. However, chromatographic separation 
to yield the well-defined, high molecular weight material could present a barrier if the 
technique were to be scaled up. Furthermore, it would be prudent to consider the potentially 
toxic effect of triazole-peptide by-products potentially produced after in vivo degradation. 
More recently Mužíková et al. utilised similar strategies to synthesise multiblock PHPMA with 
alternative degradation pathways as previously discussed in Section 1.3.2.1 and shown in 
Scheme 1.7.[59]  
 
The first PHPMA-drug conjugate to enter clinical trials was PHPMA-GFLG-doxorubicin. The 
formulation was designated PK1 (Figure 1.11) for the collaboration between the groups in 
Prague and Keele university. PK1 contained ~ 4 molecules of doxorubicin per polymer chain 
(~8.5 wt.% doxorubicin in ~30 kg mol-1 polymer chain) and has been shown to increase the 
biological half-life of doxorubicin from 5 min to 1-2 h for free doxorubicin 
hydrochloride.[150,151] Additionally, the release of Dox was modelled by incubation with the 
protease Papain.  
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Figure 1.11 – Structure of PHPMA-GFLG-doxorubicin designated PK1[151] 
 
While PK1 was well tolerated (no alopecia until doses >180 mg m-2 and no cardiotoxicity until 
doses >1680 mg m-2) it exhibited only mild efficacy. During phase II clincal trials, only 6 
partial responses were recorded from the 62 patients studied. These results highlight the need 
to develop a second generation of these materials. A number of other PHPMA-drug conjugates 
have reached clinical trials and are outlined in Table 1.1.  
 
Code Composition Status Mw (g mol-1) 
Total Drug 
Content (wt.%) 
FCE 28068 (PK1) PHPMA-GFLG-Dox Phase II 30,000 8.5 
FCE 28069 (PK2) 
PHPMA-GFLG-Dox-
galactosamine 
Phase II 25,000 7 
PCNU166148 PHPMA-camptothecin Phase I 18,000 10 
AP5280 
PHPMA-carboplatinate 
analogue 
Phase II 25,000 8.5 
AP5346 
PHPMA-DACH platinate  
analogue 
Phase II 25,000 10 
Table 1.1 – PHPMA copolymer conjugates that have entered clinical trials as anticancer agents 
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Developing new synthesis and delivery methods is critical to creating the second generation of 
PHPMA based therapies and these are discussed in the sections below. The following review 
is not exhaustive but meant to give an overview of the current state of the literature surrounding 
PHPMA. 
 
1.6 Amphiphilic Block Copolymers Based on PHPMA 
 
While previously discussed polymer-drug conjugates initiate transport via covalent attachment 
and subsequent release, other variants rely on non-covalent interactions to solubilise the drug 
for transport to the target. These materials have certain disadvantages including potential for 
slow or even sudden release of the drug. It can also be difficult to quantify the amount of drug 
bound within the polymeric structure and how much is passively associated. However these 
systems are less complex which can be beneficial when trying to assign structure-function 
relationships or scale up production. 
 
The importance of well-defined polymer systems was shown by Barz et al. when they 
compared the cellular uptake of PHPMA homopolymers and PHPMA-lauryl methacrylate 
random and block amphiphilic copolymers.[152] By comparing the homopolymer with the 
heteropolymer isomers, in the absence of any drug, the authors showed the random copolymer 
to be taken up over a wider concentration range than the block copolymer. They reason that 
random copolymers form smaller and weaker interacting aggregates which are easier for the 
cell to uptake compared to the block copolymers. As such, random copolymers may be a useful 
design if subcellular targeting is an important consideration. 
 
Amphiphilic block copolymers are of particular interest as they exhibit self-assembly and, 
depending on the polymer used, can be further modified for increased stability or 
targeting[12,15,153,154]. With the previously discussed problems with PEG, PHPMA has been used 
as a substitute material for the hydrophilic block. Copolymers based on PHPMA and 
poly(lauryl methacrylate) (PLMA) have been shown to match the capability of PEG-based 
carriers to cross the blood brain barrier (BBB).[155] Hemmelmann et al. demonstrated the ability 
of their system to deliver fluorescent marker Rhodamine 123 across human brain microvascular 
endothelial cells without damaging the barrier’s integrity.[156] PHPMA-b-PLMA copolymers 
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have also been used to stabilise, by virtue of their self-assembly into micelles, polystyrene 
nanoparticles synthesised via a miniemulsion process.[157,158] 
 
Tappertzhofen et al. synthesised poly-L-lysine-b-PHPMA polyplexes for the delivery of 
plasmid DNA to dendritic cells.[159,160] These block copolymers self-assemble in the presence 
of DNA by proton transfer to the lysine residues which creates an ionic complex at the centre 
of the aggregate with the DNA. Rather than using HPMA directly they synthesised the polymer 
precursor using pentafluorophenyl methacrylate (PFMA) to give poly-L-lysine-b-PPFMA and 
then performed post-polymerisation modification using 2-aminopropanol to yield the final 
product (Scheme 1.16). 
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Scheme 1.16 – Synthesis of poly-L-lysine-b-PHPMA by post-polymerisation modification with 2-
aminopropanol[159] 
 
This method allows for polymerisation in traditional organic solvents and later modification to 
give the desired material. Additional work by this group showed that thorough post-
polymerisation modification gave PHPMA materials virtually indistinguishable from those 
synthesised by direct polymerisation of HPMA.[161] 
 
The presence of hydroxyl moieties in the PHPMA backbone has prompted interest in using 
HPMA for both the hydrophilic and hydrophobic components of the amphiphilic molecule. 
Esterification of the hydroxyl groups with a sufficiently lipophilic acid results in hydrophobic 
HPMA. Alfurhood et al. modified HPMA with valporic acid (VPMA) and then co-polymerised 
this with additional HPMA and a HPMA based macro-CTA to yield PHPMA-b-P(HPMA-co-
VPMA) amphiphilic block copolymer which underwent spontaneous self-assembly in 
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water.[162] Valporic acid was released by hydrolysis at pH 5 and caused disassembly of the now 
completely hydrophilic linear PHPMA chains. 
 
1.7 Stimuli-Responsive Polymers Containing PHPMA 
 
Polymeric systems capable of non-linear changes to their physical properties in response to an 
environmental change are known as stimuli-responsive or ‘smart’ polymers. The changes are 
usually reversible and may alter the charge, shape, solvent-interaction and/or balance of 
hydrophilic/hydrophobic interactions. By linking drug release to the change in physical 
properties it is possible to provide site-specific delivery thereby increasing efficacy while 
reducing dosing frequency and side effects. An overview of some of these effects is outlined 
below with a focus on systems which incorporate PHPMA. 
 
1.7.1 pH Responsive 
 
Solid cancer tumours have been shown to generate an acidic micro-environment within the 
extracellular space (pH 6 – 6.8) as a result of upregulation of glycolysis and anaerobic 
respiration even in the presence of sufficient oxygen.[163,164] The use of acid responsive drug 
linkers allows for specific release within the extracellular space, increasing the likelihood of 
uptake by cancerous tissue. This was recently highlighted by the Maeda group who synthesised 
a PHPMA conjugate with pirarubicin (THP) linked via a hydrazone spacer[17]. Only ~8% THP 
was released after 24 h at 37 °C and pH 7.4, this increased to ~30 – 50% between pH 6.5 – 
6.0[165]. While extracellular release has been shown to be functional, superior release will be 
achieved at even lower pH. Endocytotic uptake exposes the polymer-conjugate to pH 5 within 
cellular lysosomes. Li et al. report a combined stimuli-responsive strategy outlined in Figure 
1.12.[166] 
 
56 
 
NHO
OH
NH
HN
O
N
OH
O O
OH
H
OH
NH2
O
O
OH
OHO
a b
HN
O
O
NHO
NHO
NH
NH
O
HN
HO
O
O
NH
N
N
N
N
H2N
OH
c d
O
O
OH
 
Figure 1.12 – Structure of combined stimuli responsive polymer 
 
When introduced to the extracellular environment, dimethylmaleic anhydride was removed and 
thus exposed cationic aminopropyl moieties. This resulted in electrostatic attraction between 
the polymer and cell membrane which helped facilitate binding between polymer bound protein 
targeting ligands and αvβ3 integrin receptors, increasing endocytotic uptake. Within the 
lysosomal compartment, cleavage of the hydrazone linker caused release of free doxorubicin. 
Incubation of the polymer at pH 5 showed ~65% doxorubicin released after 24 h.[167] This 
strategy highlights the pH responsive nature of the hydrazone group but also shows the 
potential to create synergistic effects when the conjugate structure and target environment are 
carefully considered. 
 
1.7.2 Thermally Responsive 
 
Thermally responsive polymers can exhibit two critical parameters; namely an upper critical 
solution temperature (UCST) and / or a lower critical solution temperature (LCST). For the 
LCST and UCST a polymer will undergo a solution phase transition and precipitate above or 
below the critical temperature, respectively. Systems exhibiting a LCST are generally preferred 
for drug-delivery due to the high temperatures associated with UCSTs which may cause 
degradation. In terms of the Gibbs equation (ΔG = ΔH – TΔS) polymers below their LCST are 
soluble, despite the formation of strong intermolecular bonds which restrict random mixing 
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and therefore lower entropy, because of an associated large negative enthalpy change. Above 
the LCST TΔS becomes a sufficiently negative term, and by extension (– TΔS) becomes a 
sufficiently positive term, that ΔG ≥ 0 and the polymer precipitates. PHPMA does not exhibit 
an LCST[168] on its own and so is copolymerised with monomers that do. Poly(N-
isopropylacrylamide) (PNIPAM) is one of the best known thermo-responsive polymers and is 
widely researched for drug delivery as it has a LCST close to body temperature (~33 °C).[168] 
 
Luan et al. concisely showed how the LCST of a poly(HPMA-co-NIPAM) system could be 
tuned by altering the fraction of HPMA.[169] Increasing HPMA content led to an increase in the 
LCST. Additionally, the group also reported the effect of end-group functionality on LCST. 
By removing the hydrophobic terminal dithiobenzoate group they observed a significant 
increase in the LCST for low molecular weight polymers. While there are examples of NIPAM 
based copolymers[170–173] for drug delivery they do not use HPMA and so this presents a gap in 
the current literature. 
 
While poly(HPMA-co-NIPAM) random copolymers have not been explored for drug-delivery 
applications block copolymers have been identified. Poly(HPMA-b-NIPAM) is an example of 
a double hydrophilic block copolymer (DHBC), a new type of amphiphilic block copolymer. 
These systems are of interest as ‘green’ carriers as they can be synthesised in aqueous phase 
and aggregated by altering the temperature as opposed to the conventional dialysis with organic 
co-solvents. Zhou et al. synthesised a series of poly(HPMA-b-NIPAM) DHCBs and 
investigated the pH sensitive release of Dox bound to the HPMA or NIPAM blocks.[174] They 
found attachment of Dox, via a pH labile hydrazone bond, to either the HPMA or NIPAM 
blocks had no appreciable effect on the nanoparticles formed. However, Dox release increased 
by 10% when bound to the HPMA block, which the authors rationalised as aiding the 
permeation of H+ for hydrazone cleavage. 
 
1.8 Poly-ε-caprolactone 
 
Poly-ε-caprolactone (PCL) was made commercially available after efforts to identify 
biodegradable synthetic polymers. Originally synthesised by the Carothers group in the early 
1930s, PCL is most commonly prepared via the ring-opening polymerisation of ε-caprolactone 
in the presence of a stannous octoate catalyst.[175] Alternative polymerisation methods have 
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since been explored including the use of anionic[176] and cationic[177,178] catalysts as well as free 
radical ROP.[179] A thorough review of the synthesis of PCL has been written by Labet and 
Thielemanns.[180] PCL is a hydrophobic, semi-crystalline polymer, though this decreases as a 
function of molecular weight[181], with excellent blend-compatibility and low melting point 
(59-64 °C). While PCL is readily degraded by bacteria and fungi, animals lack suitable 
enzymes for bulk macromolecular degradation.[182] While enzymes may not be involved, PCL 
has been shown to undergo in vivo degradation via a two stage hydrolytic degradation 
mechanism.[183,184] In stage 1 high molecular weight PCL (> 50,000 g mol-1) undergoes random 
hydrolytic scission. If water is unable to penetrate towards the centre of the bulk material only 
surface erosion occurs, resulting in a lower observed Mn but no change in overall mass. In stage 
2 small fragments of PCL (< 3,000 g mol-1) undergo intracellular degradation within the 
phagosomes of macrophages and giant cells to yield 6-hydroxyl caproic acid.[183] This is 
subsequently entered into the citric acid cycle and ultimately eliminated as CO2 and H2O.[185] 
Sun et al. observed 92% excretion of their tritium-labelled PCL (Mw 3,000) after 135 days.[186] 
Devices fabricated from high molecular weight PCL have been shown to exhibit a particularly 
long degradation and elimination time (ca. 3 years[184,186]), particularly when compared to other 
biodegradable hydrophobic polymers (e.g. polylactides and polyglycolides). In the 1970’s and 
80’s short degradation and total elimination times were considered desirable due to risks 
perceived with long-proliferating biomaterials. This contributed to a reduced interest in PCL. 
To date the degradation and elimination of PCL is under-researched and this is likely due to 
the significant time commitment in producing a comprehensive analysis. Improvements have 
been made; Lam, Teoh and Hutmacher reported a method of accelerated degradation which 
followed a similar profile to the in vivo degradation of PCL.[187]  
 
Over the past 30 years there has been a resurging interest in PCL within the field of tissue 
engineering. Tissue engineering benefits significantly from the properties of PCL for a number 
of reasons: (i) synthesis is inexpensive and PCL’s low melting point and rheological properties 
make it easy to manufacture; (ii) it can be made into porous 3D networks which allow for cell 
growth and the flow of nutrients and metabolic waste;[188] (iii) it already has FDA approval for 
use in medical devices and formulations. Commercially PCL has been used for long term, 
subdermal delivery of female contraceptives under the name “Capronor” and is currently sold 
as a surgical suture material under the name “MONOCRYL”. While the material exhibits a 
range of desirable properties its poor tensile strength has limited it to non-load bearing 
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biomedical applications. This has prompted research into PCL blends with carbon nanotubes 
to improve the overall mechanical properties.[189,190] A more comprehensive review of the 
tissue engineering applications of PCL are beyond the scope of this work but have been 
thoroughly covered by a number of other authors in the field.[5,191,192] 
 
The increased focus on PCL for tissue engineering has, in turn, increased interest within 
adjacent fields such as polymeric drug delivery. Its hydrophobicity provides an ideal 
environment for the association of similarly hydrophobic drug molecules. However, nanoscale 
polymer-drug conjugates are rapidly concentrated in the liver and eliminated by the 
mononuclear phagocyte system (MPS).[193] While this is potentially useful, if targeting these 
systems is desirable, most systems benefit from increased circulation times for active or passive 
targeting. A discussion of purely PCL-based nanoscale delivery systems is provided in Chapter 
4 of this thesis. To achieve improved circulation times, amphiphilic copolymers of PCL are 
synthesised by reaction with a suitably hydrophilic material, frequently PEG.  
 
PEG-PCL block copolymer synthesis is typically achieved by ROP of lactones with a PEG 
macroinitiator.[193] The resulting block copolymers have been used to encapsulate poorly water 
soluble anti-cancer drugs. Recently, Danafar et al. produced well-defined PEG-PCL diblock 
copolymer micelles to deliver the natural product sulforaphane with excellent encapsulation 
efficiency (86%).[194] Eatemadi et al. synthesised PCL-PEG-PCL copolymers and showed a 
reduction in IC50 of 29% and 46% for cisplatin and doxorubicin respectively, when associated 
with the copolymer compared to the free drug.[195] The majority of PCL-PEG nanomaterials 
are reported as spherical nanoparticles (either micelles or vesicles) however Loverde and co-
workers showed that worm-like structures exhibit a 2-fold increase in drug loading compared 
to their spherical counterparts.[196]  
 
A criticism of PCL-based nanomedicines is that formation of polymer-drug conjugates mainly 
relies on non-covalent interactions. PCL lacks a repeating pendent functionality through which 
to facilitate covalent attachment. Some methods for modifying the back-bone structure of PCL 
have been proposed. 
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Scheme 1.17 – Synthetic strategy for PEG-(PCL)8 star copolymer  
 
Buwalda et al. initially synthesised an 8-arm PEG-PCL star block copolymer before 
functionalizing with propargyl bromide in an anionic post-polymerization step. Further 
modification via photoradical thiol-yne addition of benzyl mercaptan yielded PCL with 
pendent benzylthioether (BTE) groups (Scheme 1.17).[197] The resulting PEG-(PCL-BTE)8 
micelles were analysed by TEM and found to have an average diameter of 50 nm and a 50% 
increase in drug loading and encapsulation efficiency compared to PEG-(PCL)8 (average 
diameter ~ 200 nm). The authors attribute these effects to the presence of BTE moieties and 
some degree of π-π stacking interactions. While post-polymerisation modification of the 
polymer backbone directly highlighted its effects, the degree of substitution by propargyl 
bromide was found to be only 8%, highlighting the difficulty in achieving quantitative 
modification. Zhai et al. described an alternative approach by first synthesising an ε-
caprolactone monomer derivative. 1,4-Cyclohexanediol was modified via sequential Michael 
addition, PCC oxidation and Baeyer-Villiger oxidation before undergoing ROP with mPEG 
5000 (Scheme 1.18).[198] 
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Scheme 1.18 – Synthetic route employed by Zhai et al. to yield paclitaxel modified PEG-PCL diblock 
copolymers [198] 
 
Complete deprotection of pendent t-butyl moieties was reported and esterification of 
subsequent carboxyl groups introduced pendent vinyl moieties to 28% of the total PCL block. 
Subsequent reaction with paclitaxel modified 13% of the total PCL block. While the method 
introduces more synthetic steps than the method proposed by Buwalda et al., significantly more 
pendent functionalities can be introduced when starting from a pre-modified monomer. 
 
While PEG has been shown to expand the applicability of PCL, these systems ultimately suffer 
from the same ABC-phenomenon problems as all PEG-based materials. It is therefore desirable 
to consider alternative hydrophilic polymers and potential conjugation methods to create a new 
range of amphiphilic materials.  
 
1.9 Block Copolymers based on PHPMA and PCL 
 
As previously discussed, PHPMA exhibits several desirable characteristics as a hydrophilic 
polymer including: non-toxic; non-immunogenic; pendent hydroxyl functionalities and 
no detectable initiation of the ABC-phenomenon. PCL has also been extensively explored as 
the drug solubilising, hydrophobic block in amphiphilic polymers. Only a handful of papers 
describing the synthesis and characterisation of PHPMA-PCL block copolymers have been 
published. 
 
The earliest of these papers considers the synthesis of PHPMA-b-PCL-b-PHPMA triblock 
copolymers by polymerisation of HPMA from thiol terminated homotelechelic PCL.[199] 
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Scheme 1.19 – Synthesis of PHPMA-b-PCL-b-PHPMA outlined by Lele and Leroux 
 
A range of triblock copolymers were synthesised (Mn = 4,700 – 14,700 g mol-1 ; Ð = 1.55 – 
1.80) and analysis by DLS showed they spontaneously form micelles with a bimodal 
distribution. The bulk population had a mean diameter of 30 ± 10 nm as well as some aggregate 
particles of mean diameter 150 ± 50 nm. These nanoparticles were found to load between 1 – 
4 wt% of doxorubicin via a dialysis method. In addition, the authors used the same method to 
synthesise a series of 4-arm star copolymers (Mn = 14,800 – 27,600 g mol-1 ; Ð = 1.68 – 
1.74).[200] The star polymers also self-assembled in water (average diameters between 110 ± 10 
– 150 ± 50 nm) but exhibited a unimodal distribution when analysed by DLS, even upon 9-fold 
dilution of the original solution. The authors attribute this behaviour to increased stability of 
micelles formed from star block copolymers. Additionally, the authors report 80 ± 10% 
esterification of the 4-arm star PCL with 3,3’-dithiobis(propionic acid), suggesting the presence 
of some 3 arm star or linear copolymers. While the methods outlined in these papers highlight 
the potential of PHPMA-b-PCL-b-PHPMA materials, the Ð of the material could be improved 
through the implementation of controlled polymerisation techniques such as RAFT.  
 
The Steglich esterification is a commonly used coupling reaction for end group modification 
of polymers.[201,202] This was demonstrated by the Kopeček group in their synthesis of a macro-
chain transfer agent (macro-CTA) by coupling polycaprolactone to the RAFT agent 4-cyano-
4-(phenylcarbonothioylthio)pentanoic acid. The group report synthesis of the product in good 
yield (87.5 wt.%) after reacting overnight however, as the 1H-NMR spectrum is not presented 
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it is difficult to assess the degree of esterification achieved by the Steglich strategy. (Scheme 
1.20).[201] 
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Scheme 1.20 – Synthesis of PHPMA-b-PCL via a RAFT macro-CTA 
 
The macro-CTA was subsequently used for the polymerisation of HPMA to form the diblock 
copolymer PCL-b-PHPMA (69.4%). Analysis by DLS showed the polymer to exhibit a 
unimodal distribution with mean diameter of 62.5 nm. The dispersity of the final copolymer 
(Ð = 1.27) is higher than that typically seen for PHPMA homopolymers (Scales et al. reports 
a Ð = 1.04 for a similar length PHPMA chain).[203] The dispersity of a copolymer would 
expectedly be wider than a homopolymer, especially when one of the polymer blocks was 
synthesised via a non-controlled route (as is the case here). Despite this, the PHPMA block 
dominates the structure of the copolymer (80% of the total weight) and should therefore 
dominate the dispersity of the final product. A Ð of 1.27 may suggest interference between the 
macro-CTA and the RAFT polymerisation procedure when compared to using the free RAFT 
agent. 
 
The Filippov group synthesised a series of PHPMA-b-PCL diblock copolymers with terminal 
stable nitroxyl radicals in a four step process (Scheme 1.21).[204] 
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Scheme 1.21 – Synthesis of PHPMA-b-PCL with a terminal TEMPO group 
 
Broadening of the characteristic nitroxyl radical electron paramagnetic resonance (EPR) 
spectrum provided evidence for successful micellisation of the diblock copolymer in water. 
Measurements by DLS exhibited unimodal distributions, in agreement with results from the 
Kopeček group, and cryo-TEM images confirmed their spherical nature. Additional copolymer 
nanoparticles were synthesised with TEMPO groups attached via long and short spacers to the 
hydrophilic PHPMA blocks. These were subsequently used to probe the interaction of the 
nanoparticles with various plasma proteins. No change in the nitroxyl radical EPR spectrum 
was observed when nanoparticles were incubated in PBS buffer compared to solutions 
containing human serum albumin, bovine serum albumin, IgG, human blood plasma or high 
and low-density lipoproteins. These data suggest no hard protein corona exists around 
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PHPMA-b-PCL bases nanoparticles, exemplifying PHPMA’s “stealth” properties and is in 
agreement with in vivo testing of amphiphilic PHPMA-Dox conjugates.[205] 
 
1.10 Review of Current Literature 
 
Polymer therapeutics are a continuously developing field, with the potential to circumvent 
many of the problems associated with the delivery of traditional small drug molecules. The 
synthesis of these materials has been further enhanced by advances in RDRP techniques; RAFT 
has been of particular interest herein. Incorporation of click methodologies has helped reduced 
the complexity of synthesis while also enabling more elaborate materials to be conceived. The 
major click strategies discussed included CuAAC, DA and HDA cycloadditions as well as 
thiol-ene and thiol-Michael addition mechanisms. Each strategy possesses its own advantages 
and unique problems yet altogether form a key area of modern polymer synthesis. 
 
The growing evidence around the ABC phenomenon has tarnished PEG’s reputation as the 
“gold standard” in biocompatible polymers. Other polymers, which have not yet been shown 
to promote this effect, have been considered and the development of synthetic strategies 
involving them have been discussed. Of particular interest herein are PHPMA and PCL. 
PHPMA was developed with drug delivery in mind and has shown promise, particularly in the 
delivery of anticancer drugs such as Dox. Current data suggests it does not induce the ABC 
phenomenon and does not associate with plasma proteins. PHPMA has been incorporated into 
a range of amphiphilic and stimuli-responsive polymers, which have been synthesised under 
excellent control when coupled with RAFT polymerisation. However, while many materials 
show promise and some have reached late clinical trials the leap to commercial products has 
been difficult. PCL is a biodegradable, hydrophobic polymer with a history in biomedical 
polymers and commercial applications. Increased interest in the material over the past 30 years 
has once again brought it to the forefront of research and it has been successfully incorporated 
into a wide range of amphiphilic block copolymers. However, these materials are typically, but 
not exclusively, based on a combination of PCL and PEG blocks and as such suffer from the 
effects of the ABC phenomenon previously discussed. The replacement of PEG with suitably 
hydrophilic materials seems a natural progression but to date only 4 papers (to the best of the 
author’s knowledge) have been published which detail the synthesis, characterisation and 
properties of PHPMA-PCL block copolymers. Lele and Leroux characterised PHPMA-b-PCL-
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b-PHPMA block copolymers from thiol terminated homotelechelic PCL. The synthesis of this 
should be reasonably improved by use of living polymerisation techniques such as RAFT, as 
touched on by the Kopeček group. As such, this presents a potential area for future 
developments and is one of the aims of the research described in this thesis. 
 
1.11 Project Aims 
 
Individually HPMA and PCL have a strong track record in polymer therapeutics, however their 
combination into amphiphilic materials is under researched. As such this work aimed to expand 
the availability of HPMA and PCL based materials capable of use as polymeric drug delivery 
platforms. To achieve this broad goal a number of different approaches were considered. 
Firstly, optimising the synthesis of PHPMA-b-PCL-b-PHPMA block copolymers via a 
grafting-from approach by utilising RAFT techniques in the polymerisation of HPMA. This 
was hypothesised to afford lower dispersity materials while simultaneously expanding the 
available molecular weight range for drug delivery applications, particularly in comparison to 
similar materials synthesised by Lele and Leroux.[199] Furthermore, developing click 
methodologies for conjugating PHPMA and PCL blocks would expand the, currently limited 
number of, reported strategies for synthesising these materials. 
 
Secondly, unimolecular amphiphilic branched copolymers were to be investigated as an 
alternative to self-assembling systems which may undergo undesirable disassembly and 
payload release in vivo. The use of free radical crosslinking copolymerisation was hypothesised 
to allow access to these materials in a synthetically benign manner. Successful synthesis of 
branched HPMA would expand the list of currently reported materials. 
 
Finally, hydrophobic polymers, such as PCL, can be readily purchased and formed into 
nanoscale objects by exploiting the hydrophilic/hydrophobic interactions of said polymers in 
oil-water solvent mixtures. Such nanoparticles could be utilised as a delivery platform for 
hydrophobic materials. The low cost barrier to entry was hypothesised to allow for easier 
scalability if a suitable methodology could be developed. 
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2 Synthesis of ABA Type Triblock Copolymers 
 
2.1 Introduction 
 
The work in this chapter aims to develop facile methods for the synthesis of PHPMA-b-PCL-
b-PHPMA block copolymers which achieve higher molecular weight and lower dispersity 
materials than those originally published by Lele and Leroux. To realise these improvements 
two synthetic strategies were employed. Firstly, a grafting-from approach by chain extension 
of homotelechelic dithiobenzoate terminated PCL with HPMA. This method is analogous to 
that reported by Lele and Leroux, however utilises RAFT polymerisation instead of FRP to 
polymerise HPMA. The use of RAFT was hypothesised to lower the dispersity achieved in the 
product compared to currently published procedures. Secondly, coupling of pre-synthesised 
PHPMA with homotelechelic PCL bearing suitable clickable functionalities. Synthesis of 
PHPMA prior to coupling was hypothesised to allow better control of the properties of the final 
PHPMA-b-PCL-b-PHPMA block copolymers by selecting the PHPMA starting material prior 
to conjugation. The coupling strategies investigated were CuAAC, DA, thiol-ene and thiol-
Michael. In both strategies the polymers were designed to have an Mn greater than 30,000 g 
mol-1 to avoid rapid clearance via the kidneys. 
 
2.2 Results and Discussion 
 
2.2.1 Synthesis of PHPMA homopolymers 
 
In order to synthesise block copolymers it was first necessary to synthesise the monomer N-(2-
hydroxypropyl)methacrylamide (HPMA). This was achieved via the coupling of methacryloyl 
chloride 23 and 1-aminopropan-2-ol 24 to yield the product 6 following the procedure outlined 
by Ulbrich et al.[206]  
NH2O
OH NHO
OH
+
Cl -20 °C, 2 h, DCM
23 24
6
NaHCO3
 
Scheme 2.1 – Reaction scheme for the formation of HPMA 
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The crude reaction mixture was purified by recrystallisation from DCM and HPMA (6) was 
isolated in 78% yield. As previously discussed, RAFT polymerisation was selected as the 
desired RDRP technique for this work. However, degradation of dithioester moieties by amines 
is well established[207,208] therefore the purity of the monomer and removal of the starting 
material 24 was critical. The purity of 6 was assessed by 1H NMR spectroscopy (Figure 2.1). 
 
 
Figure 2.1 – 1H NMR spectrum of HPMA monomer in DMSO 
 
1H NMR spectrum shows peaks associated with HPMA and integration values are as expected. 
The appearance of a new peak at 7.8 ppm is indicative of an amide bond and successful 
synthesis of HPMA. Recrystallisation from DCM was sufficient to remove any impurities from 
the final product. In order to form ABA block copolymers, via the click strategy, which are 
above the renal clearance threshold it was important to first optimise the synthesis of PHPMA 
homopolymers ca. 12,000 g mol-1 with good Ð (≤ 1.10). HPMA was polymerised using a 
modified version of the synthesis originally outlined by Scales et al. (Scheme 2.2).[203] 
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6
S
S
OH
CN
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, 70 °C, 16 h
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S
S
O NH
OH
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O
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Scheme 2.2 – Synthesis of PHPMA homopolymer 
 
Code Mn (NMR) (g mol-1) Mn (SEC) (g mol-1) Mw (SEC) (g mol-1) Ð 
P1 13,184 11,847 12,468 1.05 
P2 12,113 11,752 12,704 1.08 
P3 16,420 17,207 17,512 1.02 
P4 13,444 12,447 13,121 1.05 
Table 2.1 – Data for the synthesis of PHPMA homopolymers 26.  
 
The polymerisation was performed in an aqueous acetate buffered solution, as recommended 
by Scales et al., in order to minimise hydrolysis and maintain dithioester chain ends. As can be 
seen from Table 2.1 polymers were synthesised in a controlled manner (Ð ≤ 1.10) and above 
the renal clearance threshold. The polymers were analysed by 1H NMR spectroscopy and triple 
detection SEC in order to assess absolute molecular weight values of the materials.  
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Figure 2.2 – 1H NMR spectrum of PHPMA homopolymer P1 
 
Figure 2.3 – RI trace of PHPMA homopolymer P1 from SEC analysis 
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The 1H NMR spectrum of linear PHPMA expectedly shows signals at similar chemical shifts 
to the monomer (Figure 2.1). The disappearance of vinyl signals, 5.7 – 5.2 ppm, and peak 
broadening compared to the monomer spectrum suggested successful polymerisation as well 
as new aromatic signals, 7.9 – 7.4 ppm, for the terminal RAFT derived phenyl moiety. Analysis 
of the refractive index (RI) traces of the polymers from SEC analysis (Figure 2.2) showed a 
unimodal trace with no observable high molecular weight ‘shoulder’ before the main peak that 
would have been indicative of disulphide coupling of terminal thiols resulting from RAFT 
hydrolysis. The values of Mn (NMR) (Table 2.1) were derived by comparing the integrals of the 
signals e and j according to the equation Mn (NMR) = (e / j) * 143.18. The values for Mn (NMR) 
compare favourably to Mn (SEC) though discrepancies between the two methods could 
reasonably be explained as the error in determining NMR integration values. The error in such 
measurements were minimised by performing a minimum of 128 scans for all samples, though 
this did not eliminate all sources of error. Successful synthesis of PHPMA homopolymer 26 
provided a point of comparison when considering the synthesis of PHPMA-b-PCL-b-PHPMA 
copolymers. 
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2.2.2 Synthesis and Optimisation of PHPMA-b-PCL-b-PHPMA Triblock 
Copolymers via RAFT Polymerisation of a macro-CTA 
 
A general synthetic strategy for the synthesis of PHPMA-b-PCL-b-PHPMA copolymers is 
shown below (Scheme 2.3). 
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Scheme 2.3 – Strategy for the synthesis of PHPMA-b-PCL-b-PHPMA copolymers 
 
For the synthesis of block copolymer 30 a macro-CTA was first prepared by carrying out 
Steglich esterification of the terminal hydroxyl groups of commercially purchased 27 with a 
RAFT agent to afford the homotelechelic polymer 29. The procedure for Steglich esterification 
is commonly reported in the literature.[209] The success of the reaction was assessed by 1H NMR 
spectroscopy by comparison of the integral for the –CH2 protons (4.2 ppm) in the central 
ethylene bridge to that for the phenyl protons (7.9 – 7.4 ppm) from the RAFT agent. For the 
synthesis of 29a, after 24 h only 78% of available hydroxyl groups had been esterified. 
Incomplete esterification produces a mixture of PCL chains, some with the RAFT agent at only 
one terminus. This could lead to the formation of the diblock side product, PHPMA-b-PCL, in 
the subsequent polymerisation of HPMA. It was therefore important to drive this reaction to 
completion. Increasing the reaction time from 24 h to 120 h increased the degree of 
esterification to 90%. The greatest extent of esterification was achieved by increasing the 
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reaction time to one week and adding additional DCC every day over the course of the reaction. 
The 1H NMR spectrum of 29a can be seen below. 
 
 
 
 
Figure 2.4 – 1H NMR spectrum of the macro-CTA 29a 
The degree of esterification was found to be ≥ 95%. This was deemed satisfactory even if 
quantitative esterification was not achieved in all cases. It was reasoned that attempting to drive 
the reaction to completion by continued addition of commercially expensive RAFT agent 
would be too costly and time consuming especially for the development of a facile 
methodology. In the literature, the degree of esterification of macro-CTAs is not always 
reported[201] however the results presented here compare extremely well against those instances 
where it is. Vicent et al. reports only 69-75% functionalisation when synthesising macro-CTAs 
by a similar method.[209]  
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Code Solvent RAFT Agent a Acid 
b Temp. 
(°C) 
Time 
(h) 
Mn (SEC) 
(g mol-
1) 
Mw (SEC) 
(g mol-1) Ð 
Yield 
(wt. %) 
P5 DMF-Dioxane (1.5 : 2.5) A - 70 16 43,792 91,526 2.09 28 
P6 DMF-Dioxane (1.5 : 2.5) A - 70 16 29,962 62,885 2.10 27 
P7 DMF-Dioxane (1.5 : 2.5) A - 70 16 31,266 68,601 2.19 27 
P8 DMF-Dioxane (1.5 : 2.5) A 0.1M 70 16 39,827 72,550 1.82 24 
P9 NMP-Dioxane (1.5 : 2.5) A - 70 16 35,298 65,217 1.85 25 
P10 MeOH-Dioxane (1.5 : 2.5) A - 70 16 13,831 73,085 5.28 21 
P11 Acetone-MeOH (2 : 3) A - 58 16 29,432 41,544 1.41 27 
P12 Acetone-MeOH (2 : 3) A - 58 24 35,473 65,478 1.85 26 
P13 DMF-Dioxane (1.5 : 2.5) A - 58 16 18,281 32,479 1.78 19 
P14 IPA-MEK (2 : 1) A - 70 16 30,774 69,343 2.25 28 
P15 IPA-MEK (1 : 2) A - 70 16 75,584 188,060 2.49 33 
P16 DMF-Dioxane (1.5 : 2.5) B 1.2 eq. 70 16 7,895 18,234 2.31 13 
P17 Acetone-MeOH (2 : 3) B 1.2 eq. 58 16 23,024 35,538 1.54 25 
 
Table 2.2 – Data for the synthesis of PHPMA-b-PCL-b-PHPMA copolymers;.aTerminal RAFT 
moieties are defined as 29 (a/b) in Scheme 2.3; bp-toluenesulphonic acid (pTSA) in the amounts 
described were added; The feed ratio of macro-CTA : HPMA : Initiator was 1 : 238 : 0.29 for all 
reactions 
Subsequently, the RAFT grafting step to produce the triblock copolymer was investigated. 
Prior unpublished work in our group showed the ratio 1 : 238 : 0.29 of macro-CTA : HPMA : 
initiator to be suitable for the synthesis of 30 at molecular weights above the renal clearance 
threshold. Table 2.2 shows the attributes of the polymers resulting from varying solvent, acid 
additive, temperature and time. Polymers P5-P7 resulted from three initial attempts at synthesis 
of the triblock under identical conditions. While these polymers were of suitable molecular 
weight, their polydispersities were uncharacteristically high for a RAFT mediated 
polymerisation. P5-P7 were consistent in their Ðs implying some measure of control but the 
high values suggested that the thiocarbonylthiol moiety was either being degraded or that not 
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all chains were initiated simultaneously, leading to wide dispersity in the final product. The 
effect of the solvent on the rate of initiation was dismissed as it has previously been shown in 
the literature to have no effect with regards to AIBN.[210,211] 
 
Over time, DMF can degrade to give small amounts of dimethylamine.[212] The presence of 
primary and secondary amines can lead to the degradation of thiocarbonylthiol groups. Such 
aminolysis reactions are well established and their utility in forming thiols for thiol-ene 
reactions has previously been discussed (Chapter 1, section 1.3.2.2). Methods for minimising 
the effect and production of dimethylamine were therefore considered in order to improve the 
overall control of the reaction. To begin with, the addition of pTSA at a concentration of 0.1 
M was tested in the synthesis of P8 with the aim to form quaternary ammonium cations from 
any amines present and subsequently prevent nucleophilic attack on the thiocarbonyl moiety. 
A marginal increase in molecular weight was observed, compared to P6 and P7, along with a 
marked reduction in Ð evidencing that contaminants contributed to the loss of control but were 
not the sole cause. NMP is functionally similar to DMF as a solvent but more resistant to 
hydrolysis so it was used in place of DMF in an experiment to produce polymer P9 where 
similar improvements to P8 were observed (Ð 1.85) but still the Ð was not at the level expected 
for RAFT mediated polymerisation. Methanol was tested as a replacement for DMF however 
this dramatically worsened the controlled nature of the reaction (P10, Ð 5.28). Veloso et al. 
utilised matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-
TOF MS) for detailed analysis of poly(n-butyl acrylate) (PBA) synthesised by RAFT 
polymerisation in ethanol.[213] Significant amounts of dead chains were observed which they 
reasoned to form via chain transfer to the solvent.  Analysis of the RI trace in the SEC 
chromatogram of P10 shows the presence of a large shoulder at ~ 20 mL, which is comprised 
of low molecular weight chains as evidenced by a weak concurrent signal in the right angle 
light scattering (RALS) and low angle light scattering (LALS) traces, suggesting the formation 
of dead chains (Figure 2.5). 
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Figure 2.5 – SEC chromatogram of P10 including RI, in red, RALS, in green, and LALS, in black, 
traces 
The combination of chain termination and asynchronous chain initiation would reasonably 
explain the broad dispersity observed in this case. Furthermore, dioxane, as well as other cyclic 
ethers, is known to undergo reactions in the presence of free radicals.[214] While no attempts 
were made to characterise these side reactions, it is possible that the presence of dioxane has a 
retarding effect on polymerisation which in this case is observed as a loss of control in the 
RAFT mechanism. This is further corroborated by Petrova et al. who successfully synthesised 
similar PHPMA-b-PCL diblock copolymers purely in DMF.[204] As a result it was desirable to 
consider alternative solvent systems. 
 
A publication by the Kopeček group highlighted the successful synthesis of PHPMA-b-PCL 
diblock copolymers (Mw = 38,300 g mol-1 Ð = 1.27) in an acetone-methanol solvent system.[201] 
For P11, this system was replicated and these conditions gave the lowest Ð material of those 
studied while still giving a molecular weight above the renal clearance threshold. Unfortunately 
the co-solvent mixture has a boiling point of 58 °C preventing direct comparison with previous 
systems. Polymer P13 was synthesised to facilitate a comparison (DMF-dioxane at 58 °C) and 
expectedly shows a decrease in molecular weight, compared to identical reactions at higher 
temperature (P5 – P7), owing to a reduced rate of polymerisation. Additionally, the Ð of P13 
was higher than P11 further highlighting the negative impact of the DMF-dioxane system. 
While it is possible to increase the temperature of the acetone-methanol system to 70 °C by 
heating in a sealed vessel, safety considerations outweighed the value of this experiment. 
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Increasing reaction time to counteract the lower polymerisation rate was also considered (P12). 
While higher molecular weights were achieved, as expected, control by the RAFT groups could 
not be maintained and Ð also increased. As such alternative solvent systems involving alcohol-
ketone combinations were considered. MEK and IPA were selected as readily available, higher 
boiling point, analogues of acetone and methanol. The resulting polymers (P14 & P15) 
exhibited higher Ðs than polymers synthesised in the original DMF-dioxane system (P5 – P7). 
IPA-MEK co-solvent system is much less polar than the acetone-methanol co-solvent system 
which may reduce the availability of the monomer during pre-equilibrium and early 
propagation steps. As a result further investigation of the IPA-MEK solvent system was ceased 
in favour of modification of the RAFT moiety. 
 
Prior unpublished work in our group has shown that the hydrophobic thiocarbonylthiol moiety 
of 29a associates with the hydrophobic structure of PCL. Many of the amphiphilic block 
copolymers reported in the literature are based on PEG, a rather amphiphilic molecule itself, 
however our system is based on the extremely hydrophilic PHPMA. Our design, even when 
based on existing systems, is more challenging synthetically due to the marked difference in 
properties between the polymer blocks. Therefore, the use of a hydrophobic RAFT-agent seems 
to limit its availability to hydrophilic HPMA in the initial stages of the reaction, resulting in 
wide dispersity in the final product. In order to circumvent this, macro-CTA 29b was 
synthesised using the RAFT agent 1-succinimidyl-4-cyano-4[N-methyl-N-(4-
pyridyl)carbamothioylthio]pentanoate  28b. This macro-CTA is more polar than that of 28a as 
a result of the pyridine ring. This polarity can be further enhanced by protonation of the pyridyl 
moiety by addition of pTSA. Therefore, it was expected that encapsulation of the RAFT agent 
within a hydrophobic polymer would be unfavourable and thus it would remain more readily 
accessible to a hydrophilic monomer. 
 
The synthesis of 29b was achieved by following the same procedure used in synthesising 
macro-CTA 29a (Scheme 2.3). As 28b already contains an activated ester moiety, the reaction 
was initially catalysed by the presence of TEA and DMAP. However, in the initial reactions 
incomplete esterification was observed after 1 week which was reasoned to be the result of 
ester hydrolysis to yield the terminal carboxylic acid moiety. To drive the reaction to 
completion, without repeated addition of the expensive RAFT agent 28a, DCC was also added 
to the reaction mixture. 
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Figure 2.6 – 1H NMR spectrum of the macro CTA 29b 
 
Repeating the reaction with the addition of DCC, the degree of esterification was found to be 
95% from the 1H NMR spectrum (Figure 2.6). Again, while the reaction was not quantitative, 
additional esterification was reasoned to be cost-inefficient and as previously discussed 
compares extremely well against the few reported cases in the literature. While synthesis of the 
macro CTA 29b was shown to be successful, the resulting triblock copolymers (P16 & P17) 
did not support the original hypothesis regarding the availability of the RAFT agent and its 
effect on Ð  as, in DMF-dioxane (P12), the Ð of 2.31 was comparable to that with macro CTA 
29a under the same conditions (P5 – P7). A reduction in the polymerisation rate, evidenced by 
the comparatively shorter chain length, was also observed. However, in acetone-methanol 
(P13), both the molecular weight and Ð were comparable to that for P7. These data are 
rationalised by the consumption of pTSA in the formation of quaternary ammonium cations 
leading to incomplete protonation of the 4-pyridyl moiety; the protonated form of 29b is known 
to favour the polymerisation of MAMs such as HPMA.[215] For polymer P13 the absence of 
amines meant the addition of 1.2 eq. of pTSA was sufficient to protonate 29b and afford control 
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similar to P7. While P17 appears to show an improvement on P16, dead-chains were observed 
to form during the reaction as evidenced by the high molecular weight shoulder in the RI SEC 
trace at 15.8 mL retention volume (appendix 8.7).  
 
Of the discussed materials, P11 most closely exhibits the properties desired in the final product. 
As a result, the capability for self-assembly and the size of particles formed was investigated 
by dynamic light scattering (DLS). 
 
 
Figure 2.7 - Size distribution by a) intensity and b) number as measured by DLS for P11. 
Measurements were made in triplicate 
The polymer was dissolved in DMSO to a concentration of 10 mg mL-1 before addition to water 
under agitation to give a final concentration of 1 mg mL-1. Analysis of the sample by DLS 
showed a multimodal distribution when assessing the sample by the intensity of scattered light  
(Figure 2.7a) suggesting the presence of large particles/aggregates. However, assessing the 
sample by the number distribution (Figure 2.7b) shows the sample is comprised almost entirely 
of small particles, with an average particle size of 44 nm, and very few large 
particles/aggregates are present which contribute to the observed multimodal intensity 
distribution. The fact that so few particles contributed so heavily to the intensity distribution is 
because the intensity of scattering is proportional to the hydrodynamic diameter raised to the 
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6th power. Analysis of the correlation function, which measures the change in signal intensity 
between moving particles and has a sigmoid distribution for spherical particles undergoing 
Brownian motion, shows a sigmoid distribution and good agreement between the independent 
analyses (Figure 2.8). 
 
Figure 2.8 – Cumulative correlation functions of P11 as measured by DLS 
Overall, the method used to synthesise P7 presents an improvement on a similar system 
presented by Lele and Leroux, however did not provide the level of control expected for a 
RAFT polymerisation from a macro-CTA. The ‘grafting-from’ method provides a useful route 
to the synthesis of ABA-type triblock copolymers, even from materials with a marked 
difference in properties between the polymer blocks, in a one-pot fashion, however significant 
optimisation of the reaction conditions were required to achieve this in this case. 
 
2.2.3 Synthesis and Optimisation of PHPMA-b-PCL-b-PHPMA Triblock 
Copolymers via ‘click’ methodologies 
 
The importance of synthesising well defined polymers for use in biomedical applications has 
been highlighted throughout the literature. While the previously described ‘grafting-from’ 
methods are an improvement on similarly reported systems, they fall short of the very well 
defined materials desired for therapeutics (Ð ≤ 1.20). As discussed, degradation of RAFT 
functionality and the suitability of solvents limit these methods’ potential applications. A 
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natural next-step from this work therefore was to synthesise the constituent polymers separately 
before joining them in a final “click” reaction step. In chapter 1, the current uses of thiol-ene 
‘click’ reactions were considered as well as the ease of converting terminal RAFT groups to 
thiols and their subsequent use in the thiol-ene or thiol-Michael click reactions. Based on this 
review, the post-polymerisation modification of PHPMA was investigated and is discussed 
below. 
 
2.2.3.1 Synthesis of Telechelic Polymer Precursors 
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Scheme 2.4 – Post-polymerisation modification of PHPMA to give PHPMA-SH 
 
Conversion of the terminal RAFT groups to thiols was achieved by aminolysis of the 
dithioester group by n-butylamine (Scheme 2.4). Quantitative conversion was achieved and 
highlighted by the absence of phenyl protons (7.9 – 7.4 ppm) in the 1H NMR spectrum (Figure 
2.9a). 
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Figure 2.9 – a) 1H NMR spectrum of PHPMA-SH; b) RI trace of PHPMA-SH by triple detection GPC 
Analysis by GPC showed a unimodal peak in the RI trace suggesting the absence of any 
disulphide coupling products. 
 
With thiol-terminated PHPMA in hand, synthesis of its proposed reaction partner for the 
triblock copolymer, vinyl terminated PCL, began. Esterification of PCL-diol with maleic 
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anhydride or methacrylic anhydride afforded homotelechelic polymers, herein referred to as 
PCL-MA and PCL-MeA respectively (Scheme 2.5). As with the synthesis of macro-CTA 29, 
quantitative modification of both terminal hydroxyl groups was critical and assessed by 1H 
NMR spectroscopy (Figure 2.10). 
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Scheme 2.5 – Synthesis of vinyl terminated homotelechelic PCL 
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Figure 2.10 – a) 1H NMR spectrum of PCL-MeA b) 1H NMR spectrum of PCL-MA 
 
For PCL-MA the degree of esterification was calculated by comparison of the integrals g and 
(h + i) according to the equation degree of esterification = (g / (h + i)) * 100. The degree of 
esterification for PCL-MeA was similarly calculated by comparison of the integrals g and i 
according to the equation degree of esterification = ((g / 2) / i) * 100. The degree of 
esterification of both polymers used in the subsequent thiol-ene reactions were found to be ≥ 
95%.  
 
2.2.3.2 Thiol-Ene ‘Click’ Reaction 
By definition ‘click’ methodologies are efficient, high yielding and should proceed with 
equimolar quantities of starting materials thus, 2 equivalents of PHPMA-SH were added to 
PCL-MA for the polymer-polymer radical thiol-ene reaction (Scheme 2.6). 
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Scheme 2.6 – Strategy for the synthesis of PHPMA-b-PCL-b-PHPMA via thiol-ene coupling 
 
The product was first purified by dialysis in THF using a 6-8 kg mol-1 MWCO membrane to 
remove any unreacted PCL-MA while retaining the block copolymer. The dialysate was 
subsequently changed to water after 2 days and the product isolated by lyophilisation. The 
resulting polymer (P18) was analysed by 1H NMR spectroscopy (Figure 2.11). 
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Figure 2.11 - 1H NMR spectrum of P18  
 
No protons associated with PCL could be assigned to the spectrum of P18, only protons from 
31 were present, suggesting no conjugation had taken place and 32 was completely removed 
during dialysis. PCL-MA was initially chosen to reduce steric hindrance to the click reaction 
by disfavouring interactions between the bulk hydrophobic polymer and ionisable terminal 
carboxylic acid groups. However, the thiol-ene mechanism favours addition to electron rich 
alkenes, which is reduced in this case due to conjugation to adjacent carbonyl groups.[216] In 
addition, mechanistic studies have shown that reversible thiyl addition initiates fast cis-trans 
isomerism which competes with hydrogen abstraction from thiols (Scheme 2.7). The authors 
found the rate of thioether formation to be significantly affected by this reaction.[217] The 
combination of these factors was thought to contribute to the reduced efficiency of the polymer-
polymer conjugation in this case. 
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Scheme 2.7 – Mechanism of radical mediated cis-trans isomerism[217] 
Conjugation with the comparatively more electron rich PCL-MeA was subsequently attempted. 
Both thermal (AIBN) and photo initiation (DMPA) methods were tested, yielding P19 and P20 
respectively, and the products isolated as per P18. Thermal initiation produced no detectable 
conjugated product, with 1H NMR spectrum virtually identical to P18. However, 1H NMR 
spectroscopy analysis of the photoinitiated reaction (P20) showed signals associated with the 
repeat units of PHPMA, at 7.2, 4.7, 3.7, 2.9 and 1.8 – 0.7 ppm, and PCL at 4.0 ppm. This 
difference is not unexpected as thermal initiators have been reported to be less efficient with 
regards to the number of free radicals produced than photoinitiators.[106] The ratio of PCL : 
PHPMA signals was found to be 1 : 80 (Figure 2.12a) yet, given the Mn,NMR values of the 
reactant polymers, the expected ratio for 100% conversion was calculated to be 1 : 9. A new 
high molecular weight peak was found in the RI trace (Figure 2.12b), suggesting only a fraction 
of the desired thiol-ene reactions occurred. The shoulder was unlikely to be disulphide coupled 
PHPMA due to the addition of TCEP to the reaction mixture. Incomplete addition would 
expectedly leave vinyl signals in the range 6.5 – 5.0 ppm, however complete disappearance of 
vinyl signals was observed. Koo et al. report consumption of vinyl moieties via bimolecular 
termination reactions in competition with the desired chain transfer product.[218] The low 
conjugation efficiencies and disappearance of vinyl signals reported here mirror their 
observations.  
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Figure 2.12  – a) 1 H NMR spectrum and b) RI trace of P16, in black, and PHPMA-SH SM, in red. 
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While conjugation was observed under the described method, complete conjugation would 
likely require a large excess of thiol (as suggested by Koo et al.) and as such it could not be 
considered a “click” reaction according to previously outlined definitions.[41,42] While efficient 
polymer-polymer conjugation by thiol-ene addition is rare in the literature, Fairbanks and co-
workers highlight the importance of careful selection of reacting functionalities. They found 
near-quantitative coupling of norbornene terminated PEG with PEG-SH under a range of 
conditions.[219] The coupling they describe is between two polymers with similar polarity; 
utilises a primary thiol, which have been shown to favour conjugation;[220] and releases ring-
strain, which the authors suggest was a significant driving force in the reaction.[219] 
Comparatively, the reaction presented here occurs between polymers with significantly 
different polarities; utilises a tertiary thiol; and adds to a methacrylate functionality. The 
methacrylate group is likely poorly suited to conjugation of this type due to the formation of 
stable tertiary alkyl, carbonyl-conjugated radicals after addition.[221] Additionally, alkenes with 
allylic alkyl moieties are known to undergo radical induced isomerism as a result of thiyl 
initiated hydrogen abstraction (Scheme 2.8).[222,223] While most examples in the literature focus 
on abstraction from secondary carbon atoms, there is precedent for abstraction from 
methacrylate’s α-methyl group, up to 29%, in the presence of t-butoxy radicals.[224,225] 
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Scheme 2.8 – Proposed mechanism for the radical mediated “isomerism” of terminal methacrylates 
and formation of tertiary radicals. 
Given the low concentration of reactive end-groups inherent to polymer-polymer conjugation, 
the stability of tertiary radicals and potentially inhibitory side reactions, it is unsurprising that 
efficient thiol-ene addition was not achieved with the current materials. Alternative click 
reactions were therefore considered. 
 
2.2.3.3 Hetero-Diels-Alder ‘Click’ Reaction 
 
The utility of the hetero-Diels-Alder reaction was previously reviewed in section 1.3.2.1. While 
the work by the Barner-Kowollik group utilised electron deficient dithioesters, for consistency 
with other work in this thesis it was decided to attempt the RAFT-HDA reaction using RAFT 
agent 25. Synthesis of RAFT terminated homopolymers has already been discussed (section 
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2.2.1.). While more electron rich than the RAFT agents used by Barner-Kowollik and co-
workers, it was reasoned that by utilising the increased reactivity of the cyclopentadienyl group 
it would be possible to trade off against the change in RAFT agent. To test this hypothesis a 
model reaction was set up: freshly cracked cyclopentadiene was added to the RAFT agent 25. 
After 1 h the characteristic pink colour had disappeared. Analysis by UV-Vis showed the 
characteristic dithioester peak (λmax = 513 nm) had almost completely disappeared (reduction 
of λmax from 1.82 to 0.05 Abs), suggesting destruction of the chromophore by successful HDA 
coupling. With this promising result on the model, work moved on to the synthesis of 
cyclopentadienyl terminated PCL (PCL-Cp). 
 
End-group modification to give terminally functionalised cyclopentadienyl polymers has 
previously been achieved by nucleophilic substitution of alkyl bromides with cyclopentadienyl 
anions.[86] Based on this, PCL-diol 27 was first esterified with 2-bromopropinyl bromide 
(BPiB) to give a PCL-dibromide (PCL-Br). 
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Scheme 2.9 – Synthesis of homotelechelic PCL-Br  
 
The product was isolated and purified by three-fold precipitation in cold methanol to yield 
homotelechelic PCL-Br. The success of the reaction was confirmed by 1H NMR spectroscopy 
which showed the presence of new alkyl protons at 4.38 – 4.33 ppm and 1.83 – 1.82 ppm which 
corresponds to the alpha and beta carbons of BPiB respectively. The degree of esterification 
was found to be 95% by comparison of the integrals g and h according to the equation; degree 
of esterification = ((g / 4) / (h / 6)) * 100 (Figure 2.13).  
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Figure 2.13 – 1H NMR spectrum of PCL-Br 
The newly synthesised PCL-Br was subsequently reacted with sodium cyclopentadienylide 
(NaCp) in order to substitute the terminal bromine atoms for cyclopentadienyl end-groups. 
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Scheme 2.10 – Substitution of PCL-Br with sodium cyclopentadienylide 
After reaction with NaCp for 1 hour the product was isolated by precipitation in cold methanol 
however no precipitation occurred. The methanol was removed under reduced pressure and the 
resulting yellow oil analysed by 1H NMR spectroscopy and GC-MS. 
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Figure 2.14 – a) 1H NMR spectrum and b) GC-MS of product isolated from the reaction of PCL-Br 
with NaCp 
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1H NMR spectroscopy showed several broad, poorly defined peaks with chemical shifts 
equivalent to that of the PCL-Br starting material. Analysis by GC-MS showed one major peak 
in the chromatogram with a mass spectrum containing peaks at m/z 115 and 97 which correlate 
to the repeating unit of PCL. These results are attributed to undesired side reactions of the 
cyclopentadienyl anion with ester moieties causing degradation of the PCL backbone. In an 
attempt to reduce the frequency of these side reactions the experiment was repeated but the 
reaction time reduced to 30 min at -78 °C by cooling in an ethanol-dry ice bath. After reaction 
the product was isolated by precipitation in cold methanol and 10% of the starting mass of 
polymer was recovered. Analysis of the polymeric material by 1H NMR spectroscopy showed 
the presence of signals that were attributed to cyclopentadienyl moieties (Figure 2.15). 
 
Figure 2.15 – 1H NMR spectrum of PCL-Cp from altered reaction conditions (30 min at -78 °C)  
 
The integral ratio of cyclopentadienyl protons to those in the ethylene bridge of PCL suggested 
only 28% of the bromide end-groups had been substituted for cyclopentadienyl groups. 
Backbone ester groups outnumber terminal bromide moieties therefore it is much more likely 
that side reactions leading to backbone degradation occur before the desired substitution. It was 
therefore concluded that NaCp was a poor choice of reagent for synthesising cyclopentadienyl 
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terminated polyesters. An alternative strategy was proposed where the cyclopentadiene ring 
would be substituted to contain a carboxylic acid group that could later be conjugated to PCL-
diol via the previously established Steglich esterification. 
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Scheme 2.11 - Synthesis of carboxylic acid modified cyclopentadiene ring 
Scheme 2.11 shows the synthetic strategies tested for the synthesis of the ring-substituted 
cyclopentadiene 40. After addition of around half the required amount of NaCp precipitation 
was observed to occur within the reaction flask. The precipitate was attributed to the formation 
of NaBr and the salts 36 and 37. Attempts to dissolve the organic salts in dioxane, chloroform, 
DCM, dioxane-DMSO, DMSO, DMF and acetonitrile were all unsuccessful. In order to 
prevent formation of a salt a protected ester, t-butyl bromoacetate, 38 was purchased and used 
in subsequent reactions instead. A t-butyl protecting group was selected for its ease of removal 
in acidic conditions and steric bulk which would help reduce side reactions with the ester.  
 
The presence of the t-butyl group allowed for successful addition of all the NaCp, which was 
allowed to stir for 3 h at -78 °C. After quenching with methanol the resulting product was 
isolated and purified as a clear colourless liquid (98%). Initial attempts to work-up the product 
included evaporation of solvent at increased temperature, however, 1H NMR spectroscopy of 
this material showed a range of broad multiplets (appendix 8.4) which were concluded to be a 
mixture of the dimerised forms of 39. In order to prevent intermolecular Diels-Alder reactions 
the work-up was modified to have solvent evaporated at room temperature and at much lower 
pressures. 
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Figure 2.16 – 1H NMR spectrum of (1/2)-tert-butyl-methanoate-1,3-cyclopentadiene 
 
Mironov et al. investigated the isomerisation of 5-methyl cyclopentadiene rings and observed 
they underwent sigmatropic 1,5-hydrogen shifts at room temperature.[226] They found the 
resulting 1-isomer exists in equilibrium with the 2-isomer (ca. 50% of each isomer) and < 5% 
of the 5-isomer was present. These results are mirrored in the product whose 1H NMR spectrum 
is shown in Figure 2.16. Analysis by GC-MS showed only a single peak in the chromatogram 
and m/z spectrum with peaks at 124 [NaOCOtBu]+, 79 [C6H7]+ and 57 [tBu]+ which 
corresponded to the product 39. 
 
Deprotection of the t-butyl group was initiated by addition of trifluoroacetic acid (TFA) to 39. 
After isolation the product was analysed by GC-MS and 1H NMR spectroscopy. A broad 
chromatographic peak was observed around 12.5 min and m/z data correlated to the desired 
product. The abundance of the m/z peak at 57 was significantly decreased in comparison to 
that for the starting material. This was expected as m/z = 57 corresponds to the mass of the t-
butyl group. However, analysis by 1H NMR spectroscopy resulted in a complex spectrum of 
O
O
a
a
a
b
c
g
de
f
CHCl3 
a 
d 
b 
c + e + f + g 
96 
 
multiplets which suggested the presence of many compounds, contradicting the GC-MS 
results. It is well known that cyclopentadiene must be freshly prepared from its dimer by 
thermal cracking at ~ 170 °C in an rDA reaction. It is likely that (1/2)-tert-butyl-methanoate-
1,3-cyclopentadiene 40 undergoes a similar intermolecular Diels-Alder reaction to yield a 
variety of dimerised ring systems. Additionally, both the purified product and starting material 
appeared as clear colourless liquids, while in the presence of TFA, the solution turns dark 
yellow-green. It has been known for a long time that cyclopentadiene can undergo cationic 
polymerisation in the presence of strong acids such as TFA.[227,228] The extended conjugated 
pi-system results in the coloured nature of the materials which has been reported as yellow or 
brick red, although dark blue and black are also possible if cationic species are also present. 
Additionally, Sitzmann and co-workers reported the TFA catalysed dimerization of a mixture 
of 1,4-di-tert-butyl-1,3-cyclopentadiene 41 to give (E,E)-3,3′,5,5′-tetra-tert-butyl-4,5,4′,5′-
tetrahydro-1,1′-bis(cyclopentadienylidene) 43 (Scheme 2.12), though the compound was not 
reported to be coloured.[229] 
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Scheme 2.12 – Acid-catalysed dimerization of di-tert-butyl-1,4-cyclopentadiene 
It is therefore suggested that acid-catalysed polymerisation of (1/2)-tert-butyl-ethanoate-1,3-
cyclopentadiene 40  is responsible for the observed colour change upon addition of TFA and 
complex 1H NMR spectrum. The discrepancy in 1H NMR spectroscopy and GC-MS data is 
attributed to the difference in conditions required to conduct these analyses. While 1H NMR 
spectroscopy was conducted under standard conditions, GC-MS samples are heated under 
vacuum, in order to achieve atomisation, which is sufficient to crack the dimerised rings giving 
the appearance of 40. Attempts to crack 40 by heating to 200 °C at atmospheric pressure were 
unsuccessful, the starting material became charred before any distillate could be collected. 
Additional attempts to crack the material under reduced pressure were also unsuccessful. Due 
to time constraints related to the project, this work was concluded at this point. 
 
2.2.3.4 Copper Azide-Alkyne ‘Click’ Reaction 
As discussed previously (Chapter 1), the CuAAC reaction has been established as a key tool in 
the area of polymer conjugation. Its major drawback is the use of toxic copper (I) metal salts 
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which necessitate additional purification steps after synthesis. The alternative to this is the use 
of expensive ring-strained alkynes which forgo these catalysts. In an effort to reduce costs, in 
this work the CuAAC reaction was chosen for investigation, though it could be modified for 
use with ring-strained alkynes. 
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Scheme 2.13 – Schematic outline for the formation of PHPMA-b-PCL-b-PHPMA copolymers via the 
CuAAC reaction 
 
Initially, PCL-diol was modified with 4-pentynoic acid 41 via the previously established 
Steglich esterification method (Scheme 2.13, reaction 1). The degree of esterification was 
analysed by 1H NMR spectroscopy and found to be ≥ 95% (appendix 8.5), any samples less 
than this underwent additional esterification until determined to be above the threshold.  
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With the homotelechelic PCL-alkyne in hand, PHPMA required modification to contain a 
terminal azide functionality (Scheme 2.13). Firstly, 3-azidopropanol 44 was prepared by 
refluxing 3-bromopropanol 43 with sodium azide (Scheme 2.13, reaction 2). The product was 
isolated as a colourless oil (73%). Successful modification of the starting material was 
determined by a shift in -CH2 protons of 3-bromopropan-1-ol from 3.74, 3.50 and 2.05 ppm to 
3.74, 3.44 and 1.83 ppm in the 1H NMR spectrum of 3-azidopropan-1-ol (Figure 2.17). 
Additionally, a new peak at 2101 cm-1, corresponding to the azide stretching frequency, was 
observed in the IR spectrum. 
 
 
Figure 2.17 – a) 1H NMR spectrum of 3-azidopropan-1-ol 
 
Terminal carboxylic acid groups in ACVA were subsequently coupled with 44 to yield the 
azido-ester 45 (Scheme 2.13, reaction 3). In order to maximise the success of post-
polymerisation modification of PHPMA with 45, near quantitative esterification was required. 
Bi-functional azide-terminated ACVA 45 was separated from the starting material and mono-
functionalised ACVA via chromatography. The purity of 45 was assessed via 1H NMR 
spectroscopy by comparing the integral of propyl –CH2 protons from 44 (4.2 ppm) to the 
methyl protons originating from ACVA (1.7 ppm, Figure 2.18). The degree of esterification 
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was calculated to be 96%. The apparent 4 % loss in esterification is likely the result of error 
derived from NMR spectroscopy.  
 
Figure 2.18 – 1H NMR spectrum of ACVA-N3 
 
Post-polymerisation modification of PHPMA was achieved by heating the polymeric starting 
material 26 to 70 °C in the presence of 10 eq. of the diazo-radical initiator 45 (Scheme 2.13, 
reaction 4). Analysis of the product 46 by 1H NMR spectroscopy showed complete loss of 
phenyl signals relating to the terminal RAFT group. In addition, IR-spectroscopy showed the 
presence of a new peak at 2102 cm-1 (Figure 2.19b) which corresponds to the azide 
functionality of 3-azidopropanol.  
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Figure 2.19 – a) 1H NMR spectrum and b) IR spectrum of PHPMA-N3 46 
 
Synthesis of PHPMA-b-PCL-b-PHPMA via a polymer-polymer CuAAC reaction was 
subsequently attempted (Scheme 2.13, reaction 5). 2.1 eq. of PHPMA-N3 46 were added to 
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dialkynyl-PCL 42 and CuBr as the CuI source. PMDETA was added as an accelerating ligand 
and to protect  CuI from oxidation. After 6 h the reaction was stopped and the product isolated 
in 70% yield. Excess copper was removed in a 2-step process. During dialysis, EDTA was 
added to complex with copper and facilitate movement into the dialysate. After lyophilisation 
the product had a slight green colour, indicative of the presence of copper (II), and so was re-
dissolved in water and passed through a column of basic alumina. The collected filtrate was 
lyophilised again to yield the product as a white powder (63%). Analysis by GPC (Figure 2.20) 
showed a bi-modal peak in the RI trace, suggesting a mixture of starting polymer and higher 
molecular weight block copolymer. 
 
Figure 2.20 – RI trace of PHPMA-b-PCL-b-PHPMA (6 h) 47, in black, and PHPMA-N3 SM, in red. 
 
Without software capable of deconvolution of the data collected by SEC, it is difficult to 
provide a definitive summary of the properties of the conjugated material. However, the peak 
at 19.7 mL is concurrent with the trace for the azide terminated PHPMA highlighting the 
presence of unreacted starting material. The new peak at 18.9 mL was thought to be di- and/or 
tri-block copolymers of PHPMA and PCL which would appear at a lower retention volume 
due to the increased hydrodynamic volume. In order to check that coupling had successfully 
occurred, and that the new peak was not simply the result of aggregation of PHPMA and PCL, 
the starting polymers were mixed in ratios appropriate for the reaction and immediately 
analysed by GPC. A unimodal RI trace was observed and it was therefore concluded that the 
bimodal peak was the result of successful, yet incomplete, CuAAC coupling.  
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In order to achieve complete conjugation the reaction was repeated, increasing the reaction 
time from 6 h to 24 h. The same purification steps were undertaken and the product isolated as 
a white powder. Analysis by GPC once again showed a bimodal peak in the RI trace however 
the area of the curve related to the high molecular weight material had increased by 34% 
relative to the lower molecular weight peak (Figure 2.21). Furthermore, the peak between 18.0 
– 20.0 mL retention volume appears to dip around 19.0 mL, which was not observed in the 
sample reacted for 6 h. This suggests the formation of both di- and triblock material at extended 
reaction times, which is overlapping within the 18.0 – 20.0 mL region. 
 
Figure 2.21 – RI trace of PHPMA-b-PCL-b-PHPMA (24 h) 47 in black, and PHPMA-N3 SM, in red. 
 
Increasing the reaction time had increased the fraction of polymer that had successfully 
undergone conjugation however some unreacted polymer still remained. Unlike the previously 
discussed thiol-ene reaction it has been shown that CuAAC type reactions are capable of 
facilitating polymer-polymer conjugation between PHPMA and PCL. Due to time constraints, 
this aspect of the project was ceased however future work could develop this as successful 
conjugation method for synthesising well defined PHPMA-b-PCL-b-PHPMA block 
copolymers. Other groups in the literature have found success increasing reaction times to as 
long as 48 h[63] or by increasing the concentration of CuI such that the rate becomes zero-
order.[230] Testing and combining the effects of these parameters would ideally result in a 
methodology that results in complete conjugation of the polymeric starting materials.   
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2.3 Chapter Summary 
 
The work in this chapter builds upon the synthesis of PCL-PHPMA based amphiphilic block 
copolymers reported in the literature. A method for achieving near quantitative esterification  
(≥ 95% esterification as determined by 1H NMR spectroscopy) of PCL-diol to form a range of 
homotelechelic materials (RAFT macro-CTA and alkenes using an acid coupling reagent) has 
been optimised. The method reported here compares extremely well with similar syntheses 
reported in the literature. ABA-type block copolymers were synthesised under a range of 
conditions. When building from a central macro-CTA, the solvent system was shown to play a 
significant role in the successful RAFT-mediated polymerisation in terms of molecular weight 
and Ð. Acetone-methanol was observed to produce lower dispersity chains than any other 
solvent system and mirrors the success seen by the Kopeček group. By utilising RAFT 
polymerisation, higher molecular weights and narrower dispersity indices were achieved 
compared to PHPMA-b-PCL-b-PHPMA triblock materials previously reported by Lele and 
Leroux. [199]  
 
Investigation into the viability of polymer-polymer click reactions were considered with 
regards to further refinement of the copolymer’s properties. The utility of thiol-ene click 
reactions for the conjugation of polymers with ‘small molecules’ is well represented in the 
literature, however polymer-polymer conjugation requires much more stringent selection of 
functionalities and reaction conditions. Thermally decomposed AIBN was found to be 
ineffective for initiating polymer-polymer conjugation as analysis by 1H NMR spectroscopy 
only displayed signals attributable to PHPMA and no signals associated with the PCL starting 
material were identified. Photoinitiation with DMPA showed signals attributed to both 
PHPMA and PCL in the 1H NMR spectra of the products, however the ratio of PHPMA : PCL 
signals was found to be 1 : 80. For 100% coupling efficiency a PHPMA : PCL ratio of 1 : 9 
was expected, suggesting the reaction yielded only a fraction of the desired conjugation events. 
The presence of side reactions, including reversible thiol addition to the alkene; allylic 
hydrogen abstraction and bimolecular termination, as well as steric factors, with regards to 
tertiary thiyl and alkyl radicals, compound the inherently low end group concentrations to 
significantly reduce the overall reaction efficiency. 
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The potential for HDA coupling of cyclopentadienyl and dithiobenzoate terminated polymers 
was highlighted by disappearance of the characteristic dithioester peak in the UV-Vis spectrum. 
However, the cyclopentadienylide anion causes significant backbone degradation to polyesters 
and should therefore be introduced via a second chemical functionality. Synthesis of (1/2)-tert-
butyl-ethanoate-1,3-cyclopentadiene was simple and highly efficient. Removal of the t-butyl 
protecting group induced intermolecular DA reactions which yielded a complex mixture of 
products that could not be separated by distillation, even under reduced pressure. Future work 
should look to develop alternative conjugation strategies such as the use of nickelocene which 
has been used as a mild reagent for the introduction of cyclopentadienyl functionalities.[231] 
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Scheme 2.14 – Potential scheme for the introduction of terminal cyclopentadienyl moieties under mild 
conditions. Strategy developed based on the scheme presented in [231] 
 
Terminal azide functionality was introduced to PHPMA by heating in the presence of a large 
excess of azide-terminated ACVA. CuAAC reaction with homotelechelic alkyne-terminated 
PCL resulted in partial coupling of the polymers. Increasing reaction times drove the coupling 
reaction towards completion but a significant proportion of starting polymer remained. Future 
work should consider further increasing reaction times, temperature and concentration of the 
copper catalyst.  
 
There is scope for further work investigating the efficiency of both covalent and non-covalent 
drug association. To increase molecular weight is to also increase in vivo circulation, 
comparing the polymers synthesised here to other similar systems would add to the library of 
available materials. While PCL and PHPMA have individually been shown to be benign, their 
combination should not be assumed to be. A systematic study of the toxicity and 
immunogenicity of the copolymers should also be undertaken. 
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Overall, grafting-to methods were found to be ineffective in the synthesis of PHPMA-b-PCL-
b-PHPMA triblock copolymers. Grafting-from methods however were successfully performed 
using a homotelechelic dithiobenzoate terminated PCL macro-CTA with near quantitative 
incorporation of functional RAFT end-groups. Optimised reaction conditions were found to be 
molar ratios of 1 : 238 : 0.29 of macro-CTA : HPMA : AIBN for 16 h at 58 °C in an acetone-
methanol (2 : 3) solvent system which yielded an amphiphilic triblock copolymer (Mn (SEC) 
29,432 g mol-1 and Ð 1.41) that was observed to self-assemble into nanoparticles (44 nm, 
number-distribution size as measured by DLS) upon addition to water. This method allows for 
the synthesis of PHPMA-b-PCL-b-PHPMA triblock copolymers with higher molecular weight 
and, simultaneously, lower dispersity than materials reported previously by Lele and 
Leroux.[199] These materials have potential as drug-delivery platforms which do not suffer from 
the ABC phenomenon commonly observed with PEG-based materials.[4]  
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3 Synthesis of Amphiphilic Star-type Block 
Copolymers 
 
3.1 Introduction 
 
This chapter builds upon the design and synthesis of amphiphilic block copolymers previously 
discussed in Chapter 2. While PHPMA-b-PCL-b-PHPMA copolymers were shown to undergo 
aqueous self-assembly, such systems disassemble below their critical micelle concentration. It 
is possible that such conditions are met during biocirculation resulting in undesired 
disassembly and uncontrolled payload release which, worst case, may harm the patient or, best 
case, reduce the efficacy of the treatment. It is therefore desirable to explore architectures that 
do not undergo concentration dependent disassembly, such as dendrimers or hyperbranched 
polymers to avoid these issues. 
 
3.1.1 Dendrimers 
 
Dendrimers are a class of polymers comprised of branching, tree-like units originating from a 
central core. They are typically synthesised by successive addition to surface functionalities in 
a step-wise fashion (Scheme 3.1a) though convergent synthesis, by coupling dendron halves, 
is also common (Scheme 3.1b).[232] Dendrimers are characterised in terms of generations where 
the addition of a new layer, and subsequent increase in the number of surface functionalities, 
constitutes a new generation (G). Dendrimers should exhibit Ð = 1, as all macromolecules of 
the same generation are identical, and as such should provide more consistent 
pharmacokinetics.  
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Scheme 3.1 – Schematic dendrimer synthesis via a) divergent and b) convergent routes 
 
High generation dendrimers (≥ G5) have been shown to exhibit reduced renal clearance in 
comparison to linear polymers of equivalent molecular weight.[233] Sadekar et al. attributed 
their findings to reptation of linear polymers (Figure 3.1) while dendrimers underwent 
unfavourable, strain-inducing deformation to pass through the glomerular membrane. 
Linear random coil polymers may
orient one end of  the polymer chain 
into the pore and reptate through
Polymer with a globular conformation 
may deform to pass through a pore
 
Figure 3.1 – Elimination of linear vs. dendritic polymers of equivalent molecular weight as proposed  
by Sadekar et al. [233] 
 
Creating high generation dendrimers with large numbers of surface functionalities has 
commonly been the yard-stick by which successful dendrimer synthesis has been measured. 
Such syntheses are typically very long, requiring multiple deprotection-addition steps and this 
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has become a major criticism of the field. However, the use of orthogonal conjugation 
strategies has reduced the need for protecting groups, and thus deprotecting steps, improving 
the speed of dendrimer synthesis.[234] For example, by combining the orthogonality of thiol-
ene and CuAAC coupling reactions Antoni et al. synthesised a 6th generation dendrimer in only 
6 steps, citing ~3 h to synthesise and purify each generation.[235] While such strategies have 
improved the accessibility of synthesising dendrimers, their adoption into commercial 
therapeutics and medical devices has been slow compared to other polymer systems.[236,237] 
One explanation for this might lie in dendrimers’ relatively poor ability to act as drug carriers. 
Mody et al. compared the drug loading and cytotoxicity of polymeric dendrimers, liposomes 
and nanoparticles carrying docetaxel.[238] Dendrimers exhibited the lowest drug loading (ca. 28 
%) compared to liposomes (ca. 49 %) and nanoparticles (ca. 62 %) while IC50 values, of the 
drug loaded carrier, were comparable between samples, if not slightly improved for 
dendrimers. However, physical drug encapsulation under-utilises the high number of surface 
functionalities, a key feature of dendrimers. Although a direct comparison of physical versus 
chemical drug loaded dendrimers has not been reported, Kaminskas et al. did report lower 
cytotoxicity against target cancer cells of covalently bound doxorubicin-dendrimer complexes 
compared to PEGylated lysosomes encapsulating the drug.[239] Similar antitumor efficacy was 
found between the samples. These results question whether the extended synthesis of 
dendrimers outweighs the small reductions in cytotoxicity. 
 
To better utilise the high number of dendritic surface functionalities of dendrimers, Zhang et 
al. synthesised a series of surface decorated 5th generation poly(amidoamine) dendrimers (G5 
PAMAM) with acetyl, hydroxyl and carboxyl functional groups.[240] Doxorubicin was bound 
to the surface functionalities, each of which exhibited unique, pH dependent release profiles. 
Additionally, direct surface decoration of G5 PAMAM with targeting folic acid groups and the 
anti-cancer drug methotrexate was  achieved in a one-pot synthesis by Zhang et al..[241] As 
expected, the polymer-drug conjugate exhibited improved targeting and cytotoxic potency 
compared to free methotrexate. While these studies highlight the potential of dendritic surface 
functionalities, they ultimately betray the well-defined and precisely characterised nature for 
which dendrimers are prized. Analysis of G5 PAMAM dendrimers by HPLC showed the 
heterogenous nature of the dendrimers’ surface when functionalised in a statistical manner.[242] 
However, Lee et al. describe a method for the synthesis of a 3rd generation dendrimer with 
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precisely controlled 2:1 surface modification of paclitaxel-PEG.[243] Their work highlights the 
ability to synthesise modified dendrimers without compromising their highly defined nature. 
 
Given the extended synthesis and minor improvements in drug delivery discussed it would 
seem prudent to explore alternative architectures unless specific challenges can be overcome 
by properties unique to dendrimers. Hyperbranched polymers are imperfect analogues of 
dendrimers which have typically been synthesised in a one-pot procedure from readily 
available vinylic compounds.  
 
3.1.2 Synthesis of Hyperbranched Polymers 
 
Traditional free-radical polymerisation of divinyl monomers is commonly known to lead to the 
formation of gels and insoluble polymer networks; the foundational chemical principle which 
led to the modern “Polymer Age”. However addition of a suitable amount of a chain transfer 
agent suppresses network formation by limiting the polymer chain length[244] such that large 
‘infinite’ networks are not formed. Instead the reaction yields highly branched yet soluble 
polymers. The, later coined, ‘Strathclyde’ synthesis reported the copolymerisation of methyl 
methacrylate (MMA) and ethylene glycol dimethacrylate (EGDMA) in the presence of 1-
dodecanthiol (DDT) as the transfer agent which produced a series of soluble polymers.[245] 
Analysis by triple-detection SEC showed the polymers exhibited non-linear, branched 
structures. Further work by the group provided a mechanism for polymer growth[246,247] and 
considered the effect of the type of branching agent on the resulting macromolecule.[248,249] 
Modification of the original Strathclyde method by inclusion of a controlled transfer agent (e.g. 
ATRP or RAFT agent) has further developed this area. 
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Scheme 3.2 – Generalised reaction scheme for RAFT-SCVP (adapted from[250]) 
 
The two most common methods for synthesising hyperbranched polymers from vinylic 
compounds are self-condensing vinyl polymerisation (SCVP) and free-radical crosslinking 
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copolymerisation (RCC). SCVP was originally developed by Frechet et al.[251] but has 
expanded to take advantage of RDRP techniques such as NMP,[252] ATRP[253,254] and 
RAFT.[250] RAFT-SCVP involves polymerisation of an AB* inimer (a combined initiator-
monomer), where A is a vinyl moiety and B* is an initiating or chain transfer group. 
Polymerisation of the vinyl group introduces pendent RAFT moieties, each capable of initiating 
chain growth, leading to a hyperbranched structure. Furthermore, addition of a vinyl co-
monomer provides a method for preparing high molecular weight, branched polymers by 
increasing the chain length between branching units ( 
Scheme 3.2). In terms of RAFT-SCVP the vinyl moiety of the AB* inimer is commonly 
attached via the R-group of the RAFT agent as this results in hyperbranched materials with 
chain end RAFT moieties. Attachment via the Z-group places hydrolytically unstable RAFT 
moieties at the branch points. Rikkou-Kalourkoti and co-workers synthesised amphiphilic 
hyperbranched polymers from styrene and vinyl pyridine by use of a Z-group modified SCVP 
inimer (Scheme 3.3).[255] 
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Scheme 3.3 – Synthesis of amphiphilic hyperbranched polymer via a Z-group modified SCVP inimer 
reproduced from [255] 
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The degree of branching (DB) is an important parameter which is frequently used in the 
assessment of branched polymers. It has been defined as the number of branching points in a 
polymer as a fraction of the total monomer units in the macromolecule. Thus, for a perfectly 
branched molecule where every repeat unit is, or ends in, a branch the DB = 1. For RCC, DB 
can be defined according to equation (3.1) which has been utilised by a number of groups 
analysing branched systems.[256–258] 
 
 
DB = (no. of branching units) + (no. of terminal units)(no. of branching units) + (no. of terminal units) + (no. of linear units) (3.1) 
  
In comparison to SCVP, RCC involves the copolymerisation of a vinylic monomer with a 
divinyl crosslinker in the presence of a chain transfer agent (Scheme 3.4). 
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Scheme 3.4 – Generalised reaction scheme for RCC 
 
Bachler et al. recently compared SCVP and RCC as methods for synthesising a series of 
branched poly(pentafluorophenyl acrylate) materials.[257] They reported slightly increased 
polymer dispersity when RCC was used. In addition, SCVP produced materials with a higher 
overall DB (0.286 highest reported) in comparison to RCC (0.09 highest reported). Attempts 
to increase DB by increasing the initial crosslinker concentration led to the formation of gels. 
RCC therefore seems limited in the DB that can be achieved compared to SCVP. However, Pal 
and co-workers showed that comparable DB values (0.253) can be achieved by RCC if a 10 : 
1 : 1 ratio of monomer : crosslinker : RAFT agent is employed.[259] While this method was 
shown to promote high DB values, the molecular weight of the material was significantly 
reduced as a result of the low monomer : RAFT agent ratio thereby limiting the application to 
the production of highly branched, low molecular weight materials. 
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A major criticism of SCVP is its lack of versatility as the methods usually require synthesis of 
bespoke inimers. However, Yang et al. utilised hydroxyethyl methacrylate (HEMA) as a 
commercially available inimer in the synthesis of hyperbranched polyesters (Scheme 3.5).[260] 
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Scheme 3.5 – Synthesis of hyperbranched PCL using HEMA as a commercially available inimer 
 
By utilising an inimer which polymerises via two distinct routes the group were able to avoid 
additional synthetic steps, unlike the majority of reported SCVPs. However, the authors do not 
discuss potential backbiting reactions or cyclic products synthesised by Michael addition of 
terminal hydroxyl moieties to the vinyl group. It is unclear whether these reactions were not 
observed to occur or simply not mentioned in the paper. While inimer synthesis is a common 
feature in much of the literature they are not always complex, e.g. one-step inimer synthesis 
via carbodiimide coupling has been reported[261,262], however multi-step syntheses are not 
uncommon.[258,263] While SCVP can access higher branching values the scalability of the 
method could be limited by the costs and difficulty associated with the inimer synthesis. 
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3.1.3 Hyperbranched Polymers from Free-Radical Crosslinking Copolymerisation 
 
While SCVP utilises bespoke inimers, RCC employs cheap and readily available vinyl 
monomers and crosslinkers, the feed ratio of which must be carefully selected to produce 
materials with the desired characteristics.[264] It is for this reason that RAFT mediated RCC 
was selected for the synthesis of the branched polymers described later in this chapter. 
 
RCC has been of particular interest for the facile synthesis of stimuli-responsive branched 
polymers; the benefits of stimuli-responsive polymers have been discussed previously (section 
1.7). Luzon et al. utilised RAFT mediated RCC to copolymerise EGDMA and PEG-based 
monomer to synthesise branched polymers with a tuneable LCST (Scheme 3.6).[265] 
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Scheme 3.6 – Synthesis of thermoresponsive hyperbranched polymers reproduced from [265]  
 
By varying the initial feed concentration of diethylene glycol methacrylate 44 (DEGMA; 100 
– 80 %) to oligoethylene glycol methacrylate 45 (OEGMA; 0 – 20 %) the group were able to 
vary the LCST of the polymers between 17 – 46 °C respectively. The polymers were observed 
to form insoluble polymer networks when a total monomer : crosslinker ratio of 40 : 4 was 
used, however a 40 : 3 ratio produced soluble materials. Comparatively, Tai et al. synthesised 
thermoresponsive hb-PEG polymers with LCSTs ranging 22.5 – 32.8 °C.[266] By utilising a 50 
: 1 : 1.4 ratio of total monomer : RAFT agent : initiator the group were able to achieve highly 
branched and functionalised polymers with up to 34 mol % incorporation of crosslinker and 27 
mol % incorporation of vinyl groups. Aminolysis of terminal RAFT moieties and exposure to 
UV light led to thiol-ene crosslinking of the branched polymers, forming a hydrogel material 
in situ. The authors note that such materials could be beneficial for combined drug delivery 
and tissue engineering applications. 
 
114 
 
The synthesis of doubly-responsive materials was highlighted by Pal et al. when they utilised 
RCC for the copolymerisation of NIPAM and N,N′-bis(acryloyl)cystamine (BAC) (Scheme 
3.7).[259] 
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Scheme 3.7 – Synthesis of doubly-responsive P(NIPAM-co-BAC) hyperbranched polymers 
reproduced from [259] 
 
The cloud point of the polymers was found to decrease as the concentration of hydrophobic 
branching units increased. Redox-response of disulphide moieties was shown by reduction with 
tri-n-butylphosphine which yielded well defined linear polymers. Oxidation of the linear 
segments at 25 °C (below the cloud point of the linear polymers) resulted in re-formation of 
the branched structure. However, if the oxidation was performed above the cloud point then a 
crosslinked microgel was observed to form which the authors suggest is the result of 
aggregation of the linear polymers via crosslinked disulphide bonds. The authors suggest their 
material could have application in drug delivery, smart coatings and self-healing materials. 
 
More recently, RCC has been explored for synthesising branched HPMA based drug delivery 
platforms. The introduction of EGDMA added degradable linkages to the otherwise non-
degradable PHPMA structure. Tucker et al. investigated the synthesis of core-crosslinked 
PHPMA-star polymers via an “arm-first” approach (Scheme 3.8).[267] 
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Scheme 3.8 – Synthesis of PHPMA core-crosslinked star polymers. Reproduced from [267] 
 
Linear PHPMA was utilised as a macro-CTA for the RCC of EGDMA and methotrexate-
modified HPMA to yield a series of core-crosslinked star polymers. The optimised drug loaded 
polymer was estimated to contain 10 star arms and absolute Mw = 124,000 g mol-1 (as 
determined by SEC-MALS) with 20 wt % covalent incorporation of the anti-cancer drug 
methotrexate. Enzymatic drug release by incubation with porcine liver esterase showed only 
30% drug cleavage after 96 h. The authors suggested that drug release was limited by steric 
hindrance and are considering alternative polymer-drug conjugation methods. Such systems 
may benefit from an alternative, core-first approach which would allow for a range of core 
architectures to be considered. 
 
While most reports focus on either an RCC or SCVP approach to synthesising branched 
polymers, Wei et al. combined the two approaches to synthesise a branched, biodegradable, 
HPMA based polymer for the delivery of Dox (Scheme 3.9).[268] 
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Scheme 3.9 – Synthesis of HPMA based branched polymers via a combined RCC and SCVP 
approach reproduced from [268] 
 
The combination of biodegradable RAFT inimers and crosslinking agents allowed the group 
to achieve high molecular weight (Mw = 165 kg mol-1, Ð = 1.68) branched polymers with Dox 
loading found to be 5.67 wt %. Unfortunately, no data for the degree of branching was reported 
thus it is difficult to assess the effectiveness of the combined SCVP-RCC approach. 
 
It has also recently been shown that hyperbranched architectures can be achieved by RCC 
homopolymerisation of solely divinyl monomers.[269] The method exploits deactivation-
enhanced atom transfer radical polymerisation (DE-ATRP) to maintain most species in a 
dormant state and promote a short kinetic chain length. Short polymer chain lengths are further 
enhanced by the high monomer : initiator feed ratio (e.g. 2:1) which decreases the probability 
of intramolecular cyclisation and promotes intermolecular reactions resulting in a 
hyperbranched structure. 
117 
 
3.2 Conclusions on Current Literature 
 
Dendrimers form a uniquely well-defined class of macromolecules due to the controlled nature 
of their step-wise synthesis. As monodisperse materials they have often been considered to 
have more consistent pharmacokinetics than other branched macromolecules. Dendrimers have 
been shown to be capable drug delivery platforms, by either physical encapsulation or direct 
attachment, however they offer only minor improvements compared with other polymeric 
carriers and require extended synthetic procedures to realise, even when utilising orthogonal 
strategies. Comparatively, hyperbranched polymers are less regular in their structure but can 
be obtained via one-step syntheses. 
 
The strategies of SCVP and RCC were considered and while the former generally achieves 
materials with a higher overall DB the strategy requires the synthesis of bespoke inimers. 
Conversely, polymers synthesised by RCC are generally less branched but they can be realised 
with inexpensive and readily available monomers and crosslinkers. Much of the recent 
literature on RCC synthesised polymers has focused on stimuli-responsive materials based on 
PEG and NIPAM. Only a handful of reports consider branched polymers based on HPMA and 
as such presents an area of further development that has been expanded upon by the work 
presented in this chapter. 
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3.3 Results and Discussion 
 
Amphiphilic star copolymers are an alternative architecture to amphiphilic ABA-type triblock 
copolymers discussed in Chapter 2. These materials have the potential to be effective drug 
delivery platforms which avoid the concentration dependent self-assembly seen with linear 
block copolymers. As such these materials will not spontaneously disassemble, leading to 
potentially harmful payload release, during biocirculation. RCC was selected as a lower cost 
strategy which avoids the synthesis of bespoke inimers commonly found when using a SCVP 
method. The synthetic strategy for the synthesis of amphiphilic star copolymers based on 
HPMA is outlined in Scheme 3.10.  
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Scheme 3.10 – Envisioned synthetic strategy for the synthesis of PHPMA-star-(hb-PAPMA) 
copolymers 
A bottom-up approach to the synthesis of the hyperbranched core was selected to allow for in-
depth characterisation of its structure which is expected to affect drug loading and release in 
the final material. Once characterised and the reaction conditions optimised, the hyperbranched 
PHPMA (hb-PHPMA) core 47 could be made suitably hydrophobic via acetylation of pendent 
hydroxyl moieties (APMA) to give hb-PAPMA 48. Making the core suitably lipophilic was 
important to realise as part of the potential use of these systems was as hydrophobic drug 
carriers. Reactive thiocarbonyl groups from the original RAFT mediated synthesis could then 
be re-initiated in the controlled polymerisation of additional HPMA to ultimately yield the 
amphiphilic star copolymer 49 (PHPMA-star-(hb-PAPMA)).  
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3.3.1 Synthesis and Characterisation of Hyperbranched PHPMA 
 
Code Reaction Time (h) Molar ratios 
a 
Mn (NMR) 
(g mol-1) 
Mn (SEC) 
(g mol-1) 
Mw 
(g mol-1) 
Ð α 
P21 6 100 : 1 : 1 : 0.2 13,606 17,054 24,064 1.41 0.33 
P22 6 100 : 1 : 1 : 0.2 12,527 18,711 24,929 1.33 0.38 
P23 16 100 : 1 : 1 : 0.2 19,454 42,694 84,070 1.97 0.44 
P24 24 100 : 1 : 1 : 0.2 21,826 84,974 163,288 1.92 0.43 
P25 6 100 : 1 : 2 : 0.2 15,910 27,915 89,575 3.21 0.30 
P26 6 100 : 1 : 5 : 0.2 18,826 107,692 318,929 2.96 0.22 
P27 6 100 : 1 : 10 : 0.2 Gel Gel Gel Gel Gel 
P28 6 100 : 2 : 1 : 0.2 4,183 7,676 9,688 1.26 -2.4 
P29 6 100 : 5 : 1 : 0.2 - - - - - 
P30 6 100 : 10 : 1 : 0.2 - - - - - 
P31 6 100 : 2 : 2 : 0.2 8,993 10,079 16,927 1.68 0.027 
P32 6 100 : 5 : 5 : 0.2 2,194 3,628 10,377 2.86 0.077 
P33 6 100 : 10 : 10 : 0.2 736 658 2,044 3.11 0.16 
Table 3.1 – SEC data for the synthesis of hb-PHPMA cores; aMolar ratios are of HPMA : RAFT : 
EGDMA : Initiator; bvalue of α derived from SEC data using the Mark-Houwink equation  
 
Code Mn (g mol-1) Mw (g mol-1) Ð 
P21A 15,201 15,765 1.04 
P25A 16,275 17,500 1.08 
P26A 16,698 18,452 1.11 
P27A 88,757 101,582 1.14 
Table 3.2 – SEC data for polymers isolated after degradation of branches by reaction with NaOH (1 
M) for 24 h. 
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Code DB0 B0,RU B0,m DB BRU Bm P 
P21 0.066 15 8 0.036 28 4 4 
P22 0.064 16 8 0.037 27 5 4 
P23 0.041 25 12 0.016 64 5 7 
P24 0.014 69 9 0.012 81 7 1 
P25 0.066 15 13 0.038 27 7 6 
P26 0.095 10 72 0.037 27 28 44 
P27 Gel Gel Gel Gel Gel Gel Gel 
P28 0.12 9 6 0.074 13 4 2 
P29 ND ND ND ND ND ND ND 
P30 ND ND ND ND ND ND ND 
P31 0.12 8 9 0.072 14 5 4 
P32 0.23 4 6 0.17 6 4 2 
P33 0.26 4 1 0.22 5 1 0 
Table 3.3 – Data for the degree of branching and associated values where DB0 is the total degree of 
branching as defined by equation (3.3); B0,RU is the total average number of repeat units before a 
branch as calculated by 1/ DB0; B0,m is the total average number of branches per molecule as 
calculated by (Mn / MWmonomer) / B0,RU; DB is the degree of branching as defined by Equation  
; BRU is the average number of repeat units before a branch as calculated by 1/ DB; Bm is the average 
number of branches per molecule (Mn / MWmonomer) / BRU; P is the average number of pendent groups 
per molecule as calculated by B0,m – Bm   
 
The synthesis of hyperbranched polymers via a modified Strathclyde methodology has been 
discussed previously (vide supra), as well as the synthesis of PHPMA homopolymers (section 
1.5 and 2.2.1). Introduction of crosslinking was achieved by the addition of ethylene glycol 
dimethacrylate (EGDMA, 1 eq. to RAFT agent) to yield the polymer P21. Incorporation of 
EDGMA was confirmed by 1H NMR spectroscopy (Figure 3.2). New signals derived from the 
ethylene units of EGDMA were observed between 4.4 – 3.9 ppm, while pendent vinyl moieties 
from mono-reacted EGDMA are observed at 5.7 and 5.4 ppm.  
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Figure 3.2 – 1H NMR spectrum of hb-PHPMA P21 
Molecular weight and Ð increased, compared to linear PHPMA, as expected and this was 
attributed to branching via EGDMA. The value of Mn(NMR) was determined by comparison of 
the integrals e, j, j’, k and k’ to the end group signal r according to the equation ((e / r) * 143.18) 
+ (((j + j’ + k + k’) / 4) / r) * 198.22). This was further evidenced by a decrease in the Mark-
Houwink alpha (α) value which is indicative of a more compact, branched structure. The Mark-
Houwink equation relates a polymer’s intrinsic viscosity to its molecular weight: 
 
 [η] = KMα (3.2) 
  
Where [η] is the intrinsic viscosity of a polymer, K and α are constants dependent on the 
polymer, solvent and temperature, and M is the molecular weight of a polymer. A plot of log 
([η]) vs. log (M) provides a linear relationship where α is the gradient of that line. A value of 
α = 0.67 has previously been measured for linear PHPMA in 0.1 M KCl(aq) at 25 °C.[270] 
Comparatively, a value of α = 0.81 in DMF containing 0.05 M LiBr at 25 °C is reported here. 
The conditions match the SEC conditions employed in this project. 
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The degree of branching, as defined by equation (3.3), has been used by other researchers as a 
quantitative assessment of branching (vide supra). A similar treatment was applied for the 
assessment of branched polymers discussed herein. For our system branching units were 
defined as units of EGDMA; terminal units as terminal dithiobenzoate and carboxyl groups 
derived from the RAFT agent; and linear units as the repeating monomer units. Integration of 
1H NMR spectroscopy signals unique to those units (e.g. k, k’, j and j’ for branching units, 
Figure 3.2), after correcting to a single proton, described the average number of said units 
within a macromolecule. As such, 1H NMR spectroscopy integrals were substituted into 
equation (3.3) to derive an expression for the total degree of branching (DB0): 
 
 DB0 = (k + k' + j + j'/4) + (2r)(k + k' + j + j'/4) + (2r) + e (3.3) 
 
Twice the integral of the para benzene proton (r) was used to account for the two functional 
ends of the RAFT agent. Division of the combined ethylene bridge signals, derived from 
EGDMA, by 4 ensured the integration value represented a single repeating unit. From equation 
(3.3) it was possible to derive DB0 (Table 3.3). The reciprocal of DB0 gave the average number 
of repeat units before a branch (B0,RU) while the number-average number of repeat units (= Mn 
/ MWmonomer) divided by B0,RU estimated the total average number of branches per 
macromolecule. However, equation (3.3), and all values derived thereof, assumes that all 
EGDMA units have reacted completely and that no monofunctionalised EGDMA was present. 
It is clear from the 1H NMR spectrum (Figure 3.2) that this is not the case due to the presence 
of vinyl signals (m + n) at 5.7 and 5.4 ppm. Therefore equation (3.3) was further modified to 
account for this: 
 DB =  ((k + k' + j + j'/4) - m) + (2r)((k + k' + j + j'/4) + (2r) + e  (3.4) 
 
   
Subtraction of the vinyl signal from the numerator removed the contribution of mono-reacted 
EGDMA from the degree of branching. From equation (3.4) it was possible to derive DB, the 
average number of repeat units before a branch (BRU) and estimated average number of 
branches per molecule (Bm) (Table 3.3). As B0,m treated mono- and di-functionalised EGDMA 
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units identically while Bm only considered di-functionalised EGDMA as a branch, subtracting 
the value of Bm from B0,m gave an estimation of the average number of pendent vinyl groups 
per macromolecule (P). Thus, P21 is hb-PHPMA with an average of 4 branches and 4 pendents 
per molecule. Altogether these data provide a comprehensive description of key characteristics 
in hyperbranched polymers. However, it was not possible to distinguish intermolecular 
branching (the joining of two independent polymer chains resulting in a large increase in 
molecular weight) from intramolecular branching (incorporation of both EGDMA vinylic ends 
within the same macromolecule which generates more 3D character but does not affect 
molecular weight). Values for Bm are therefore a combination of both inter- and intramolecular 
branching and the calculation Mn/Bm does not provide an accurate molecular weight estimate 
of the branched polymers’ constituent chains. 
 
Comparison of P21 and P22 highlights the consistency of the synthetic method as only slight 
variation in molecular weight between identical runs was observed. Polymers P22 – P24 
considered the effect of increasing reaction time on the hyperbranched structure. As expected, 
molecular weight and Ð increase as a function of time, though there was no significant change 
in Ð between 16 – 24 h. Bm remained the same between 6 – 16 h however increased by 2 
between 16 – 24 h. P increased by 4 between 6 – 16 h however decreased by 6 between 16 – 
24 h. These results were accounted for by considering the progression of the reaction over time 
(Figure 3.3). 
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Figure 3.3 – Representation of RAFT copolymerisation of HPMA and EGDMA. Reproduced from 
[271] 
In the early stages the reaction mirrors RAFT mediated homopolymerisation of HPMA due to 
the high feed ratio of HPMA. Incorporation of EGDMA quickly follows due to the increased 
reactivity of methacrylates compared to methacrylamides[272] as well as the bifunctional nature 
of EGDMA. As a result P22 was observed to have Bm = 5 and P = 4 after 6 h. As the reaction 
proceeded between 6 – 16 h, EGDMA continued to be incorporated, as evidenced by the 
increase in P, however Bm appears to remain constant due to the increasing HPMA chain length, 
evidenced by the increase in BRU. In addition, α was observed to increase during this period 
suggesting a return to a more open, linear structure. The increase in BRU between 16 – 24 h 
highlights the continued polymerisation of HPMA throughout the reaction. However, 
incorporation of new EGDMA units had virtually ceased and pendent vinyl groups were 
consumed, as evidenced by only a minor increase in Bm and simultaneous decrease in P. The 
value of α was not observed to change significantly, despite increasing HPMA content, 
suggesting the 3D structure continued to develop during this period possibly via intramolecular 
cyclisation or coupling of hyperbranched molecules. Similar growth mechanism have been 
reported by Bannister et al.[271] and Tai and co-workers.[266] 
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While increasing reaction time afforded more branched structures it was at the expense of 
synthetically useful pendent vinyl groups and overall large molecular weights. Increasing the 
ratio of EGDMA in the feed (P25 – P27) was therefore considered as a way to achieve higher 
branching without extended reaction time. For P25 BRU was observed to remaine constant 
while Bm increased by 3 in comparison to P21; a higher fraction of EGDMA had been 
incorporated relative to HPMA as desired. This result is mirrored when EGDMA is increased 
to 5 eq. (P26) however increasing to 10 eq. led to gelation of the reaction mixture and formation 
of an insoluble polymer (P27). Increasing the initial concentration of EGDMA led to the 
formation of polymers with increasing molecular weight, Ð and DB which is in agreement with 
similar work in the literature.[273] A small decrease in Ð between P25 and P26 was observed 
and thought to be due to the formation of very high molecular weight material that was 
insoluble or filtered out prior to analysis by SEC. In order to show that the large Ð values were 
the result of the branching mechanism and not a loss of control by the RAFT agent, EGDMA 
branches (composed of ester linkages) in P21 and P25 – P27 were hydrolysed and the resulting 
constituent polymer chains analysed by SEC (Table 3.2). 
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Scheme 3.11 – Scheme for the degradation of hb-PHPMA  
 
Degradation of EGDMA links afforded well defined linear copolymers of HPMA and 
methacrylic acid (MAA). The Ð of the degraded polymers compares favourably with PHPMA 
homopolymers and suggests no loss of control by the RAFT mechanism. Additionally, the high 
dispersity of hyperbranched polymers were shown to be the result of varying degrees of 
intermolecular crosslinking. This was best exemplified by P27 (formed a gel) which yielded 
soluble chains of P27A (Ð = 1.12) after degradation. These results are in agreement with 
similar studies conducted by Pal et al. who investigated the degradation of hb-PEG polymers 
synthesised by RAFT mediated RCC.[273] Values for Mn, as calculated by SEC, compare 
closely to the values of Mn (NMR). By its nature, 1H NMR spectroscopy provides an accessible 
method for assessing the length of constituent chains in hyperbranched polymers synthesised 
126 
 
by this method. Care should be taken when assessing polymers with high levels of branching 
as the discrepancy in molecular weight between the two methods, likely due to the difference 
in molecular weight between indistinguishable HPMA and MAA repeat units, would become 
amplified. 
 
A later step in the synthesis of 49 required re-initiation of RAFT thioester moieties in order to 
form the hydrophilic ‘arm’ segments. In order to introduce additional terminal RAFT groups 
P28 – P30 were synthesised. As expected, increasing the initial RAFT concentration afforded 
fairly well defined polymers with lower molecular weights and comparable branching to 
previous methods. Increasing to 5 or 10 eq. of RAFT effectively suppressed the reaction such 
that no polymer was recovered after 6 h. As decreasing the HPMA : EGDMA ratio facilitated 
increased branching and decreasing the HPMA : RAFT ratio decreased the kinetic chain length, 
it was reasoned that decreasing the HPMA : EGDMA : RAFT ratio (P31) would facilitate the 
formation of highly branched polymers comprised of several smaller chains. Analysis of P31 
showed a polymer of higher molecular weight than P28 but with comparable degrees of 
branching. Continuing to decreasing the initial feed ratio (P32 and P33) suppressed the 
polymerisation, leading to the formation of low molecular weight materials with minimal 
branching. The low branching is also evidenced by the increasing value of α from 0.027 for 
P31 to 0.160 for P33. However, unlike P29 and P30, polymeric material from P32 and P33 
could be isolated as a result of the higher initial EGDMA feed. Finally, decreasing the HPMA 
: RAFT ratio significantly affected the yield of all reactions (P31 (5 wt.%), P32 (0.5 wt.%) and 
P33 (0.5 wt.%)) making the method highly inefficient in terms of material cost. 
 
3.3.2 Acetylation of hb-PHPMA to form a Hydrophobic Core 
 
In order to increase the hydrophobicity of hb-PHPMA, backbone hydroxyl groups were 
acetylated. As a potential drug delivery system this was an important parameter to achieve due 
to the hydrophobic nature of many therapeutic agents. Acetylated PHPMA (PAPMA) was 
envisioned to be accessible by reaction with acetic anhydride in the presence of a suitable 
catalyst (Scheme 3.12). 
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Scheme 3.12 – General scheme for the acetylation of backbone hydroxyl groups in hb-PHPMA to 
give hb-PAPMA 
As with previously discussed hydroxyl functionalisation (vide supra) a critical parameter was 
near-complete conversion (≥ 95 %) of hydroxyl to ester functionality. In addition, for the 
synthesis of 49 in a controlled manner from the macro-RAFT agent 47 (Scheme 3.10), maximal 
retainment of RAFT end groups was desirable. From these parameters a range of methods were 
considered (Table 3.4). 
 
Code Time (h) Temp (°C) Catalyst % Acetylation % RAFT 
 P34 3 20 Pyridine 100 40 
P35 3 20 DBU 100 69 
 P36 3 20 DMAP.HCl 100 79 
 P37 48 70 - 100 105 
Table 3.4 – Methods for acetylating linear PHPMA polymers. % RAFT represents the percentage of 
RAFT end groups remaining after acetylation as measured by comparison of 1H NMR spectra 
 
PHPMA is insoluble in chloroform as assessed by stirring the polymer (100 mg) in chloroform 
(5 ml) for one week; the solution remained a cloudy pink suspension. The end of the acetylation 
reaction was assessed by visual dissolution of the sample in chloroform and confirmed by 1H 
NMR spectroscopy. Analysis of PAPMA by 1H NMR spectroscopy in DMSO-d6 gave a 
spectrum with significant peak broadening, suggesting poor dissolution of the sample due to 
increased hydrophobicity. In contrast, analysis of samples in CDCl3 showed a new signal for 
the acetyl group at 2.1 ppm, while the HPMA signal e  (Figure 3.4b) was observed to shift to 
5.0 ppm and d was split into two peaks between 3.6 – 2.9 ppm (a similar effect is observed 
when HPMA monomer is analysed in CDCl3, Figure 3.4b).  By comparing the number of repeat 
units (by 1H NMR spectroscopy) in the starting polymer to the acetylated product an estimation 
of the percentage of RAFT end groups remaining could be made (Table 3.4). The number of 
repeat units was determined by the ratio of the signal e to j for both PHPMA and PAPMA 
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polymers. As the acetylation reaction did not involve addition of monomer, any apparent 
increase in the number of repeat units, after acetylation, must in fact be due to a decrease in the 
intensity of RAFT end group signals.  
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Figure 3.4 – 1H NMR spectra of a) PAPMA P34 and b) HPMA monomer in CDCl3 
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Initial attempts at acetylation utilised pyridine as the catalyst (P34). While all hydroxyl groups 
were found to have undergone esterification, a 60% reduction in the RAFT signal was 
observed. Amines have previously been used to degrade RAFT dithioester moieties and a 
similar mechanism was suspected to be at work here. Significant loss of RAFT groups was 
deemed unacceptable for successful synthesis of 49 thus a non-nucleophilic base, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), was selected as a catalyst for the synthesis of P35. 
However, while the degree of acetylation was suitable the loss of RAFT groups, 31% loss, was 
similarly deemed too high. As a result an acid mediated catalysis method was investigated with 
the goal of reducing the degree of RAFT degradation by reducing the probability of 
nucleophilic attack on the thiocarbonyl moiety. Liu et al. reported the use of the salt 
DMAP.HCl as a recyclable catalyst for the acetylation of inert alcohols.[274] While the 
degradation of RAFT groups was reduced via this route (P36) their retention was not 
maximised. As such, a non-catalytic route was trialled. Reaction of PHPMA under reflux (P37) 
resulted in complete acetylation of hydroxyl groups and no apparent loss of RAFT groups by 
1H NMR spectroscopy (Figure 3.5). 
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Figure 3.5 – 1H NMR spectra of a) PHPMA starting material and b) PAPMA P37  
However, further analysis of P37 by SEC (Figure 3.6) showed a bimodal peak comprised of 
higher molecular weight material at 19.0 min and a peak at 19.8 min which overlays with the 
PHPMA starting material. The bimodal peak was not observed to disappear after dissolving 
the material in DMF and stirring in the presence of TCEP for 24 h and thus is not thought to 
be due to disulphide formation between thiols resulting from hydrolysis and oxidation of RAFT 
end groups. 
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Figure 3.6 – SEC RI trace of P37, in red, overlaid with PHPMA starting material, in purple. 
Analysis of previously acetylated polymers, P34 – P36 showed they also exhibited bimodal 
peaks after the acetylation reaction. Further polymerisation of P37 as a RAFT macroinitiator 
with additional HPMA resulted in no observed change in the polymer by 1H NMR spectroscopy 
or SEC (Figure 3.7). 
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Figure 3.7 – SEC RI trace of P37, in purple, overlaid with product, in red, after polymerisation with 
fresh HPMA. 
As a result of this data, post-polymerisation modification of PHPMA 6 with acetic anhydride, 
as a model for synthesis of 48, was found not to be a viable route to PAPMA for the purpose 
of exploiting the living properties of RAFT moieties. To circumvent the issues discussed, the 
original strategy (Scheme 3.10) was modified such that acetylated HPMA (APMA) was 
synthesised first and later polymerised to yield the hydrophobic hyperbranched core. 
 
3.3.3 Direct Synthesis of an Acetylated Hyperbranched HPMA Core 
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Scheme 3.13 – Synthesis of APMA monomer and subsequent homopolymerisation 
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Acetylation of HPMA by reaction with acetic anhydride was achieved as outlined in Scheme 
3.13. The product was isolated in good yield (75%) and identified by 1H and 13C NMR 
spectroscopy (Figure 3.8). 
 
Figure 3.8 – a) 1H and b) 13C NMR spectra of APMA 
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Previous work in the research group found RAFT mediated homopolymerisation of APMA to 
be unsuccessful under a range of conditions (results not shown) and this was similarly found 
when attempted here (Table 3.5, P38). Alfurhood et al. also observed no product when they 
attempted the homopolymerisation of HPMA monomers esterified with valproic acid 
(VPMA).[162] However, they reported the successful copolymerisation of various feed ratios of 
VPMA and HPMA; chain extension with additional HPMA yielded a block copolymer suitably 
amphiphilic to self-assemble in water. Copolymerisation of HPMA with APMA was therefore 
attempted here (Scheme 3.14) for a range of feed ratios (Table 3.5). 
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Scheme 3.14 – Reaction scheme for the synthesis of poly(HPMA-co-APMA) 
 
Code Molar Ratios a Yield (mg) Yield (wt. %) 
 P38 0 : 100 : 1 : 0.2 8.4 mg 1.2 % 
 P39 50 : 50 : 1 : 0.2 5.7 mg 0.8 % 
 P40 33 : 66 : 1 : 0.2 12.5 mg 1.8 % 
 P41 25 : 75 : 1 : 0.2 12.3 mg 1.7 % 
 P42 12.5 : 87.5 : 1 : 0.2 11.2 mg 1.6 % 
Table 3.5 – Results of the copolymerisation of HPMA and APMA as per Scheme 3.14 
. a Molar ratios are HPMA : APMA : RAFT : Initiator 
 
Conversion of monomer to polymer for all feed ratios was found to be minimal after 6 h (< 2 
%). Alfurhood et al. reported the use of the trithiocarbonate RAFT agent 50 (Scheme 3.15) as 
opposed to the dithioester based RAFT agent 28a. The reaction was therefore modified to more 
closely follow the published procedure. The homopolymerisation of HPMA was assessed first 
to provide a reaction for comparison (Scheme 3.15). 
136 
 
NHO
OH
S S
OH
11
S CN
O S S11
S
OH
CN
OO NH
OH
x
AIBN, DMAc, 70 °C, 6 h
6
50
51
 
Scheme 3.15 – Reaction scheme for the homopolymerisation of HPMA with a trithiocarbonate RAFT 
agent 
 
The reaction afforded well-controlled PHPMA (Mn,SEC = 7789 g mol-1, Ð = 1.10) in low yield 
(26%). Copolymerisation of HPMA and APMA was subsequently attempted under similar 
reaction conditions to the homopolymerisation of HPMA (Scheme 3.16).  
S S
OH
11
S CN
ONHO
OH
S
S
S
O NH
OH
x
AIBN, DMAc, 70 °C, 6 h
NHO
O O
+
co
NHO
O O
OH
y
CN
O11
 
Scheme 3.16 – Reaction scheme for the copolymerisation of HPMA and APMA with a 
trithiocarbonate RAFT agent 
 
Code Molar Ratios a HPMA (%) APMA (%) Yield (wt. %) 
 P43 50 : 50 : 1 : 0.2 46 54 25 
 P44 33 : 66 : 1 : 0.2 36 64 23 
 P45 25 : 75 : 1 : 0.2 31 69 19 
 P46 12.5 : 87.5 : 1 : 0.2 11 89 7 
Table 3.6 – Results of the copolymerisation of HPMA and APMA as per Scheme 3.16. a Molar ratios 
are HPMA : APMA : RAFT : Initiator. Percentage fractions of HPMA and APMA were estimated by 
analysis of 1H NMR spectra 
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 Figure 3.9 – 1H NMR spectrum of poly(HPMA-co-APMA) P43 
 
Successful incorporation of both HPMA and APMA monomers was confirmed by 1H NMR 
spectroscopy, in particular overlapping amide peaks between 7.6 – 7.0 ppm and the appearance 
of the hydroxyl peak (g) at 4.7 ppm (Figure 3.9), which was found to disappear upon addition 
of D2O. The fraction of incorporated HPMA was estimated by finding the signal labelled e as 
a fraction of e’ + g. The fraction of APMA in the polymer structure was therefore estimated as 
1 – fraction of HPMA. A minimal feed ratio of 50% APMA (P43) was selected to promote the 
hydrophobicity of the copolymer product. Optimal incorporation of APMA, without a 
significant drop in yield, was found when it comprised 75% (P45) of the initial monomer 
concentration. As expected, the fraction of incorporated monomer closely follows the monomer 
feed ratios within a small degree of error. All of the polymers (P43 – P45) produced clear pink 
solutions when stirred in chloroform. However, 1H NMR spectra recorded in CDCl3 exhibited 
significant peak broadening, similar to P34 – P37 dissolved in DMSO-d6, suggesting a degree 
of amphiphilicity. This was deemed acceptable as PEG exhibits amphiphilicity and has 
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successfully been utilised as the hydrophilic and hydrophobic component in various block 
copolymers (sections 1.4, 1.5 and 1.8). Having successfully synthesised a series of linear 
PHPMA-co-PAPMA polymers, the developed method was employed in the synthesis of 
hyperbranched PHPMA-co-PAPMA polymers. 
 
3.3.4 Synthesis of Amphiphilic PHPMA-star-(hb-(PHPMA-co-PAPMA)) Copolymer 
 
A combination of the previously developed methodologies (Sections 3.3.1 and 3.3.3) were 
utilised for the synthesis of a hyperbranched PHPMA-co-PAPMA core (hb-(PHPMA-co-
PAPMA)) polymers (Figure 3.10). 
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Figure 3.10 – Schematic for the synthesis of hb-(PHPMA-co-PAPMA) core and subsequent PHPMA-
star-(hb-(PHPMA-co-PAPMA)) polymer 
Code Molar ratios a 
Mn 
(g mol-1) 
Mw 
(g mol-1) 
Ð 
HPMA 
(%) 
APMA 
(%) 
No. of 
RAFT end 
groups 
P47 25 : 75 : 1 : 1 : 0.2 121,503 134,507 1.11 26 74 20 
P48 25 : 75 : 1 : 2 : 0.2 129,339 167,787 1.30 27 73 30 
P49 25 : 75 : 1 : 5 : 0.2 142,001 191,984 1.35 29 71 40 
Table 3.7 – SEC data for hb-(PHPMA-co-PAPMA) polymers. a Molar ratios are HPMA : APMA : 
RAFT : EGDMA : Initiator. Polymerisations were performed for 6 h at 70 °C. 
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Code DB’0 B’0,RU B’0,m DB’ B’RU B’m P’ 
P47 0.21 5 149 0.14 7 98 51 
P48 0.23 4 173 0.16 6 115 57 
P49 0.37 3 303 0.25 4 204 99 
Table 3.8 – Data for the degree of branching and associated values derived from 1H NMR 
spectroscopy data as calculated by equations (3.5) and (3.6) 
 
All products (P47 – P49) were found to exhibit ca. 3 : 1 ratio of APMA : HPMA, as a result of 
the initial monomer feed ratio, produced clear pink solutions when stirred in chloroform and 
gave well resolved 1H NMR spectra when dissolved in DMSO-d6, in agreement with  similar 
observations regarding P45. Overlapping signals between the RAFT R-group and backbone 
signals from HPMA, APMA and EGDMA repeat units meant that equations (3.3) and (3.4) 
could not be used in the assessment of branching in this case. The equations were therefore 
modified to assess EGDMA as a fraction of the total number of repeat units by excluding the 
contribution of RAFT end groups (Table 3.8 and Figure 3.12): 
 DB0′  =  ((k + k' + l + l')/4)((k + k' + l + l')/4) + e (3.5) 
   
 DB′  =  ((k + k' + l + l')/4) - m)(k + k' + l + l')/4) + e  (3.6) 
 
In agreement with previously discussed data (Table 3.1 and Table 3.3) molecular weight, Ð 
and the degree of branching increased with increasing EGDMA feed concentrations. However, 
the degree of branching and molecular weights, of hb-(PHPMA-co-PAPMA) compared to hb-
(PHPMA) samples, were found to be significantly greater in all cases while SEC analysis 
showed the materials to still be fairly well defined (Ð = 1.11 – 1.35). The data presented 
represents a significant increase in the degree of branching for polymers synthesised by RCC 
in comparison to the current literature. [256–258] It was proposed that for this system, EGDMA is 
consumed early on in the polymerisation process due to the increased reactivity of 
methacrylates vs. methacrylamides[272] in addition to the reduced reactivity of the HPMA-
APMA co-monomer system. [162] Due to the large amount of incorporated crosslinking units, 
high molecular weight materials are readily accessed as the reaction proceeds. Further 
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polymerisation of HPMA and APMA in a controlled manner afforded well defined, high 
molecular weight and highly branched materials. The polymers were observed to exhibit an 
increasingly compact structure when analysed by SEC (Figure 3.11). 
 
Figure 3.11 – Overlay of RI traces for P47, in black, P48, in red, and P49, in blue. 
SEC separates materials based on their hydrodynamic volume, such that materials which 
occupy the largest volume in solution are detected first while smaller materials elute slower 
and are detected at higher retention volumes. While P47 was found to have the lowest 
molecular weight of the three polymers, it was observed to elute at 21.9 mL while P48 and P49 
eluted at 22.2 and 22.5 mL respectively. Increasing molecular weight while simultaneously 
eluting at larger retention volumes suggests an increasingly compact structure is formed as the 
EGDMA feed concentration is increased.  
 
As the R group of the trithiocarbonate RAFT agent 50 overlapped with signals for the polymer 
backbone, an assessment of terminal RAFT groups by 1H NMR spectroscopy was not feasible. 
Instead, UV-absorbance of the polymers (P47 – P49) was compared to an absorbance vs RAFT 
concentration calibration curve (appendix 8.6) in order to determine the concentration of RAFT 
groups. The average number of RAFT groups per molecule (Table 3.7) was estimated by taking 
the moles of polymer as a fraction of the moles of RAFT groups. As expected, the number of 
RAFT groups increased with increased branching. 
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The surface RAFT groups were reinitiated in the presence of additional HPMA monomer 
(Table 3.9) to form the hydrophilic arms of the star polymer 49 (Figure 3.10) which were then 
analysed by SEC and 1H NMR spectroscopy (Figure 3.12). 
 
Code Starting Material Mn (g mol
-1) Mw (g mol-1) Ð 
P50 P47 138,659 148,431 1.07 
P51 P48 284,151 332,447 1.17 
P52 P49 243,295 308,756 1.27 
Table 3.9 – SEC data for PHPMA-star-(hb-(PHPMA-co-PAPMA)) polymers. All reactions were 
performed for 6 h at 70 °C. Molar ratios were 100:1:0.2 of HPMA : macroCTA : initiator 
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Figure 3.12 – Overlay of 1H NMR spectra a) P47 b) P50 and RI traces from SEC analysis of P47, in 
red, and P50, in black, as representative examples. 
 
Successful re-initiation of surface RAFT moieties was achieved as evidenced by the increase 
in molecular weight and shift towards lower retention volumes for star polymers compared to 
their respective starting materials. In addition, analysis of the 1H NMR spectra showed a 
decrease in the ratio of integral of proton e’ (Figure 3.12a and b) of APMA relative to HPMA 
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(e) which suggested an increase in the number of HPMA units within the polymer structure. In 
all cases the dispersity of the materials decreased, which further evidenced retention of RAFT 
moieties and successful homopolymerisation of HPMA.  
 
Comparison of molecular weight data for the products and their respective starting materials, 
in conjunction with the number of RAFT groups derived from UV-Vis data, suggested that P50 
contained ~ 6 HPMA units per RAFT group. This could suggest poor availability of the RAFT 
moieties resulting in short chain growth.  Comparatively, P51 contained ~ 36 HPMA units per 
RAFT group and P52 contained ~ 18 HPMA units per RAFT group. These data suggest that 
higher total RAFT moieties result in increased average chain length, possibly due to improved 
availability, though at 40 RAFT groups the average chain length decreased suggesting steric 
crowding may prevent further growth. As such these data suggest the number of RAFT groups 
may influence the extent of chain growth and is an important parameter when designing core-
crosslinked materials. 
 
The reactions highlighted show that hb-(PHPMA-co-PAPMA) polymers could be successfully 
used as a macro-CTA for chain extension and the homopolymerisation of HPMA, extending 
the work originally presented by Alfurhood et al.[162]  
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3.4 Chapter Summary 
 
The work in this chapter considered the synthesis of hyperbranched polymers as the centre of 
amphiphilic core-crosslinked star polymers based on HPMA. A number of branched 
architectures have been reported in the literature and were considered with regards to the facile 
synthesis of branched polymers. While dendritic polymers were reported in the literature to be 
highly branched and extremely well defined, their extended synthesis limits their application 
in developing facile methodologies. In contrast, hyperbranched polymers can typically be 
synthesised via a one-pot reaction. Two of the most common methods for synthesising 
hyperbranched polymers are SCVP and RCC which were recently compared in the synthesis 
of branched HPMA materials. While SCVP was shown to yield materials with higher overall 
DB, the method requires bespoke inimers which was thought to be less conducive to facile 
syntheses. As a result, an RCC methodology was selected for the synthesis of a branched 
HPMA core in this project. After optimisation of the method, a novel PHPMA-star-(hb-
(PHPMA-co-PAPMA)) copolymer was synthesised for the first time. 
 
EGDMA was chosen as an inexpensive, readily available branching agent with a precedent for 
use in hyperbranched formulations. Additionally, the ester functionality added degradable 
linkages to the otherwise non-degradable PHPMA structure. This was an important feature to 
allow for excretion from the body and avoid potentially toxic bioaccumulation. When the 
EGDMA feed concentration was kept constant, the DB was found to decrease as a function of 
time. Incorporation of EGDMA was reasoned to occur early in the polymerisation, despite its 
lower concentration relative to HPMA, due to the presence of two reactive ends and the 
increased reactivity of methacrylates compared to methacrylamides.  
 
A range of experimental conditions were considered in order to optimise the molecular weight 
and DB of the HPMA core. An initial feed ratio of 10 : 1 of EGDMA : RAFT agent was found 
to induce formation of an insoluble network while a ratio of 5 : 1 produced soluble product, 
suggesting the maximum EGDMA feed ratio lies between those values. Increasing the feed 
concentration of the RAFT agent without altering the concentration of EGDMA reduced the 
total molecular weight of the materials. However, by increasing the feed of the RAFT agent 
and EGDMA in tandem higher degrees of branching at lower molecular weight could be 
achieved in some cases. While the data suggests the molecular weight and degree of branching 
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could be selected by careful manipulation of the initial EGDMA : RAFT feed ratio these 
materials were isolated in extremely low yield which calls into question the feasibility of those 
feed ratios for larger scale development. 
 
Complete acetylation of pendent hydroxyl moieties in the branched HPMA core was observed 
under acid and base catalysed conditions. However, unacceptable loss of terminal RAFT 
functionality was also observed even in the absence of a catalyst. Building on the work of 
Alfurhood et al. hyperbranched APMA cores were therefore synthesised directly via 
copolymerisation of HPMA and APMA monomers. Analysis by 1H NMR spectroscopy 
showed the monomers were incorporated with close agreement to the initial feed ratio of the 
monomers. Terminal RAFT moieties were quantified by UV-Vis spectrophotometry, between 
20 – 40 moieties per molecule, and increased with increasing EGDMA feed concentration. The 
macro-CTAs were successfully re-initiated with additional HPMA to form amphiphilic core-
crosslinked star polymers as evidenced by changes in the 1H NMR spectrum and SEC 
chromatograms. This represents the first reported synthesis of PHPMA-star-(hb-(PHPMA-co-
PAPMA)) copolymers. Extensive characterisation of these material’s branching parameters via 
1H NMR spectroscopy was also reported. 
 
Future work should determine the drug loading parameters for the hyperbranched polymers 
described here with a look towards investigating the influence of the various branching 
parameters on drug loading, release and cytotoxicity. Furthermore, pendent vinyl groups 
provide a readily accessible handle for additional modification to the polymer’s properties or 
attachment of markers for in vivo analysis. Investigation into the elimination of branched 
polymers and their degradation products in vivo would also be beneficial in guiding further 
development of these materials.   
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4  Charge Controlled Nanoprecipitation of Poly-ε-
caprolactone 
 
4.1 Introduction 
 
As discussed in previous chapters, optimising the synthesis of amphiphilic polymers can be 
extremely challenging and the use of costly reagents or complex methodologies may limit 
scalability of the method. In contrast, commercially available, hydrophobic polymers, such as 
PCL, can be readily purchased and formed into nanoscale objects by exploiting the 
hydrophilic/hydrophobic interactions of said polymers in oil-water solvent mixtures.[275,276] 
Such systems typically do not require the use of specialist equipment or techniques but exploit 
readily available materials and are therefore eminently more scalable. Common methods for 
producing nanoscale polymers include interfacial polymer deposition (IPD) and 
nanoprecipitation. This chapter focuses on nanoprecipitation of PCL as an alternative strategy 
to the use of amphiphilic polymers for the formation of nanocarriers. 
 
4.1.1 Synthesis of Nanoparticles by Interfacial Polymer Deposition 
 
Polymeric nanocapsules can be readily synthesised by IPD. Initially, the polymer and drug 
molecule (if appropriate) are dissolved in a co-solvent mixture containing a water miscible 
solvent and a hydrophobic solvent e.g. acetone and benzyl benzoate.[184] Addition of the co-
solvent mixture to an aqueous phase containing a stabilising surfactant results in the formation 
of finely dispersed droplets of the hydrophobic solvent, at the interfacial surface of which the 
polymer subsequently precipitates and is stabilised by any surfactant, leading to the formation 
of nanocapsules with an oil phase core.[277] The core has benefits in the delivery of lipophilic 
drugs, though care should be taken to investigate the potentially toxic side effects of 
introducing hydrophobic solvents in vivo.[275,278] 
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Figure 4.1 – Schematic representation of interfacial polymer deposition 
 
Fessi et al. first reported the use of IPD for the preparation of poly(lactic acid) (PLA) 
nanocapsules 260 ± 20 nm in diameter containing 2.4 wt.% paclitaxel.[279] Mosqueira et al. 
investigated the effects of the hydrophobic solvent on the mean diameter of nanocapsules 
formed.[280] They were able to adjust the particle diameter between 170 – 370 nm depending 
on the solvent employed, highlighting the importance of solvent selection to this method. More 
recently, Mandal et al. reported the formation of poly(lactide-co-glycolic acid) (PLGA) 
nanocapsules, 194 ± 2 nm, with drug loading of the antiretroviral drug Rilpivirine equal to 8 
wt.% using DCM as the hydrophobic solvent.[281] While Bulcão et al. evaluated the toxicity of 
PCL nanocapsules in vivo and found no appreciable toxicity, such toxicological studies are rare 
in the literature.[282] As a result, IPD was not investigated as a method for producing PCL-based 
nanocarriers in this work. 
 
4.1.2 Synthesis of Nanoparticles by Nanoprecipitation in a Co-Solvent 
 
Nanoprecipitation, also referred to as solvent displacement, shares a similar methodology to 
IPD but does not utilise a hydrophobic solvent component to generate finely dispersed droplets 
in the bulk aqueous phase. 
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Figure 4.2 – Schematic representation of nanoprecipitation 
 
Initially, the polymer is dissolved in a water-miscible solvent which is subsequently added to 
water undergoing shear mixing.[283,284] A decrease in the interfacial tension of the solvent 
phases upon mixing leads to the formation of organic solvent droplets.[285] Unlike IPD, further 
diffusion of the water-miscible organic solvent into the bulk solution results in precipitation of 
the hydrophobic polymer and formation of polymeric nanomaterials with dimensions similar 
to the initially formed organic solvent droplets. Unlike IPD, nanoparticles produced by 
nanoprecipitation do not exhibit a liquid oil phase core. 
 
A number of parameters of the nanoprecipitation procedure have been identified as important 
in determining the final particle diameter. The initial polymer concentration,[286] mixing 
speed,[287] solvent injection rate[288], organic/aqueous solvent ratio[283] and organic solvent type 
have all been investigated for their effect on particle size. A number of water-miscible organic 
solvents have been employed for dissolution of polymers prior to nanoprecipitation. 
Acetone[276] is commonly employed for its ease of removal by evaporation however binary 
solvent mixtures, such as acetone-methanol or acetone-ethanol,[289,290] have also been 
considered. Govender et al. prepared PLGA particles with a mean diameter of 160 nm via 
nanoprecipitation from acetonitrile.[291] Beck-Broichsitter et al. directly compared the effect of 
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solvent on the formation of PLGA nanoparticles. They observed the mean particle diameter to 
be 140.0 ± 5.2, 148.3 ± 4.0 and 184.7 ± 5.5 nm for acetone, acetonitrile and THF 
respectively.[292] The authors suggest the increased viscosity and lower diffusion coefficient of 
acetonitrile and THF in water compared to acetone as the reason for the observed increase in 
particle size. 
 
4.1.3 Charge Controlled Nanoprecipitation 
 
While nanoprecipitation of hydrophobic polymers has been shown to be a facile method for 
the preparation of polymeric nanoparticles, particle diameter can vary significantly between 50 
– 500 nm.[283,293–295] As discussed previously in section 1.2  of this thesis the size of polymeric 
carriers must be carefully considered. Nanoparticles between 10 - 250 nm are sufficiently large 
to avoid rapid renal clearance and achieve extended biocirculation yet small enough to avoid 
detection and clearance via the MPS.[296] A number of groups have further reported that 
additional enhancements to the EPR effect can be observed for nanoparticles ˂ 50 nm.[297–299] 
Furthermore, trans-membrane uptake of ultra-small hydrophobic nanoparticles[300,301] presents 
an alternative uptake mechanism to the more commonly observed endocytotic uptake of 
amphiphilic polymers. In order to achieve ultra-small nanoparticles (≤ 50 nm) via self-
assembly of amphiphilic block copolymers typically requires a high ratio of the hydrophilic to 
hydrophobic block which has been observed to reduce encapsulation efficiency.[302–304] Reisch 
et al. recently presented a method for the formation of ultra-small nanoparticles by utilising 
terminal ionisable moieties which was termed ‘charge controlled nanoprecipitation’ (Figure 
4.1).[305] 
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Scheme 4.1 – Synthesis of polymers with terminal ionisable moieties. Reproduced from [305] 
 
Nanoprecipitation of PGLA and PMMA polymers bearing terminal -NMe3, -COOH and -SO3H  
groups, in solutions of sufficient pH for end-group ionisation, resulted in a series of 
nanoparticles between 150 – 25 nm. Sulphonate terminated polymers were observed to produce 
consistently smaller nanoparticles than those baring terminal carboxyl groups. With regards to 
PCL, near-complete esterification of terminal hydroxyl groups was achieved for the synthesis 
of carboxyl (80%) and sulphonate (78%) terminated polymers. The charge controlled 
nanoprecipitation method presents a novel method for the formation of ultra-small 
nanoparticles which has been nominally explored in the literature. The work presented in this 
chapter initially builds upon the work of Reisch et al. by driving the esterification of PCLs’ 
terminal hydroxyl moieties and investigating the effect of a range of pH values on nanoparticle 
diameter.  
 
4.2 Results and Discussion 
 
4.2.1 Optimisation of the Precipitation of PCL-diol 
 
In order to demonstrate the applicability of charge controlled nanoprecipitation to the 
production of nanoparticles, within the context of the current work, it was necessary to first 
optimise the formation of PCL-diol nanoparticles. The optimised conditions could then be 
applied to the charge controlled nanoprecipitation of carboxyl terminated PCL between pH 7 
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– 13 and form a baseline for comparison against this method. Furthermore, in order to ensure 
the accuracy of the data extensive repeats were performed. For each experiment three 
independent repeats were performed with freshly prepared polymer solutions and for each 
variable a further three repeats were also performed for a total of nine repeats per data point. 
 
4.2.1.1 Effect of Polymer Concentration on Particle Size 
 
The concentration of the initial polymer solution was first investigated for its effects on the 
sizes of nanoparticles produced. A range of PCL solutions of varying concentration (1, 5, 10, 
25 and 50 mg mL-1) were produced by dissolution of PCL-diol in acetone. Acetone was selected 
for its low viscosity and high diffusion coefficient in water which should promote polymer 
diffusion and formation of low diameter nanoparticles. The nanoparticles were produced by 
solvent displacement in 10 mL of water and the sizes of particles immediately analysed by DLS 
(Figure 4.3). 
PCL concentration 
(mg ml-1) 
Average Particle Diameter 
(nm) 
1 136 ± 22 
5 212 ± 11 
10 241 ± 14 
25 387 ± 43 
50 378 ± 80 
 
Table 4.1 – Effect of initial polymer concentration on particle diameter. Particle diameter is reported 
as the intensity distribution. Error represents ± 1 SD, n = 9 
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Figure 4.3 – Effect of initial polymer concentration on particle diameter. Particle diameter is reported 
as the intensity distribution.  Error bars represent ± 1 SD, n = 9. 
 
As can be seen in Figure 4.3 the smallest particles (136 ± 22 nm) were produced with an initial 
polymer concentration of 1 mg mL-1. Particle size increases as a function of initial polymer 
concentration until between 25 – 50 mg mL-1 (387 ± 43 – 378 ± 80 nm). The results are 
expected as at lower initial polymer concentrations the probability of chain aggregation during 
mixing is reduced. As the polymer concentration increases so does the viscosity of the polymer 
solution and so diffusional separation of the chains is reduced. Thus, for low initial polymer 
concentrations small particles are produced initially and are maintained throughout the mixing 
process. As the initial polymer concentration increases so does the probability of aggregation 
leading to increased particle diameter. The data suggests a particle size maxima is achieved 
around 25 mg mL-1 while further increasing the concentration only serves to increase the 
distribution of particle sizes with minimal change to the average particle diameter. The 
narrowest particle distribution is achieved with an initial polymer concentration of 5 mg mL-1 
(212 ± 11 nm) though this may simply be due to reduced variability when measuring a larger 
sample size compared with particles formed using a 1 mg mL-1 polymer solution. As a result 
of these data an initial polymer concentration of 1 mg mL-1 was selected for all subsequent 
work. 
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4.2.1.2 Effect of Solution Volume on Particle Size 
 
Having established the smallest particles were formed by using an initial polymer concentration 
of 1 mg mL-1 the effect of total solution volume was subsequently investigated (Figure 4.4). 
PCL-OH was dissolved in acetone to a concentration of 1 mg mL-1 before 1 mL of solution 
was added to different volumes of water (1 – 10 mL) under agitation. 
 
Total H2O Volume (mL) Average Particle Diameter (nm) 
1 230 ± 3 
2 161 ± 10 
5 119 ± 2 
10 107 ± 11 
 
Table 4.2 – Effect of total water volume on particle diameter. Particle diameter is reported as the 
intensity distribution. Error represents ± 1 SD, n = 9 
 
 
Figure 4.4 – Effect of total water volume on particle diameter. Particle diameter is reported as the 
intensity distribution. Error bars represent ± 1 SD, n = 9. 
 
The smallest particle diameter was observed when the polymer solution was added to 10 mL 
of water (107 ± 11 nm). The diameter of particles was found to increase as the volume of water 
was decreased, reaching a maximum when the polymer solution was mixed with 1 mL of water 
(230 ± 3 nm). The sizes of particle formed when using 5 mL of water (119 ± 2 nm) were 
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comparable to those formed when using 10 mL of water (107 ± 11 nm). The results were as 
expected, decreasing the volume of water had a similar effect to increasing the initial polymer 
concentration and led to increased particle diameter. Similarities in particle diameter can be 
seen when comparing particles produced by mixing 1 mL of 1 mg mL-1 polymer solution with 
1 mL water (230 ± 3 nm, Figure 4.4) and mixing 1 mL of 5 mg mL-1 polymer solution with 10 
mL water (212 ± 11 nm, Figure 4.3), which have a similar final polymer concentration. The 
comparability of the data suggests the most important parameter in determining particle size is 
actually the final solution concentration. In order to further test this hypothesis the total solution 
volume was held constant, at 5 mL, and the ratio of water to polymer solution was varied 
(Figure 4.5).   
Ratio of H2O : Acetone Average Particle Diameter (nm) 
1 230 ± 3 
2 161 ± 10 
5 119 ± 2 
10 107 ± 11 
 
Table 4.3 – Effect of solvent ratio on particle diameter. Particle diameter is reported as the intensity 
distribution. Error represents ± 1 SD, n = 9 
 
Figure 4.5 – Effect of solvent ratio on particle diameter. Particle diameter is reported as the intensity 
distribution. Error bars represent ± 1 SD, n = 9. 
 
The data closely matches that gathered when varying the volume of water (Figure 4.4) despite 
the differences in the final solution volume between the two experiments. The data presented 
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therefore suggests that final solution concentration and not volume is a key factor in 
determining particle size. Due to the low variability observed in the data gathered using 5 mL 
of water and a H2O : Acetone ratio of 5 : 1 these parameters were selected for subsequent 
charge controlled nanoprecipitation.  
 
4.2.1.3 Effect of pH on Particle Size 
 
Having optimised the conditions for the nanoprecipitation procedure, it was necessary to 
investigate the effects of using different pH buffered solutions on the particle diameter. 
Furthermore these data would provide a baseline for comparison when performing charge 
controlled nanoprecipitation of carboxyl functionalised PCL. 
 
pH Average Particle Diameter (nm) 
7.4 662 ± 95 
8.0 130 ± 7 
9.0 124 ± 8 
10.0 143 ± 26 
11.0 154 ± 10 
12.0 193 ± 4 
13.0 273 ± 33 
 
Table 4.4 – Effect of pH on particle diameter. Particle diameter is reported as the intensity 
distribution. Error represents ± 1 SD, n = 9 
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Figure 4.6 – Effect of pH on particle diameter. Particle diameter is reported as the intensity 
distribution. Error bars represent ± 1 SD, n = 9. 
 
Precipitation of PCL-diol at physiological pH generated particles with the largest diameter of 
all those analysed (662 ± 95 nm). In contrast, a dramatic reduction in particle diameter (130 ± 
7 nm) was observed when precipitated in a pH 8.0 buffered solution. It is currently unclear why 
the change in pH was so impactful though the reason may not be due to pH alone as different 
salts were used to produce the pH 7.4 and 8.0 solutions. The pH 7.4 buffered solution was 
produced from the dissolution of commercially available phosphate buffered saline tablets 
containing phosphate and sodium chloride. Comparatively, the pH 8.0 buffer solution was 
produced by using of Na2[B4O5(OH)4].8H2O and HCl(aq). As such, the difference in buffering 
salts may have contributed to the difference in observed particle diameter. 
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A small decrease in the particle diameter was observed at pH 9.0 (124 ± 8 nm) compared to 
particles formed at pH 8.0. From pH 10.0 onwards, particle diameter was observed to increase 
with pH. PCL is known to degrade in the presence of a strong base[187], such as sodium 
hydroxide, and chain scission could explain the increase in particle diameter as a function of 
pH. To test this hypothesis 1H NMR spectroscopy of PCL-diol was taken before and after 
nanoprecipitation in the pH buffered solutions (Figure 4.7). 
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Figure 4.7 – 1H NMR spectra of PCL-diol a) prior to nanoprecipitation and b) after nanoprecipitation 
in pH 13.0 buffered solution. 
 
PCL-diol was isolated by first dialysing in distilled water, to remove the salts, before 
lyophilisation to yield the pure material. The Mn (NMR) for both samples was calculated by 
comparing integration values of the signals labelled e, 4.2 ppm, and d, 4.0 ppm, according to 
the equation Mn (NMR) = (e / (g / 2)) * 114.14. The Mn (NMR) of PCL-diol prior to precipitation 
was found to be 2144 g mol-1 while Mn (NMR) after precipitation was found to be 2128 g mol-1. 
Only a small difference in molecular weight was observed by this method and is likely the 
result of error inherent to the NMR spectroscopy instrument. As such it cannot be concluded 
that chain scission is responsible for the increase in particle diameter.  
 
4.2.2 Synthesis of Homotelechelic PCL with Ionisable Termini 
 
Having optimised the conditions for reducing the particle size of PCL-diol via 
nanoprecipitation and generating results for comparison, it was subsequently necessary to 
synthesise homotelechelic PCL with terminal carboxyl groups. Ionisable end groups would 
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allow for the particle size diameter to be altered using the charge controlled nanoprecipitation 
method discussed in section 4.2.3. Maleic anhydride and 3,6-oxo-1,2,3,6-tetrahydrophthalic 
anhydride (oTHPA) 54 were selected as suitable reagents to introduce terminal carboxyl 
groups. Maleic anhydride was selected as it is low cost and readily available, highly desirable 
to the development of facile methodologies. Additionally, synthesis of oTHPA was trivial and 
the starting materials also had low associated costs and were easily accessible. Anionic terminal 
groups were selected as cationic materials have been observed to exhibit higher 
cytotoxicity.[306] The synthesis of PCL-MA has been discussed previously in this thesis (section 
2.2.3.1) and was similarly synthesised for this work. The synthesis of PCL-oTHPA 55 is 
outlined in Scheme 4.2. 
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Scheme 4.2 – Synthesis of PCL-oTHPA 55 
 
oTHPA was first synthesised by the DA reaction of maleic anhydride and furan according to 
the procedure outlined by Woodward and Baer.[307] Crystals of the product precipitated from 
the solution and were purified by vacuum filtration and washing with cold diethyl ether in good 
yield (76%). The product was analysed by 1H NMR spectroscopy and exhibits a single vinyl 
proton signal (c) at 6.6 ppm evidencing successful DA coupling. Furthermore, only 2 additional 
signals are observed at 5.3 ppm (b) and 3.3 ppm (a) (Figure 4.8). 
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Figure 4.8 – 1H NMR spectrum of oTHPA 
 
With oTHPA in hand it was subsequently used for the end group modification of PCL-diol to 
afford homotelechelic PCL-oTHPA 55 (Scheme 4.2). As with the synthesis of other modified 
PCLs described throughout this thesis, quantitative modification of both terminal hydroxyl 
groups was critical and assessed by 1H NMR spectroscopy (Figure 4.9).  
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Figure 4.9 – 1H NMR spectrum of PCL-oTHPA 
 
Successful synthesis of PCL-oTHPA was determined by the appearance of new peaks at 6.4 
and 5.2 ppm. The degree of esterification was calculated by comparison of the integrals g and 
m + l according to the equation, degree of esterification = (g / (m + l) * 100. The degree of 
esterification was found to be 97%.  
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4.2.3 Charge Controlled Nanoprecipitation of Carboxyl Terminated PCL in a range 
of pH Buffered Solutions 
 
Charge controlled nanoprecipitation of PCL-MA was investigated first via the methodology 
developed previously for the nanoprecipitation of PCL-diol (section 4.2.1). 
 
pH Average Particle Diameter (nm) 
7.4 60 ± 6 
8.0 40 ± 4 
9.0 22 ± 1 
10.0 23 ± 1 
11.0 21 ± 2 
12.0 26 ± 5 
13.0 51 ± 4 
 
Table 4.5 – Effect of pH on particle diameter for PCL-MA. Particle diameter is reported as the 
intensity distribution. Error represents ± 1 SD, n = 9 
 
Figure 4.10 – Effect of co-solvent pH on the diameter of PCL-MA nanoparticles. Particle diameter is 
reported as the intensity distribution. Error bars represent ± 1 SD, n = 9. 
 
0
10
20
30
40
50
60
70
7.0 8.0 9.0 10.0 11.0 12.0 13.0
D
ia
m
et
er
 (n
m
)
pH
163 
 
The pKa of carboxylic acids in water is typically in the range 3 – 4.[308] As such the majority 
of carboxyl groups are charged (-COO-) across the investigated pH range. The presence of 
charged groups reduces the hydrophobicity of PCL and promotes electrostatic repulsion which 
was observed as a reduction in particle size. The diameter of the particles was observed to 
decrease linearly from 60 ± 6 nm at pH 7.0 to 22 ± 1 nm at pH 9.0. A particle diameter minima 
was found between pH 9 – 11 with only small variations in particle size observed within this 
range. The smallest diameter nanoparticles were observed to form at pH 11 (21 ± 2 nm). As 
such the data suggests complete ionisation of all terminal carboxyl groups at pH 9.0 and above. 
As the pH was increased from 12 to 13 the particle diameter was observed to increase as well 
as the variability of the data. No changes in molecular weight were observed when analysing 
the samples by 1H NMR spectroscopy, in agreement with previous analyses. Increasing the pH 
to 12 and 13 additionally increased the ionic strength of the buffer solution. As such a higher 
concentration of counter ions were present in the electric double layer surrounding the carboxyl 
groups present on the nanoparticles’ surface. Increased shielding of the particles’ charge could 
increase the hydrophobicity of the particles, promoting aggregation and increasing particle 
diameter. However, no investigation of the electric double layer was undertaken and as such 
the exact reason for the increase in particle diameter remains unclear. 
 
Having investigated the effect of pH on the particle size of PCL-MA nanoparticles, the 
experiments were repeated using previously synthesised PCL-oTHPA. The data for PCL-
oTHPA were compared to those gathered for PCL-MA (Figure 4.11). 
 
pH Average Particle Diameter (nm) 
7.4 44 ± 10 
8.0 26 ± 11 
9.0 14 ± 1 
10.0 19 ± 5 
11.0 16 ± 2 
12.0 19 ± 2 
13.0 57 ± 7 
 
Table 4.6 – Effect of pH on particle diameter for PCL-oTHPA. Particle diameter is reported as the 
intensity distribution. Error represents ± 1 SD, n = 9 
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Figure 4.11 – Comparison of nanoparticle diameters produced via charged controlled 
nanoprecipitation of PCL-MA, in black, and PCL-oTHPA, in red.  Error bars represent ± 1 SD, n = 9. 
 
An almost identical trend in particle diameter was observed for the precipitation of PCL-
oTHPA nanoparticles as for PCL-MA nanoparticles. At all pH values, except pH 13, PCL-
oTHPA nanoparticles were observed to be ≥ 5 nm smaller than PCL-MA nanoparticles 
produced via the same methodology. The reduction in particle size is attributed to the presence 
of the bridging ether moiety which further increases the hydrophilicity of the polymer terminus. 
Furthermore, the smallest particles of PCL-oTHPA were observed to form at pH 9 (14 ± 1 nm), 
in contrast to pH 11 for PCL-MA (21 ± 2 nm). Overall, charge controlled nanoprecipitation of 
carboxyl terminated PCL presents a significant improvement over conventional solvent-
displacement methods when attempting to access ultra-low nanoscale materials.   
0
10
20
30
40
50
60
70
7.0 8.0 9.0 10.0 11.0 12.0 13.0
D
ia
m
et
er
 (n
m
)
pH
165 
 
4.3 Chapter Summary 
 
Nanoprecipitation is a facile methodology for the production of polymeric nanoparticles which 
commonly utilises commercially available materials and simple laboratory equipment. 
However, the diameter of particles reported in the literature by this method varies significantly. 
The importance of carefully selected precipitation parameters was highlighted in this work 
when developing the method for nanoprecipitation of PCL-OH. Particle diameter was shown 
to vary between 387 ± 43 and 107 ± 11 as influenced by the initial and final polymer 
concentrations. Furthermore, the data shown here supports the conclusions previously reported 
by Reisch et al regarding the strong influence of terminal polymer moieties on particle size and 
utility of the charge controlled nanoprecipitation method. The formation of polymeric 
nanoparticles with average diameters ˂ 100 nm was achieved via precipitation of carboxyl 
terminated PCLs in a range of alkaline solutions. The smallest particle diameter recorded was 
14 ± 1 nm for PCL-oTHPA precipitated in pH 9 buffer solution. The hydrophilicity of the 
polymer terminus was also shown to contribute to the final particle diameter by comparison of 
PCL-MA and PCL-oTHPA nanoparticles formed by this method. 
 
While the data presented in this chapter is preliminary it serves to highlight the facile nature of 
charge controlled nanoprecipitation to the formation of particles with an average diameter ˂ 
100 nm. In the future, the synthesis of polymers with a wider variety of ionisable terminal 
moieties could provide additional control over the properties of nanoparticles and the sizes 
achieved. While particles baring an overall positive charge have been observed to exhibit 
higher cytotoxicity[306], compared with negatively charged particles, polymers with cationic 
terminal groups could be synthetically interesting. Furthermore, the polymers synthesised in 
this work bare terminal vinyl moieties which went unexplored as synthetic handles for further 
modification of the polymer properties. The utility of thiol-ene and thiol-Michael coupling has 
already been explored in this work and could conceivably be extended to the introduction of 
additional ionisable groups, for example by thiol-ene coupling with thioglycolic acid. The 
influence of multiple ionisable groups on the properties of nanoparticles produced by this 
method is currently unexplored.  
 
Due to the availability of equipment this work only characterised particles by DLS methods. 
This work would benefit from a more comprehensive analysis including independent 
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verification of particle size by imaging techniques such as transmission electron microscopy 
(TEM); quantification of the particles’ surface charge, such as zeta potential measurements; 
determination of long term particle stability, including the influence of changing buffer solution 
after particle formation and determination of the nanoparticles’ drug loading potential. Such 
analysis would guide future developments in this area and provide a more comprehensive 
overview of the factors at work in such systems.   
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5 General Conclusions 
In Chapter 1 the current state of polymer therapeutics was considered with regards to the range 
of synthetic strategies explored and the choice of materials for investigation. RDRP techniques, 
such as RAFT polymerisation, are advantageous compared to FRP techniques when control 
over molecular weight and dispersity are of concern, such as in biomedical applications. RAFT 
polymerisation was selected as the RDRP technique for the work in this these as it has excellent 
functional group tolerance and does not requiring the use of potentially toxic transition metal 
catalysts. 
 
While PEG has long been considered the “gold standard” in biocompatible polymers, research 
into the ABC phenomenon prompted investigation into alternative materials. PHPMA and PCL 
have a track record of use in biomedical materials and current data suggests PHPMA does not 
induce the ABC phenomenon. While there is an extensive body of research into these materials 
individually only four reports of combined PHPMA-PCL materials exist in the literature. While 
PHPMA-b-PCL-b-PHPMA block copolymers are known their synthesis via RDRP techniques, 
specifically RAFT polymerisation, was not. As a result the work in this thesis looked to expand 
the current body of research into these materials. 
 
Having identified a current gap in the literature with regards to the controlled synthesis of 
PHPMA-PCL block copolymers, Chapter 2 discussed the development methodologies to 
synthesise them. A grafting-from approach, based on the work of Lele and Leroux, using 
homotelechelic dithiobenzoate terminated PCL as a macro-CTA for the RAFT polymerisation 
of HPMA was first optimised. The ideal reaction conditions, as determined by the material 
with molecular weight >30,000 g mol-1 and lowest overall dispersity, was found when molar 
ratios of 1 : 238 : 0.29 of macro-CTA : HPMA : AIBN were reacted for 16 h at 58 °C in an 
acetone-methanol (2 : 3) solvent system which yielded an amphiphilic triblock copolymer (Mn 
(SEC) 29,432 g mol-1 and Ð 1.41) that was observed to self-assemble into nanoparticles (44 nm, 
number-distribution size as measured by DLS) upon addition to water. While this presented an 
improvement compared to materials reported by Lele and Leroux, even lower dispersity’s (< 
1.20) were desired. Pre-formed linear PHPMA and commercially purchased PCL were 
modified for conjugation via a range of click chemistries, CuAAC, hetero-DA, thiol-ene and 
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thiol-Michael. Ultimately, these methods did not yield useful quantities of PHPMA-b-PCL-b-
PHPMA block copolymers and further investigation into these methods was concluded. 
 
While PHPMA-b-PCL-b-PHPMA copolymers were shown to undergo aqueous self-assembly 
in Chapter 2, disassembly occurs below the associated critical micelle concentration. It is 
possible that such conditions are met during biocirculation resulting in undesired disassembly 
and uncontrolled payload release which, worst case, may harm the patient or, best case, reduce 
the efficacy of the treatment. Chapter 3 therefore considered the synthesis of HPMA based 
hyperbranched polymers, that do not undergo concentration dependent disassembly, as an 
alternative to materials discussed in Chapter 2. RCC was selected as the preferred synthetic 
strategy as it does not require the synthesis of bespoke inimers, which was thought to be less 
conducive to facile synthesis. Three novel amphiphilic PHPMA-star-(hb-(PHPMA-co-
PAPMA)) copolymers (Mn 139 – 243 kg mol-1, Ð 1.07 – 1.27) were synthesised for the first 
time using this method and the degree of branching, number of RAFT end groups and number 
of pendent vinyl moieties characterised by 1H NMR spectroscopy. 
 
Chapters 2 and 3 highlighted some of the difficulties when optimising the synthesis of 
amphiphilic polymers. Even if such methods can be developed, the use of costly reagents or 
complex methodologies may limit scalability of the method. Chapter 4 considered the use of 
charge controlled nanoprecipitation as a scalable method for producing hydrophobic 
nanoparticles. While nanoprecipitation is a facile methodology the diameter of particles 
reported in the literature by this method varies significantly. Data presented here showed the 
particle diameter to vary between 387 ± 43 and 107 ± 11 (error is ± 1 S.D.) as influenced by 
the initial and final polymer concentrations. The formation of polymeric nanoparticles with 
average diameters ˂ 100 nm was achieved via precipitation of carboxyl terminated PCLs in a 
range of alkaline solutions. The smallest particle diameter recorded was 14 ± 1 nm (error is ± 
1 S.D.)  for PCL-oTHPA precipitated in pH 9 buffer solution. 
 
Overall, synthesis of PHPMA-b-PCL-b-PHPMA block copolymer at higher molecular weight 
and lower dispersity than previously reported materials from a homotelechelic dithiobenzoate 
macro-CTA was achieved. Furthermore, three novel PHPMA-star-(hb-(PHPMA-co-
PAPMA)) copolymers were synthesised and the branching parameters of the hydrophobic core 
characterised by 1H NMR spectroscopy. Preliminary work into developing a scalable synthetic 
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procedure for producing PCL nanoparticles was undertaken. Under optimal conditions PCL-
oTHPA nanoparticles were produced with a number-average particle diameter of 14 ± 1 nm 
(error is ± 1 S.D.).  
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6 Experimental 
 
6.1 Materials 
 
All manipulations of air and moisture sensitive compounds were performed under an 
atmosphere of nitrogen. Reagents were purchased from Sigma (1-aminopropan-2-ol 97%, 
methacryloyl chloride 97%, maleic anhydride 99%, methacrylic anhydride 94%, N-acetyl-L-
cysteine 99% and 4,4′-azobis(4-cyanovaleric acid) ≥75%) and used as recieved. 
Polycaprolactone (Mn = ca. 2,000), dimethylaminopyridine,  dicyclocarbodiimide,  4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid 97% and 1-succinimidyl-4-cyano-4-[N-methyl-N-(4-
pyridyl)carbamothioylthio]pentanoate were purchased from Sigma-Aldrich and dried under 
vacuum for at least 4 hours prior to use. Azobis(isobutyronitrile) was purchased from Sigma, 
recrystallised from methanol and dried for 4 hours prior to use. 
 
6.2 Experimental Characterisation Methods 
 
6.2.1 Nuclear Magnetic Resonance 
 
Deuterated solvents were purchased from Cambridge Isotopes Laboratories, Inc. NMR spectra 
were recorded using either a 400 MHz Bruker NMR or 500 MHz Bruker ADVANCE NMR 
spectrometer. All chemical shifts are expressed as parts per million relative to tetramethylsilane 
(δH = 0.00 ppm) and coupling constants are given in Hertz to the nearest 0.5 Hz. 1H NMR 
spectra are referenced to residual protic solvent peaks: 2.50 ppm for DMSO-d6, 3.31 for MeOD 
or 7.26 ppm for CDCl3. The data is reported in the form: chemical shift (δ) in ppm, multiplicity  
(s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, multiplet), integration, coupling 
constants (J) in Hz, assignment. 13C-NMR spectra were recorded at 75 MHz and referenced to 
either CDCl3 at 77.0 ppm or DMSO-d6 at 39.5 ppm. The data is reported in the form: chemical 
shift (δ) in ppm, multiplicity, integration, coupling constants (J) in Hz, assignment.  
 
6.2.2 Size Exclusion Chromatography  
 
SEC analysis was performed on a Viscotek 270 GPCmax with separation performed via three 
sequential single-pore styrene-divinyl benzene columns (300 mm x 8.0 mm, D-4000, D-2500, 
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D-2000). Triple detection analysis was achieved with a Viscotek 270 Dual Modular SEC 
Detector (including viscometer, right angle and low angle light scattering detector) and 
VE3580 Viscotek RI concentration detector. Samples were prepared by dissolving 1-3 mg of 
polymer in 1 mL solution of DMF with 0.01 M LiBr and filtering through 0.45 μm filter prior 
to analysis. GPC measurements were performed at 0.7 ml/min flow rate at 50 °C and the data 
analysed using OmniSEC 5.12 software. Polymer dn/dc values were determined online 
assuming 100% mass recovery during GPC analysis. 
 
6.2.3 Dynamic Light Scattering 
 
Measurements for the determination of particle diameter and size distribution was recorded 
using a Zetasizer Nano S (Malvern Instruments). Data were recorded as the mean value of the 
diameter of the size distribution per intensity and reported either as such or as per number 
where indicated in the text. Samples were measured at least three times and the error (bars) 
reported as ± 1 SD. 
 
6.2.4 Gas Chromatography-Mass Spectrometry 
 
GC-MS spectra were recorded on an Agilent Technologies 7890A GC system connected to an 
Agilent Technologies 5975C inert XL EI/CI mass selective detector (MSD) operating in 
electron impact (EI) mode and the conditions were as follows: inj. vol. 1 μL, inj. temp. 250 °C, 
column Agilent HP-5MS (30 m × 0.25 mm), oven temperature gradient 0 – 10 min, 30 °C; 10-
21 min, 30 – 250 °C (20 °C ramp per minute). 
 
6.2.5 Fourier Transform Infrared Spectroscopy 
 
Infrared spectra were recorded using Agilent technologies 640 FT-IR spectrometer with MKII 
Golden Gate Single Reflection ATR System. 
 
6.2.6 Ultra-Violet Visible Spectroscopy 
 
UV-Vis spectra were recorded on a Biochrom Libra S50 spectrophotometer at room 
temperature in a disposable plastic cuvette or quartz cuvette according to the solvent used. 
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Measurements were performed as wavelength scanning between 200 and 800 nm with 
subtraction of a blank sample. Raw data was exported to Microsoft Excel for analysis. 
 
6.3 Synthetic Methods 
 
6.3.1 N-(2-hydroxypropyl)methacrylamide (HPMA) 
 
1-Aminopropan-2-ol (43.1 g, 0.574 mol) and anhydrous sodium hydrogen carbonate (67.0 g, 
0.798 mol) were added to a round-bottomed flask and placed under a N2 atmosphere by x3 
vacuum-refill cycles. A suspension was formed by adding DCM (dry, 60 mL) and stirring 
vigorously. To the attached pressure equalizing dropping funnel, a fresh bottle of methacryloyl 
chloride (50 mL, 53.5 g, 0.512 mol) was dissolved in DCM (dry, 60 mL). The reaction flask 
was then cooled to -20 °C in an ethanol-dry ice bath and allowed to equilibrate for 30 min. The 
methacryloyl chloride solution was added dropwise at a rate of 1 drop per second. Once 
addition was complete the reaction flask was allowed to warm to room temperature with 
continuous stirring. After 30 min, anhydrous sodium sulphate (10 g, 0.070 mol) was added to 
the solution and left to stir for 1 hour. After stirring, the solution was filtered, washed with 
DCM (3 x 20 mL) and the combined filtrates concentrated on a rotary evaporator. This 
concentrated solution was then left at -20 °C for 16 hours and the crystals formed were filtered 
and re-crystallised from acetone. The final product appears as transparent crystals (28.4 g, 
78%). 
 
FTIR: ṽ (cm-1) (neat): 3300 (s br, -OH), 3266 (s br, amide N-H), 3089 (w, sp2 C-H) , 2974 (m, 
sp3 C-H), 2931 (m, sp3 C-H), 1653 (s, amide C=O), 915 (s, sp2 C-H) 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 1.02 (d, 3H, J = 6.0, H-f), 1.87 (s, 3H, H-a) 3.09 (m, 
2H, H-d) 3.72 (m, 1H, H-e) 4.56 (d, 1H, J = 6.5, H-g), 5.32 (s, 1H, H-b) 5.69 (s, 1H, H-b), 7.83 
(broad s, 1H, H-c) 
13C (75 MHz, DMSO-d6), δ (ppm): 19.1 (C-h), 21.5 (C-a), 47.2 (C-d), 65.6 (C-e), 119.4 (C-h) 
140.4 (C-b), 168.1 (C-i) 
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6.3.2 N-(2-acetoxypropyl)methacrylamide (APMA) 
 
HPMA (5.07 g, 0.0354 mol) was dissolved in acetic anhydride (23.0 mL, 0.244 mol) and cooled 
to 0°C. To this, triethylamine (9.0 mL, 0.064 mol) and DMAP (0.111 g, 0.909 mmol) were 
added and left to stir for 16 h. The mixture was diluted with ethyl acetate (35 mL) and added 
to ice. Na2CO3 was added to the mixture with stirring until no further gas (CO2) evolved and a 
basic pH was verified in the aqueous layer. The mixture was extracted with additional ethyl 
acetate (3 x 35 mL) and the combined organic layers washed with CuSO4 (3 x 20 mL) and 
brine (35 mL portions until the brine layer was colourless). The organic phase was dried with 
anhydrous MgSO4 and the solvent evaporated to yield the crude product as a brown oil (4.10 
g). The product was purified by column chromatography on silica (hexane/ethyl acetate [1:1]) 
(Rf = 0.34) to give a pale yellow oil (4.92 g, 75 %). 
 
FTIR: ṽ (cm-1) (neat): 3332 (m, N-H), 2982 (w, sp2 C-H), 2935 (m, sp3 C-H), 1657 (s, amide 
C=O), 928 (s, sp2 C-H) 
1H NMR (500 MHz, CDCl3), δ (ppm): 1.26 (d, 3H, J = 6.4, H-f), 1.96 (s, 3H, H-a), 2.06 (s, 3H, 
H-g), 3.40 (dd, 1H, J = 7.6, 6.0, H-d) 3.52 (dd, 1H, J = 5.6, 3.6, H-d), 5.04 (m, 1H, H-e), 5.33 
(s, 1H, H-b) 5.69 (s, 1H, H-b), 6.30 (broad s, 1H, H-c) 
13C (75 MHz, CDCl3), δ (ppm): 17.7 (C-g), 18.6 (C-a), 21.2 (C-f), 44.4 (C-d), 70.0 (C-e), 119.6 
(C-b), 139.8 (C-h), 168.5 (C-i), 171.1 (C-j) 
 
6.3.3 3,6-oxo-1,2,3,6-tetrahydrophthalic anhydride (oTHPA) 
 
Maleic anhydride (6.47g, 0.0660 mol) was dissolved in diethyl ether (50 mL) and to this 
solution, furan (4.50 mL, 4.21 g, 0.0619 mol) was added. The solution was left to react for 7 
days after which large yellow crystals were observed to have formed in the flask. The crystals 
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were filtered, washed with cold diethyl ether (3 x 10 mL) and finally dried under vacuum  
(8.29g, 76%). 
 
FTIR: ṽ (cm-1) (neat): 3101 (sp2 C-H), 3002 (sp3 C-H), 1780 (C=O), 1083 (C-O-C) 
1H NMR (300 MHz, d-DMSO), δ (ppm):  3.31 (s, 2H, H-c), 5.35 (s, 2H, H-b), 6.58 (s, 2H, H-
a) 
13C (75 MHz, d-DMSO), δ (ppm): 49.53 (C-c), 82.10 (C-b), 137.31 (C-a), 171.99 (C-d) 
 
6.3.4 (1/2)-tert-Butyl-methanoate-1,3-cyclopentadiene 
 
t-Butyl bromoacetate (2.0 mL, 0.012 mol) was diluted in freshly distilled THF (10 mL) under 
an inert atmosphere before being cooled to -78 °C. Separately, sodium cyclopentadienylide 
(8.0 mL, 0.016 mol) was diluted in freshly distilled THF (20 mL) under an inert atmosphere 
before being added dropwise to the reaction solution. After 3 h, the reaction was quenched with 
methanol (10 mL) and the solvent removed under reduced pressure before being filtered to give 
a colourless liquid. The product was purified by homogenisation with chloroform (50 mL) and 
extraction with water (2 x 50 mL) and brine (50 mL). The organic layer was dried over MgSO4 
and the solvent removed under reduced pressure at room temperature to give a clear, colourless 
liquid (2.79 g, 97 %). 
 
1H NMR (500 MHz, CDCl3), δ (ppm): 1.45 (s, 9H, H-a), 2.98 (d, 2H, J = 15.0, H-d), 3.31 (d, 
2H, J = 15.0, H-b), 6.18 (m, 1H, H-c), 6.31 (m, 1H, H-e), 6.42 (m, 1H, H-g), 6.50 (m, 1H, H-
f) 
13C (75 MHz, CDCl3), δ (ppm): 28.3 (C-a), 37.3 (H-b), 41.6 (H-d), 81.0 (H-i), 129.6 (C-c/g), 
132.4 (C-e), 134.0 (C-f), 139.6 (C-c/g), 171.0 (C-h) 
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6.3.5 Removal of t-Butyl protecting group from (1/2)-tert-Butyl-methanoate-1,3-
cyclopentadiene 
 
Trifluoroacetic acid (10.0 mL, 0.131 mol 40% v/v in CHCl3) was added dropwise to (1/2)-tert-
Butyl-ethanoate-1,3-cyclopentadiene (2.07 g, 0.0115 mol) to give a dark yellow-green 
solution. The solution was left to react for 16 h after which the solution appeared dark green. 
Excess TFA was removed by azeotropic distillation with CHCl3 (5 x 10 mL) before further 
drying under high vacuum. Product was isolated as a colourless liquid (1.37 g, 97%) 
 
1H NMR (400 MHz, CDCl3), δ (ppm):  Spectra contained multiple broad and overlapping peaks 
preventing useful assignment, see appendix 8.4. 
 
6.3.6 Polycaprolactone macro-CTA modified with 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid 
 
PCL-diol (1.13 g, 0.377 mmol), 4-cyano-4-(thiobenzoylthio)pentanoic acid (1.04 g, 3.72 
mmol) and DMAP (0.05 g, 0.41 mmol) were added to a flask and placed under a N2 atmosphere 
by atmosphere by x3 vacuum-refill cycles. The solids were dissolved in DCM (dry, 3 mL) 
before cooling in a ice bath. Seperately DCC (0.866 g, 4.20 mmol) was similarly placed under 
an inert nitrogen atmosphere and dissolved in DCM (dry, 2 mL) before being added dropwise 
to the reaction solution. The flask was covered in foil and left to stir overnight whilst coming 
to room temperture. Each day for the next 3 days additional DCC (0.510 g, 2.47 mmol) was 
added to the reaction solution before leaving the solution to react for an additional 2 days. After 
this time the solution was filtered and the solids washed with DCM (3x 5 mL) until they 
appeared as a white solid. The combined filtrates were then concentrated on a rotavap (ca. 5 
mL) and the product isolated by precipitating in cold methanol (<5 °C, 300 mL) three times. 
The final product was dried under vaccum to give a pink coloured solid (0.563 g, 56 %).  
 
 
O
O
O
O
O
O O
S
O
NC
S
O
CNS S
x ya
b
c
d
e
f
g
h
i
j
k
l
OH
O
b
e
g h
c
d
f a
176 
 
FTIR: ṽ (cm-1) (neat): 2944 (sp3 C-H), 1732 (C=O), 1173 (C-O) 
1H NMR (500 MHz, CDCl3), δ (ppm): 1.29 (m, 2H, H-c), 1.58 (m, 4H, H-b + d), 2.24 (t, 2H, 
J = 6.0, H-a), 2.59 (m, 4H, H-h + i), 3.62 (t, 2H, J = 6.0, H-f), 4.01 (t, 2H, J = 7.4, H-e), 4.16 
(t, 2H, J = 4.8, H-g), 7.33 (m, 2H, H-k), 7.50 (m, 2H, H-l), 7.85 (m, 1H, H-j) 
 
Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
2,013 1,695 3,163 1.87 56 
 
 
6.3.7 Polycaprolactone macro-CTA modified with 1-succinimidyl-4-cyano-4-[N-
methyl-N-(4-pyridyl)carbamothioylthio]pentanoate 
 
PCL-diol (1.08 g, 0.360 mmol), 1-succinimidyl-4-cyano-4-[N-methyl-N-(4-
pyridyl)carbamothioylthio]pentanoate (1.36 g, 3.35 mmol) and DMAP (52.1 g, 0.426 mmol) 
were added to a flask and placed under a N2 atmosphere by x3 vacuum-refill cycles and the 
flask covered in foil. The solids were then dissolved in DCM (dry, 3 mL) before triethylamine 
(0.50 mL, 0.36 g, 3.6 mmol) was added and the solution allowed to react overnight. Seperately 
DCC (0.866 g, 4.20 mmol) was placed under an inert nitrogen atmosphere and dissolved in 
DCM (dry, 2 mL). After reacting overnight, the reaction flask was cooled in an ice bath before 
the DCC solution was added dropwise. The flask was then left to stir overnight whilst coming 
to room temperture. Each day for the next 2 days additional DCC (0.503 g, 2.44 mmol) was 
added to the reaction solution before leaving the solution to react for an additional 2 days. After 
this time the solution was filtered and the solids washed with DCM (3x 5 mL) until they 
appeared as a white solid. The combined filtrates were then concentrated on a rotavap (ca. 5 
mL) and the product isolated by precipitating in cold methanol (<5 °C, 300 mL) three times. 
The final product was dried under vaccum to give a light-yellow coloured solid (0.517 g, 42 
%).  
 
FTIR: ṽ (cm-1) (neat): 2945 (sp3 C-H), 2866, 1721 (C=O), 1175 (C-O) 
O
O
O
O
O
O O
S
O
NC
S
O
CN
NN
S S
x ya
b
c
d
e
f
g
h
i
NN
j
k
l
177 
 
1H NMR (500 MHz, CDCl3), δ (ppm): 1.32 (m, 2H, H-c), 1.58 (m, 4H, H-b + d), 2.24 (t, 2H, 
J = 7.5, H-a), 2.46 (m, 4H, H-i + h), 3.70 (s, 5H, H-f + j), 4.51 (t, 2H, J = 7.4, H-e), 4.23 (t, 2H, 
J = 6.2, H-g), 7.25 (d, 2H, J = 6.4, H-k), 8.71 (d, 2H, J = 6.4, H-l) 
 
Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
2,231 2,783 4,572 1.64 42 
 
 
6.3.8 Polycaprolactone terminated with maleic Anhydride (PCL-MA) 
 
PCL (2 g, 0.67 mmol) maleic anhydride (0.65 g, 6.63 mmol) and DMAP (0.0514 g, 0.41 mmol) 
were added to a flask and placed under a N2 atmosphere by x3 vacuum-refill cycles. The solids 
were then dissolved in THF (dry, 50 mL), covered in foil and left to react for 24 h. The solution 
was concentrated by rotary evaporation before precipitating in cold methanol three times. The 
product was isolated as a brown solid (1.33 g, 67%).  
 
FTIR: ṽ (cm-1) (neat): 3440 (H-bond –OH), 2945 (sp3 C-H), 1721 (C=O), 1175 (C-O)  
1H NMR (500 MHz, CDCl3), δ (ppm): 1.38 (m, 2H, H-c), 1.63 (m, 4H, H-b + d), 2.31 (t, 2H, 
J = 7.4,H-a), 3.67 (m, 2H, H-f), 4.08 (t, 2H, J = 7.4, H-e), 4.12 (m, 2H, H-g), 5.56 (s, 2H, H-i), 
6.11 (s, 2H, H-h) 
 
Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
2,069 2,486 4,326 1.73 67 
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6.3.9 Synthesis of polycaprolactone modified with methacrylic anhydride (PCL-
MeA) 
 
PCL (2 g, 0.67 mmol) and DMAP (0.0514 g, 0.41 mmol) were added to a flask and placed 
under a N2 atmosphere by x3 vacuum-refill cycles. The solids were then dissolved in THF (dry, 
50 mL) before methacrylic anhydride (1 mL, 1.04 g, 6.68 mmol) was added via syringe. The 
flask was covered in foil and left to react for 24 h. The solution was then concentrated by rotary 
evaporation before precipitating in cold methanol three times. The product was isolated as a 
white powder (1.07 g, 53%).  
 
FTIR: ṽ (cm-1) (neat): 2946 (sp3 C-H), 1721 (C=O), 1165 (C-O) 
1H NMR (500 MHz, CDCl3), δ (ppm): 1.34 (m, 2H, H-c), 1.55 (m, 4H, H-b + d), 2.31 (t, 2H, 
J = 7.5,H-a), 3.62 (m, 2H, H-f), 4.06 (t, 2H, J = 7.4, H-e), 4.26 (t, 2H, J = 4.8, H-g), 6.33 (d, 
1H, J = 21.1, H-i), 6.43 (d, 1H, J = 21.1, H-f) 
 
Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
3,092 3,298 6,167 1.87 53 
 
 
6.3.10 Synthesis of polycaprolactone modified with 3,6-oxo-1,2,3,6-tetrahydrophthalic 
anhydride (PCL-oTHPA) 
 
PCL (2.0 g, 0.66 mmol), oTHPA (1.1 g, 6.73 mmol) and DMAP (0.052 g, 0.41 mmol) were 
added to a flask and placed under a N2 atmosphere by x3 vacuum-refill cycles. The solids were 
then dissolved in THF (dry, 50 mL) and left to react for 3 days. The solution was then 
concentrated by rotary evaporation before precipitating in cold methanol. The solid material 
was then re-dissolved in THF and dialysed (MWCO = 1 kg mol-1) against THF (200 mL) for 1 
day. The product was isolated by lyophilisation as a flaky, white solid (1.36 g, 68%). 
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1H NMR (300 MHz, CDCl3), δ (ppm): 1.34 (m, 2H, H-c), 1.63 (m, 4H, H-b + d), 2.27 (t, 2H, 
J = 7.4,H-a), 2.69 (d, 2H, J = 9.2, H-i), 2.77 (d, 2H, J = 9.2,H-h), 3.64 (m, 2H, H-f), 4.06 (t, 
2H, J = 7.5, H-e), 5.20 (s, 4H, H-j + k), 6.40 (s, 2H, H-l) 
 
Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
2,401 2,931 4,748 1.62 68 
 
 
6.3.11 Synthesis of PHPMA-b-PCL-b-PHPMA by thiol-ene click of PHPMA and  
vinyl terminated PCL 
 
6.3.11.1 Thermally initiated reaction: 
PHPMA (100 mg, 0.0125 mmol), TCEP (5 mg, 0.02 mmol) and vinyl terminated PCL (PCL-
MA/PCL-MeA) (18.8 mg, 0.006 mmol) were placed under a nitrogen atmosphere by x3 
vacuum-refill cycles before  dissolving in DMF-Dioxane (5 mL, 1.5:1). Separately, an AIBN 
stock solution (0.035 g, 0.2 mmol in 1 mL DMF) was made and an aliquot (0.1 mL) was 
transferred to the reaction vessel. The reaction solution was sparged with N2 for 30 min before 
transferring to a pre-heated oil bath at 70 °C and left to react for 16 h. The reaction was 
quenched by exposure to air and freezing in liquid nitrogen. The product was purified by 
dialysis (MWCO 6-8 kg mol-1) against THF for 24 h before the dialysate switched to water and 
left for 2 days, changing the water every 3 h. The final product was isolated by lyophilisation 
as a light brown solid (84.2 mg, 71 wt.%). 
 
FTIR: ṽ (cm-1) (neat): 3353 (H-bonded –OH), 2972 (sp3 C-H), 1636 (amide C=O) 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 0.82 (br, 2H, H-b), 1.04 (br, 3H, H-f), 1.56 (br, 3H, 
H-a), 2.91 (br, 2H, H-d), 3.66 (br, 1H, H-e), 4.70 (br, 1H, H-g), 7.16 (br, 1H, H-c) 
 
Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
13,238 14,458 17,053 1.18 71 
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6.3.11.2 Photoinitiated reaction: 
PHPMA (100 mg, 0.0125 mmol), TCEP (5 mg, 0.02 mmol) and vinyl terminated PCL (PCL-
MA/PCL-MeA) (18.8 mg, 0.006 mmol) were dissolved in DMF-Dioxane (5 mL, 1.5:1). 
Separately, an DMPA stock solution (0.050 g, 0.2 mmol in 1 mL DMF) was made and an 
aliquot (0.1 mL) was transferred to the reaction vessel. The reaction solution was sparged with 
N2 for 30 min before irradiating with 264 nm light for 16 h. The reaction was quenched by 
exposure to air and freezing in liquid nitrogen. The product was purified by dialysis (MWCO 
6-8 kg mol-1) against THF for 24 h before the dialysate switched to water and left for 2 days, 
changing the water every 3 times a day. The final product was isolated by lyophilisation as a 
light brown solid (83.8 mg, 70 wt.%). 
 
 
1H NMR (500 MHz, DMSO-d6), δ (ppm):  0.81 (br, 2H, H-b), 1.02 (br, 3H, H-f), 1.57 (br, 2H, 
H-a), 2.93 (br, 2H, H-d), 3.69 (br, 1H, H-e), 3.98 (t, 2H, J = 7.4, H-h), 4.70 (br, 1H, H-g), 7.17 
(br, 1H, H-c) 
 
Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
13,622 14,877 16,548 1.11 71 
 
6.3.12 Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) 
 
6.3.12.1 Via dithiobenzoate RAFT agent: 
In a typical reaction, HPMA (0.716 g, 5 mmol) and 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid (14.4 mg, 0.05 mmol) were placed under an inert N2 
atmosphere by x3 vacuum-refill cycles. The solids were then dissolved in acetate buffer (5 mL, 
pH 5.6) to give a red-pink solution. Separately a stock solution of ACVA (0.0142 g, 0.05 mmol 
in 1 mL MeOH) was made and an aliquot (0.1 mL) of this solution was added to the reaction 
vessel. The reaction solution was then cooled in an ice-water bath before being degassed by 
bubbling with N2 for 30 min. After 30 min, the flask was transferred to a pre-heated oil bath 
(70 °C) and left to react for 16 h. The reaction was then quenched by exposing the solution to 
HO
S O
O
O
O
O S
OH
O
CN
O
OO
O
NC
O
x y
m n
HN O
OH
O NH
OH
h
i
j
k
l
a
b
c
d
e f
g
181 
 
the air and freezing in liquid nitrogen. The solution was then transferred to a piece of dialysis 
tubing (1 kg mol-1 MWCO) and dialysed against water for 2 days, changing the water 3 times 
a day. After dialysing the solution was frozen and lyophilised to yield the final product as a 
light pink solid. 
 
 
FTIR: ṽ (cm-1) (neat): 3349 (H-bonded –OH), 2973 (sp3 C-H), 1636 (amide C=O) 
1H NMR (400 MHz, DMSO-d6), δ (ppm): 0.81 (br, 2H, H-b), 1.02 (br, 3H, H-f), 1.57 (br, 3H, 
H-a), 2.91 (br, 2H, H-d), 3.67 (br, 1H, H-e), 4.70 (br, 1H, H-g), 7.17 (br, 1H, H-c), 7.46 (s, 2H, 
H-i), 7.61 (t, J = 7.3, 1H, H-j), 7.80 (d, J = 8.5, 2H, H-h) 
 
Code Mn (NMR) Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
P1 13,184 11,847 12,468 1.05 52 
P2 12,113 11,752 12,704 1.08 51 
P3 16,420 17,207 17,512 1.02 63 
P4 13,444 12,447 13,121 1.05 59 
 
6.3.12.2 Via trithiocarbonate RAFT agent: 
HPMA (0.716 g, 5 mmol) and 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic 
acid (20.2 mg, 0.05 mmol) were placed under an inert N2 atmosphere by x3 vacuum-refill 
cycles. The solids were then dissolved in DMAc (5 mL) to give a pale yellow solution. 
Separately a stock solution of AIBN (0.082 g, 0.05 mmol in 1 mL DMAc) was made and an 
aliquot (0.1 mL) of this solution was added to the reaction vessel. The reaction solution was 
then cooled in an ice-water bath before being degassed by bubbling with N2 for 30 min. After 
30 min, the flask was transferred to a pre-heated oil bath (70 °C) and left to react for 16 h. The 
reaction was then quenched by exposing the solution to the air and freezing in liquid nitrogen. 
S
S
NHO
OH
CN
OH
O
a
b
c
def
g
h
i
j
x
182 
 
The solution was then transferred to a piece of dialysis tubing (1 kg mol-1 MWCO) and dialysed 
against water for 2 days, changing the water 3 times a day. After dialysing the solution was 
frozen and lyophilised to yield the final product as a light pink solid. 
 
FTIR: ṽ (cm-1) (neat): 3348 (H-bonded –OH), 2973 (sp3 C-H), 1639 (amide C=O) 
1H NMR (400 MHz, DMSO-d6), δ (ppm): 0.81 (br, 2H, H-b), 1.02 (br, 3H, H-f), 1.57 (br, 3H, 
H-a), 2.91 (br, 2H, H-d), 3.67 (br, 1H, H-e), 4.70 (br, 1H, H-g), 7.17 (br, 1H, H-c) 
 
Mn (SEC) Mw (SEC) Ð Yield (wt. %) 
7,789 8,568 1.10 26 
 
6.3.13 Synthesis of Poly(N-(2-acetoxypropyl)methacrylamide) (PAPMA) 
 
In a typical reaction, APMA monomer (0.926 g, 5 mmol) and the RAFT agent, either 4-cyano-
4-(phenylcarbonothioylthio)pentanoic acid (14 mg, 0.05 mmol) or 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (20.2 mg, 0.05 mmol), were placed 
under an inert N2 atmosphere by x3 vacuum-refill cycles. The solids were then dissolved in 
DMAc (5 mL) to give a pale yellow solution. Separately a stock solution of AIBN (17.0 mg, 
0.1 mmol in 1 mL DMAc) was made and an aliquot (0.1 mL) of this solution was added to the 
reaction vessel. The reaction solution was then cooled in an ice-water bath before being 
degassed by bubbling with N2 for 30 min. After 30 min, the flask was transferred to a pre-
heated oil bath (70 °C) and left to react for 16 h. The reaction was quenched by exposing the 
solution to the air and freezing in liquid nitrogen. The solution was then dialysed (1 kg mol-1 
MWCO) against water for 2 days, changing the water 3 times a day. After dialysis the solution 
was frozen and lyophilised to yield the final product as a pale yellow solid (2.4 mg, ˂ 1%). 
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Insufficient material was isolated for characterisation. 
 
6.3.14 Synthesis of linear PHPMA-co-PAPMA 
 
In a typical reaction, HPMA (0.359 g, 2.5 mmol) APMA (0.464 g, 2.5 mmol), and 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (20.2 mg, 0.05 mmol) were placed 
under an inert N2 atmosphere by x3 vacuum-refill cycles. The solids were then dissolved in 
DMAc (5 mL) to give a pale yellow solution. Separately a stock solution of AIBN (17.0 mg, 
0.1 mmol in 1 mL DMAc) was made and an aliquot (0.1 mL) of this solution was added to the 
reaction vessel. The reaction solution was then cooled in an ice-water bath before being 
degassed by bubbling with N2 for 30 min. After 30 min, the flask was transferred to a pre-
heated oil bath (70 °C) and left to react for 16 h. The reaction was then quenched by exposing 
the solution to the air and freezing in liquid nitrogen. The solution was then transferred to a 
piece of dialysis tubing (1 kg mol-1 MWCO) and dialysed against THF for 1 day and then water 
for 2 days, changing the water 3 times a day. After dialysing the solution was frozen and 
lyophilised to yield the final product as a pale yellow solid. 
 
1H NMR (400 MHz, DMSO-d6), δ (ppm): 0.78 – 1.23 (br m, 16H, H-a + a’ + b + b’ + f + f’), 
2.00 (br, 3H, H-h), 2.92 (br, 2H, H-d’), 3.07 (br, 2H, H-d), 3.68 (br, 1H, H-e), 4.70 (br, 1H, H-
g), 4.81 (br, 1H, H-e’), 7.11 (br, 1H, H-c), 7.40 (br, 1H, H-c’) 
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Code Molar Ratio a Mn  (SEC) Mw  (SEC) Ð Yield (wt. %) 
P43 50 : 50 : 1 : 0.2 9,867 13044 1.32 25 
P44 33 : 66 : 1 : 0.2 9,144 13579 1.49 23 
P45 25 : 75 : 1 : 0.2 6,278 8557 1.36 19 
P46 12.5 : 87.5 : 1 : 0.2 4,629 7212 1.56 7 
a Molar ratios are HPMA : APMA : RAFT : Initiator 
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6.3.15 Synthesis of hyperbranched PHPMA by RAFT polymerisation (HB-PHPMA) 
 
In a typical reaction, HPMA monomer (0.7160 g, 5 mmol) and 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid (14.0 mg, 0.05 mmol) were placed under an inert N2 
atmosphere by x3 vacuum-refill cycles. Separately, EGDMA was freshly filtered through a 
short column of basic alumina before being added to the reaction vessel (0.01 mL, 0.05 mmol). 
The mixture was then dissolved in acetate buffered H2O (pH 5.6) and MeOH (4:1, 5 mL total). 
Separately a stock solution of ACVA (28.0 mg, 0.1 mmol in 1 mL MeOH) was made and an 
aliquot (0.1 mL) of this solution was added to the reaction vessel. The reaction solution was 
then cooled in an ice-water bath before being degassed by bubbling with N2 for 30 min. After 
30 min, the flask was transferred to a pre-heated oil bath (70 °C) and left to react for 16 h. The 
reaction was then quenched by exposing the solution to the air and freezing in liquid nitrogen. 
The solution was then transferred to a piece of dialysis tubing (1 kg mol-1 MWCO) and dialysed 
against water for 2 days, changing the water 3 times a day. After dialysing the solution was 
frozen and lyophilised to yield the final product as a pale pink solid. 
 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 0.81 (br, 2H, H-b), 1.02 (br, 3H, H-f), 1.58 (br, 3H, 
H-a), 2.91 (br, 2H, H-d), 3.67 (br, 1H, H-e), 4.09 – 4.29 (br, 8H, H-j + j’ + k + k’), 4.71 (br, 
1H, H-g), 5.40 (br, 1H, H-m), 5.70 (br, 1H, H-n), 7.18 (br, 1H, H-c), 7.46 (s, 2H, H-i), 7.61 (t, 
1H, J = 7.2, H-j), 7.80 (d, 2H, J = 9.5, H-h) 
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Code Molar ratios a 
Mn (NMR) 
(g mol-1) 
Mn (SEC) 
(g mol-1) 
Mw 
(g mol-1) 
Ð 
Yield 
(wt. %) 
P21 100 : 1 : 1 : 0.2 13,606 17,054 24,064 1.41 28 
P22 100 : 1 : 1 : 0.2 12,527 18,711 24,929 1.33 30 
P23 100 : 1 : 1 : 0.2 19,454 42,694 84,070 1.97 36 
P24 100 : 1 : 1 : 0.2 21,826 84,974 163,288 1.92 38 
P25 100 : 1 : 2 : 0.2 15,910 27,915 89,575 3.21 27 
P26 100 : 1 : 5 : 0.2 18,826 107,692 318,929 2.96 25 
P27 100 : 1 : 10 : 0.2 Gel Gel Gel Gel Gel 
P28 100 : 2 : 1 : 0.2 4,183 7,676 9,688 1.26 24 
P29 100 : 5 : 1 : 0.2 - - - - - 
P30 100 : 10 : 1 : 0.2 - - - - - 
P31 100 : 2 : 2 : 0.2 8,993 10,079 16,927 1.68 19 
P32 100 : 5 : 5 : 0.2 2,194 3,628 10,377 2.86 11 
P33 100 : 10 : 10 : 0.2 736 658 2,044 3.11 12 
a Molar ratios are HPMA : RAFT : EGDMA : Initiator 
 
6.3.16 Acetylation of linear PHPMA (AcOPHPMA) using: 
 
6.3.16.1 Acetic anhydride, no catalyst 
In a typical reaction, PHPMA (50 mg) was added to a mixture of CHCl3 (2 mL) and acetic 
anhydride (2 mL, 0.018 mmol). The suspension was stirred for 48 h to give a clear pink 
solution. The solution was dialysed against THF for 24 h, changing the dialysate 3 times. After 
dialysis the solvent was removed under reduced pressure to yield the product as a pink solid 
(44.6 mg, 89 %). 
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1H NMR (400 MHz, CDCl3), δ (ppm):  0.94 (br, 2H, H-b), 1.25 (br, 3H, H-f), 1.70 (br, 3H, H-
a), 2.10 (br, 3H, H-g), 3.11 – 3.46 (br, 2H, H-d), 4.97 (br, 1H, H-e), 6.47 (br, 1H, H-c), 7.53 
(br, 1H, H-j) 
 
Mn  (SEC) Mw  (SEC) Ð Yield (wt. %) 
13,452 14,157 1.05 89 
 
6.3.16.2 Acetic anhydride with a catalyst 
In a typical reaction, PHPMA (50 mg) was added to a mixture of CHCl3 (2 mL), acetic 
anhydride (2 mL, 0.018 mmol) and a catalyst: DBU (0.3 µL, 0.002 mmol), Pyridine (0.16 µL, 
0.002 mmol), or DMAP.HCl (0.32 mg, 0.002 mmol). The suspension was stirred for 3 h to 
give a clear pink solution. The solution was dialysed against THF for 24 h, changing the 
dialysate 3 times. After dialysis the solvent was removed under reduced pressure to yield the 
product as a pink solid (47.8 mg, 96 %). 
 
 
1H NMR (400 MHz, CDCl3), δ (ppm):  0.94 (br, 2H, H-b), 1.25 (br, 3H, H-f), 1.70 (br, 3H, H-
a), 2.10 (br, 3H, H-g), 3.11 – 3.46 (br, 2H, H-d), 4.97 (br, 1H, H-e), 6.47 (br, 1H, H-c), 7.53 
(br, 1H, H-j) 
 
Mn  (SEC) Mw  (SEC) Ð Yield (wt. %) 
14,089 15,315 1.09 96 
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6.3.17 Hyperbranched PHPMA-co-PAPMA by RAFT polymerisation (HB-PHPMA-
co-PAPMA) 
 
HPMA (0.179 g, 1.25 mmol), APMA (0.695 g, 3.75 mmol) and the RAFT agent 4-Cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (20.2 mg, 0.05 mmol) were placed 
under an inert N2 atmosphere by x3 vacuum-refill cycles. The solids were then dissolved in 
DMAc (5 mL) to give a pale yellow solution. Separately, EGDMA was freshly filtered through 
a short column of basic alumina before being added to the reaction vessel (0.01 g, 0.01 mL, 
0.05 mmol) and a stock solution of AIBN (17.0 mg, 0.1 mmol in 1 mL DMAc) was made and 
an aliquot (0.1 mL) of this was added to the reaction vessel. The reaction solution was then 
cooled in an ice-water bath before being degassed by bubbling with N2 for 30 min. After 30 
min, the flask was transferred to a pre-heated oil bath (70 °C) and left to react for 16 h. The 
reaction was quenched by exposing the solution to the air and freezing in liquid nitrogen. The 
solution was then dialysed (1 kg mol-1 MWCO) against water for 2 days, and the dialysate 
changed 3 times a day. After dialysis the solution was frozen and lyophilised to yield the final 
product as a pale yellow solid. 
 
1H NMR (400 MHz, DMSO-d6), δ (ppm): 0.72 – 1.81 (br m, 29H, H-a + a’ + b + b’ + f + f’ + 
i + i’ + j + j’ + o), 1.99 (br, 3H, H-h), 2.92 (br, 2H, H-d’), 3.07 (br, 2H, H-d), 3.67 (br, 1H, H-
e), 4.09 – 4.29 (br, 8H, H-l + l’ + k + k’), 4.71 (br, 1H, H-g), 4.81 (br, 1H, H-e’), 5.40 (br, 1H, 
H-m), 5.70 (br, 1H, H-n), 7.18 (br, 1H, H-c), 7.40 (br, 1H, H-c’) 
 
Code Molar Ratio a Mn  (SEC) Mw  (SEC) Ð Yield (wt. %) 
P47 25 : 75 : 1 : 1 : 0.2 121,503 134,507 1.11 33 
P48 25 : 75 : 1 : 2 : 0.2 129,339 167,787 1.30 31 
P49 25 : 75 : 1 : 5 : 0.2 142,001 191,984 1.35 36 
a Molar ratios are HPMA : APMA : RAFT : EGDMA : Initiator 
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6.3.18 Synthesis of PHPMA-star-(HB-PHPMA-co-PAPMA) by RAFT polymerisation 
 
HPMA (0.318 g, 2 mmol) and HB-PHPMA-co-PAPMA macroCTA (0.2 g, 0.0015 mmol) were 
dissolved in DMAc (2 mL) to give a pale yellow solution. Separately a stock solution of AIBN 
(1.2 mg, 0.0073 mmol in 1 mL DMAc) was made and an aliquot (0.1 mL) of this solution was 
added to the reaction vessel. The reaction solution was placed under an inert N2 atmosphere by 
5 x freeze-pump-thaw cycles. The reaction vessel was transferred to a pre-heated oil bath (70 
°C) and left to react for 16 h. The reaction was quenched by exposing the solution to the air 
and freezing in liquid nitrogen before purification by dialysis (1 kg mol-1 MWCO) against 
water for 2 days, the dialysate was changed 3 times a day. After dialysis the solution was frozen 
and lyophilised to yield the final product as a pale white solid. 
 
1H NMR (400 MHz, DMSO-d6), δ (ppm): 0.72 – 1.81 (br m, 29H, H-a + a’ + b + b’ + f + f’ + 
i + i’ + j + j’ + o), 1.97 (br, 3H, H-h), 2.80 – 3.24 (br, 4H, H-d + d’), 3.58 (br, 1H, H-e), 3.80 – 
4.45 (br, 8H, H-l + l’ + k + k’), 4.67 (br, 1H, H-g), 4.83 (br, 1H, H-e’), 5.71 (br, 1H, H-m), 
6.07 (br, 1H, H-n), 7.00 – 8.00 (br, 2H, H-c + c’) 
 
Code Mn (g mol-1) Mw (g mol-1) Ð Yield (wt. %) 
P50 138,659 148,431 1.07 14 
P51 284,151 332,447 1.17 17 
P52 243,295 308,756 1.27 16 
 
 
 
11
O NH
OH
NH
O
O
O O
co
O O
O
x y a
co co
OO
O O
*
∗
b
b
CN
OH
O
SS
O
S
NH
OH
m
n
a
b
d
e
f
g
c
a'
b'
d'
e'f '
h
i
j
k l
o
i'
j'
k' l'
i' j'
m + n
190 
 
6.3.19 Synthesis of thiol terminated PHPMA by aminolysis 
 
PHPMA (0.1 g, 0.698 mmol) was placed under an inert N2 atmosphere by x3 vacuum-refill 
cycles before being dissolved in DMF (1 mL) and then degassed with N2 for 30 min. After 
purging, n-butylamine (100 μl, 0.074 g, 1.01 mmol) and tris(2-carboxyethyl)phosphine 
hydrochloride (0.2704 g, 1.08 mmol) were added. The mixture was then stirred for 1 hour at 
room temperature. The product was isolated by dialysis (1 kg mol-1 MWCO) against water 
followed by lyophilisation to yield a white solid (0.0849 g, 78%). 
 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 0.82 (br, 2H, H-b), 1.04 (br, 3H, H-f), 1.56 (br, 3H, 
H-a), 2.91 (br, 2H, H-d), 3.66 (br, 1H, H-e), 4.70 (br, 1H, H-g), 7.16 (br, 1H, H-c) 
 
Mn  (SEC) Mw  (SEC) Ð Yield (wt. %) 
12,538 13,177 1.05 89 
 
 
6.3.20 Synthesis of PHPMA-b-PCL-b-PHPMA 
 
6.3.20.1 From macro-CTA 29a 
In a typical reaction, PCL-RAFT (29a) (0.075 g, 0.025 mmol) and HPMA (0.8508 g, 5.94 
mmol) were placed under an inert N2 atmosphere by x3 vacuum-refill cycles. The solids were 
then dissolved in the solvent system (5 ml). Separately a stock solution of AIBN (12.2 mg, 
0.074 mmol in 1 mL DMF) was made and an aliquot (0.1 mL) of this solution was added to 
the reaction vessel. The reaction solution was then cooled in an ice-water bath before being 
degassed by bubbling with N2 for 30 min. After 30 min, the flask was transferred to a pre-
heated oil bath (70 °C) and left to react for 16 h. The reaction was then quenched by exposing 
the solution to the air and freezing in liquid nitrogen. The solution was then transferred to a 
piece of dialysis tubing (6-8 kg mol-1 MWCO) and dialysed against water for 2 days, changing 
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the water 3 times a day. After dialysing the solution was frozen and lyophilised to yield the 
final product as a white solid.  
 
FTIR: ṽ (cm-1) (neat): 3349 (H-bonded –OH), 2970 (sp3 C-H), 1728 (ester C=O), 1634 (amide 
C=O) 
1H NMR (500 MHz, d-DMSO), δ (ppm): 0.81 (br, 2H, H-b), 1.02 (br, 3H, H-f), 1.31 (m, 2H, 
H-m), 1.54 (m, 4H, H-l + n), 1.66 (br, 3H, H-a), 2.27 (t, 2H, J = 7.2, H-k), 2.91 (br, 2H, H-d), 
3.68 (br, 1H, H-e), 3.98 (t, 2H, J = 6.5, H-o), 4.11 (t, 2H, J = 4.1, H-p), 7.17 (br, 1H, H-c), 7.46 
(t, 2H, J = 7.2, H-i), 7.60 (t, 1H, J = 8.3,H-j), 7.80 (d, 2H, J = 7.3, H-h) 
 
Code Solvent Acid b Temp. (°C) 
Time 
(h) Mn (SEC) Mw Ð 
Yield 
(wt. %) 
P5 DMF-Dioxane (1.5 : 2.5) - 70 16 43,792 91,526 2.09 28 
P6 DMF-Dioxane (1.5 : 2.5) - 70 16 29,962 62,885 2.10 27 
P7 DMF-Dioxane (1.5 : 2.5) - 70 16 31,266 68,601 2.19 27 
P8 DMF-Dioxane (1.5 : 2.5) 0.1M 70 16 39,827 72,550 1.82 24 
P9 NMP-Dioxane (1.5 : 2.5) - 70 16 35,298 65,217 1.85 25 
P10 MeOH-Dioxane (1.5 : 2.5) - 70 16 13,831 73,085 5.28 21 
P11 Acetone-MeOH (2 : 3) - 58 16 29,432 41,544 1.41 27 
P12 Acetone-MeOH (2 : 3) - 58 24 35,473 65,478 1.85 26 
P13 DMF-Dioxane (1.5 : 2.5) - 58 16 18,281 32,479 1.78 19 
P14 IPA-MEK (2 : 1) - 70 16 30,774 69,343 2.25 28 
P15 IPA-MEK (1 : 2) - 70 16 75,584 188,060 2.49 33 
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6.3.20.2 From macro-CTA 29b 
 
In a typical reaction, PCL-sRAFT (29b) (0.0753 g, 0.025 mmol) and HPMA (1.0034 g, 7.01 
mmol) were placed under an inert N2 atmosphere by x3 vacuum-refill cycles. The solids were 
then dissolved in DMF-dioxane (5 mL, 1.5:2.5 ratio). Separately a stock solution of ACVA 
(0.0245 g, 0.087 mmol in 1 mL DMF) was made and an aliquot (0.1 mL) of this solution was 
added to the reaction vessel. pTSA (11.5 μl, 14.3 mg, 0.075 mmol) was added at this stage if 
used in the reaction. The reaction solution was then cooled in an ice-water bath before being 
degassed by bubbling with N2 for 30 min. After 30 min, the flask was transferred to a pre-
heated oil bath (70 °C) and left to react for 16 h. The reaction was then quenched by exposing 
the solution to the air and freezing in liquid nitrogen. The solution was then transferred to a 
piece of dialysis tubing (6-8 kg mol-1 MWCO) and dialysed against water for 2 days, changing 
the water 3 times a day. After dialysing the solution was frozen and lyophilised to yield the 
final product as a white solid.  
 
FTIR: ṽ (cm-1) (neat): 3342 (H-bonded –OH), 2972 (sp3 C-H), 2933, 1733 (ester C=O), 1634 
(amide C=O) 
1H NMR (500 MHz, d-DMSO), δ (ppm): 0.81 (br, 2H, H-b), 1.02 (br, 3H, H-f), 1.31 (m, 2H, 
H-m), 1.54 (m, 4H, H-l + n), 1.66 (br, 3H, H-a), 2.27 (t, 2H, J = 7.2,H-k), 2.91 (br, 2H, H-d), 
3.68 (br, 1H, H-e), 3.98 (t, 2H, J = 6.5, H-o), 4.11 (t, 2H, J = 4.1, H-p), 7.17 (br, 1H, H-c) 
 
Code Solvent Acid b Temp. (°C) 
Time 
(h) Mn  (SEC) Mw Ð 
Yield 
(wt. %) 
P16 DMF-Dioxane (1.5 : 2.5) 1.2 eq. 70 16 7,895 18,234 2.31 13 
P17 Acetone-MeOH (2 : 3) 1.2 eq. 58 16 23,024 35,538 1.54 25 
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6.3.21 Production of PCL nanoparticles via nanoprecipitation 
 
In a typical procedure, ε-polycaprolactone (50 mg, 0.017 mmol) (or a modified PCL) was 
dissolved in acetone (50 mL, filtered through 0.45 µm) to give a stock solution (1 mg mL-1). 
Separately, the aqueous phase (H2O or buffered solution, 5 mL, filtered through 0.45µm) was 
added to a scintilation vial and set to stir at 600 rpm. The PCL stock solution (1 mL) was added 
to the aqueous phase via syringe needle (21G, 0.8192 mm outer diameter) and allowed to stir 
for 1 min before measurements were taken. All measurements were repeated in triplicate for 
each variable and each experiment repeated in triplicate for a total of 9 replicates per data point. 
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8 Appendix 
8.1 HPMA 13C NMR 
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8.2 PHPMA-b-PCL-b-PHPMA 1H NMR 
8.3 GC-MS of (1/2)-tert-Butyl-methanoate-1,3-cyclopentadiene 39 
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8.4 1H NMR of (1/2)-tert-Butyl-methanoate-1,3-cyclopentadiene after deprotection 
with TFA 
 
8.5 1H NMR of homotelechelic alkyne terminated PCL 42 
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8.6 Calibration curve for the determination of RAFT end groups in hb-(PHPMA-
co-PAPMA) 
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8.7 SEC RI Trace of P17 
 
 
 
8.8 Dynamic Light Scattering Data 
8.8.1 Analysis of P11 
Run Z-Ave (d.nm) PdI 
Pk 1 Mean 
Int (d.nm) 
Pk 2 Mean 
Int (d.nm) 
Pk 3 Mean 
Int (d.nm) 
Pk 1 
Area Int 
(%) 
Pk 2 
Area Int 
(%) 
Peak 3 Area 
Intensity (%) 
Mean Count 
Rate (kcps) 
1 202 1 779.9 87.66 19.12 75.3 15 7.7 376.3 
2 147.3 0.244 177.2 4636 25.73 97.2 2.7 0.1 189.4 
3 271.6 0.595 876.9 122.3 28.88 50.6 39.9 8 88.5 
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8.8.2 Effect of Initial Polymer Concentration 
Day 1    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) 
Pk 2 Mean Int 
(d.nm) 
Pk 3 Mean Int 
(d.nm) 
1 167.4 0.100 188.3 0 0 
1 139.8 0.095 155.2 0 0 
1 138.6 0.213 129.8 0 0 
5 186.5 0.054 200 0 0 
5 206.1 0.065 222.2 0 0 
5 235.7 0.263 249.5 0 0 
10 210.3 0.111 237.8 0 0 
10 225.6 0.056 244.3 0 0 
10 203.6 0.043 215.8 0 0 
25 452.5 0.351 494 4210 0 
25 354.3 0.301 468.4 5038 0 
25 391.2 0.386 339.1 1436 4985 
50 510.7 0.586 599.5 216.7 5390 
50 370.1 0.355 361.8 3746 0 
50 427.5 0.369 426.7 4781 0 
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Day 2    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 109.8 0.07 119.3 0 0 
1 91.75 0.114 104.7 0 0 
1 100.1 0.114 114.7 0 0 
5 180.3 0.065 193.4 0 0 
5 202.7 0.048 215.7 0 0 
5 199.8 0.069 215.1 0 0 
10 253.8 0.197 266.9 4789 0 
10 252.5 0.114 276.5 0 0 
10 221.4 0.002 229.4 0 0 
25 417.9 0.332 411.6 4561 0 
25 346.2 0.238 338.8 5278 0 
25 346.7 0.213 378.2 5341 0 
50 491.6 0.441 304.8 0 0 
50 614.3 0.538 299.8 0 0 
50 415.1 0.466 303.9 0 0 
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Day 3    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 131.5 0.066 142.2 0 0 
1 115.6 0.053 123.5 0 0 
1 131.5 0.088 145.4 0 0 
5 197.1 0.056 211.1 0 0 
5 194.5 0.107 218.5 0 0 
5 171.9 0.021 180.4 0 0 
10 227.4 0.106 251.8 0 0 
10 210.9 0.055 225.7 0 0 
10 205.7 0.086 224.8 0 0 
25 282.7 0.167 344.7 0 0 
25 286.9 0.185 361.9 0 0 
25 310.9 0.104 342.7 0 0 
50 386.9 0.395 329.6 1292 5017 
50 585.6 0.644 440.1 5376 0 
50 520.1 0.454 336.5 0 0 
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8.8.3 Effect of Total Water Volume 
Day 1    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 236.9 0.057 252.7 0 0 
1 217.1 0.075 231.6 0 0 
1 233.7 0.041 239 0 0 
1 177.4 0.085 192 0 0 
1 163 0.006 169.3 0 0 
1 168.6 0.002 175.1 0 0 
1 128.6 0.052 137.6 0 0 
1 117.8 0.086 128.8 0 0 
1 105.4 0.083 114.2 0 0 
1 125.1 0.022 131.4 0 0 
1 118.7 0.081 128.8 0 0 
1 107.2 0.092 119.6 0 0 
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Day 2    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 225.6 0.004 233.5 0 0 
1 230.6 0.009 238.4 0 0 
1 224.4 0.016 230.9 0 0 
1 168.3 0.025 176.5 0 0 
1 160.7 0.087 174.9 0 0 
1 163.8 0.002 170.2 0 0 
1 119.7 0.086 129.3 0 0 
1 122.1 0.194 120.5 0 0 
1 119.3 0.049 127.7 0 0 
1 104.9 0.083 115.4 0 0 
1 108.3 0.06 117.4 0 0 
1 112.3 0.111 127.2 0 0 
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Day 3    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 221 0.019 227.8 0 0 
1 233.9 0.013 244.7 0 0 
1 244.1 0.009 254.2 0 0 
1 144.7 0.026 152.1 0 0 
1 156.1 0.017 163.8 0 0 
1 149.4 0.058 160.2 0 0 
1 124.1 0.062 133.1 0 0 
1 117.2 0.045 124.6 0 0 
1 113.2 0.074 122.7 0 0 
1 95.65 0.078 104.9 0 0 
1 93.66 0.081 102.6 0 0 
1 93.58 0.113 106.4 0 0 
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8.8.4 Effect of Water : Acetone Ratio 
Day 1    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 258.7 0.089 261.6 0 0 
1 278.8 0.037 285.2 0 0 
1 263.4 0.063 276.7 0 0 
1 147.5 0.057 156.6 0 0 
1 181.3 0.006 187.6 0 0 
1 212.1 0.079 233.3 0 0 
1 131.4 0.024 138 0 0 
1 124.2 0.056 132.9 0 0 
1 119.5 0.066 129.3 0 0 
1 110.9 0.097 123.7 0 0 
1 105.8 0.089 116.7 0 0 
1 113.6 0.094 126.1 0 0 
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Day 2    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 306 0.03 313.6 0 0 
1 280 0.003 290.3 0 0 
1 272 0.029 278.8 0 0 
1 185.2 0.027 190.5 0 0 
1 169.8 0.018 177.8 0 0 
1 168.1 0.036 172 0 0 
1 124 0.042 131.5 0 0 
1 110.4 0.058 117.6 0 0 
1 116.6 0.076 126.5 0 0 
1 100.7 0.085 110.5 0 0 
1 97.07 0.064 104.6 0 0 
1 87.37 0.092 96.24 0 0 
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Day 3    
PCL conc (mg ml-1) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 309.9 0.057 315.7 0 0 
1 299.9 0.026 308.4 0 0 
1 430.6 0.046 442 0 0 
1 169.8 0.043 173.8 0 0 
1 193 0.104 218 0 0 
1 174 0.027 178.6 0 0 
1 124.2 0.076 135.1 0 0 
1 120.1 0.08 131 0 0 
1 108.3 0.052 115.2 0 0 
1 99.83 0.09 110 0 0 
1 109.9 0.097 122.8 0 0 
1 107.1 0.075 115.8 0 0 
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8.8.5 Effect of pH on PCL-OH 
Day 1     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 502.5 0.036 525.1 0 0 
1 7.4 478.6 0.019 497.5 0 0 
1 7.4 871.1 0.065 957.9 0 0 
1 8 123.6 0.036 130.5 0 0 
1 8 124.8 0.042 132.2 0 0 
1 8 124 0.073 134.1 0 0 
1 9 113.9 0.068 122.9 0 0 
1 9 106.4 0.08 115.5 0 0 
1 9 116.5 0.071 125.7 0 0 
1 10 134.9 0.044 142.6 0 0 
1 10 119.1 0.041 126.2 0 0 
1 10 124.4 0.064 132.6 0 0 
1 11 132.2 0.136 139.8 0 0 
1 11 152.1 0.062 163.7 0 0 
1 11 151.9 0.026 159.3 0 0 
1 12 208 0.022 217.8 0 0 
1 12 206.2 0.102 196.5 0 0 
1 12 157.8 0.078 171.9 0 0 
1 13 319.3 0.073 346.2 0 0 
1 13 279.5 0.015 292 0 0 
1 13 281.2 0.019 289.5 0 0 
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Day 2     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 944.4 0.146 1133 0 0 
1 7.4 550.4 0.045 561.6 0 0 
1 7.4 563.1 0.018 580.1 0 0 
1 8 126.8 0.051 135 0 0 
1 8 127.4 0.051 134.6 0 0 
1 8 132.3 0.038 139.8 0 0 
1 9 112.2 0.112 120.4 0 0 
1 9 113 0.063 121.8 0 0 
1 9 102.3 0.067 109.8 0 0 
1 10 130.1 0.024 136.2 0 0 
1 10 140.1 0.054 148.6 0 0 
1 10 182.2 0.197 231.6 0 0 
1 11 120.6 0.138 125.9 0 0 
1 11 138.9 0.085 152 0 0 
1 11 144 0.037 151.9 0 0 
1 12 176.8 0.021 185.1 0 0 
1 12 174.4 0.186 179.1 0 0 
1 12 207.2 0.04 219 0 0 
1 13 279.7 0.046 296.5 0 0 
1 13 240.7 0.015 248.4 0 0 
1 13 238.7 0.017 246.6 0 0 
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Day 3     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 511.2 0.111 543.9 0 0 
1 7.4 534.7 0.043 565.5 0 0 
1 7.4 593.9 0.15 593.1 0 0 
1 8 111 0.081 120.6 0 0 
1 8 110.9 0.036 117.1 0 0 
1 8 117.9 0.08 128.8 0 0 
1 9 137.1 0.245 163.8 4539 0 
1 9 108.3 0.063 116.3 0 0 
1 9 109.9 0.062 118.9 0 0 
1 10 125.7 0.064 135.1 0 0 
1 10 116.3 0.29 101.3 0 0 
1 10 122.8 0.068 131.1 0 0 
1 11 155.4 0.014 160.6 0 0 
1 11 150.5 0.061 162 0 0 
1 11 159.8 0.023 167.4 0 0 
1 12 168.2 0.043 177.5 0 0 
1 12 185.8 0.048 197.3 0 0 
1 12 181 0.051 190.6 0 0 
1 13 259.7 0.052 276.2 0 0 
1 13 283.7 0.501 185.8 0 0 
1 13 279.6 0.177 275.1 0 0 
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8.8.6 Effect of pH on PCL-MA 
Day 1     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 51.88 0.218 54.96 5217 0 
1 7.4 58.74 0.262 39.95 0 0 
1 7.4 57.66 0.258 68.7 4967 0 
1 8 37.87 0.261 40.95 4933 0 
1 8 40.3 0.321 38.8 234 5265 
1 8 40.83 0.311 40.5 5174 443.8 
1 9 182.6 0.344 18.55 86.69 0 
1 9 102.3 0.308 21.73 110.1 0 
1 9 68.38 0.22 24.14 129.2 0 
1 10 298 0.352 23.74 131.9 0 
1 10 100.9 0.369 19.97 77.71 0 
1 10 81.75 0.364 22.85 115.8 0 
1 11 129.8 0.387 18.43 47.5 0 
1 11 153.4 0.45 21.51 52.34 0 
1 11 126 0.461 19.53 61.59 0 
1 12 120.7 0.361 19.17 48.39 0 
1 12 149.3 0.44 18.35 39.28 0 
1 12 88.08 0.221 24.58 145.5 0 
1 13 65.41 0.242 48.71 0 0 
1 13 1114 1 66.56 0 0 
1 13 65.2 0.329 46.43 121.4 0 
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Day 2      
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 55.46 0.287 59.86 5171 0 
1 7.4 62.98 0.305 60.68 5560 0 
1 7.4 55.23 0.267 56.91 4697 0 
1 8 41.18 0.345 42.41 199 5095 
1 8 75.37 0.282 34.82 88.17 0 
1 8 48.85 0.359 53.18 5324 0 
1 9 138.6 0.428 19.68 151.2 0 
1 9 151.9 0.549 19.18 52.19 0 
1 9 55.2 0.308 26.68 106.8 0 
1 10 57.56 0.323 27.54 120.9 0 
1 10 108 0.401 19.28 43.85 0 
1 10 113.3 0.601 22.51 124.4 0 
1 11 953.1 1 20.56 0 0 
1 11 318 0.367 23.11   0 
1 11 71.81 0.276 24.99 134.3 0 
1 12 68.45 0.31 31.87 110.6 0 
1 12 65.86 0.299 28.78 120.4 0 
1 12 102.5 0.304 25.33   0 
1 13 55.53 0.263 50.73 0 0 
1 13 58.17 0.3 44.09 222.9 5512 
1 13 67.08 0.359 46.5 169.4 5409 
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Day 3     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 58.63 0.331 76.46 5012 0 
1 7.4 84.2 0.424 45.04 135.3 0 
1 7.4 62.04 0.376 76.37 5209 0 
1 8 39.72 0.35 41.87 5126 262.3 
1 8 40.09 0.235 30.17 131 5560 
1 8 66.27 0.302 34.89 112.2 0 
1 9 64.5 0.207 23.55 89.23 0 
1 9 110.2 0.411 20.74 51.88 0 
1 9 44.5 0.263 26.6 124.4 5560 
1 10 67.3 0.257 26.12 98.25 0 
1 10 166.9 0.595 22.55 127.6 0 
1 10 70.48 0.322 26.43 81.93 0 
1 11 142.2 0.399 17.16   0 
1 11 85.44 0.215 26.06 74.45 0 
1 11 99.68 0.292 20.72   0 
1 12 61.07 0.28 22.2 91.68 0 
1 12 36.25 0.38 30.1 219 5144 
1 12 124.1 0.421 35.94   5255 
1 13 48.32 0.301 53.16 5369 0 
1 13 60.83 0.308 54.85 5560 0 
1 13 56.6 0.322 48.85 5506 0 
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8.8.7 Effect of pH on PCL-oTHPA 
Day 1     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 74.46 0.280 31.05 76.16 0 
1 7.4 53.81 0.34 34.51 110.4 5372 
1 7.4 71.31 0.311 41.26 226.9 0 
1 8 66.95 0.342 34.32 111.8 5560 
1 8 264.7 0.494 14.11 56.97 0 
1 8 51.11 0.254 19.46 115.8 5.475 
1 9 102.1 0.234 15.44 105 0 
1 9 114.8 0.223 12.89 112.3 0 
1 9 290.7 0.532 12.35 115.7 0 
1 10 81.3 0.356 16.4 130.9 0 
1 10 189.8 0.432 14.62 85.93 0 
1 10 88.46 0.41 16.6 141 0 
1 11 116.7 0.264 15.07 112.7 0 
1 11 124.4 0.289 19.24 117.3 0 
1 11 52.33 0.274 18.16 153.8 0 
1 12 195.4 0.367 17.85 113.9 0 
1 12 118.7 0.24 20.97 122.1 0 
1 12 165.7 0.32 20.23 125.5 0 
1 13 62.05 0.34 41.41 0 0 
1 13 53.57 0.39 91.16 4745 0 
1 13 60 0.195 59.36 0 0 
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Day 2     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 49.82 0.194 40.61 197.8 0 
1 7.4 67.94 0.216 39.32 0 0 
1 7.4 49.69 0.23 46.23 0 0 
1 8 58.49 0.192 17.7 99.31 0 
1 8 82.1 0.338 17.89 89.52 0 
1 8 190.4 0.364 15.19 85.31 0 
1 9 157 0.3 16.93 112 0 
1 9 117.1 0.468 15.21 109.2 0 
1 9 168.2 0.374 13.27 89.21 0 
1 10 209.1 0.258 16.63 110.1 0 
1 10 267.7 0.401 12.28 82.22 0 
1 10 224.9 0.834 43.47 134.8 12.14 
1 11 242.4 0.446 15.41 107.9 0 
1 11 700.3 0.759 11.98 80.86 0 
1 11 163.4 0.309 14.6 105 0 
1 12 249.5 0.638 17.69 119.3 0 
1 12 171.7 0.325 21.02 128.7 0 
1 12 278.1 0.721 13.64 90.69 0 
1 13 49.78 0.439 68.38 5207 0 
1 13 44.35 0.32 43.44 5070 0 
1 13 168.7 0.49 36.94 11.82 0 
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Day 3     
PCL conc (mg ml-1) pH Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm) Pk 3 Mean Int (d.nm) 
1 7.4 97.01 0.236 50.69 0 0 
1 7.4 95.88 0.591 106.6 2547 0 
1 7.4 62.72 0.27 9.821 49.16 0 
1 8 68.81 0.304 20.31 89.57 0 
1 8 59.28 0.533 27.09 125.8 5394 
1 8 65.41 0.336 67.41 5560 0 
1 9 439.5 0.636 9.66 58.56 0 
1 9 100.2 0.335 14.28 91.81 0 
1 9 100 0.375 15.12 131.3 0 
1 10 180.8 0.5 15.49 90.58 0 
1 10 147.9 0.334 15.29 100.1 0 
1 10 146.2 0.288 16.26 78.8 0 
1 11 199.4 0.663 15.51 88.98 0 
1 11 347.9 0.629 13.95 66.31 0 
1 11 133.7 0.263 19.74 117.4 0 
1 12 216.4 0.401 21.72 126.2 0 
1 12 142.4 0.338 21.01 124.9 0 
1 12 149.2 0.515 18.64 89.13 0 
1 13 60.72 0.318 65.97 31.84 0 
1 13 43 0.282 48.94 4837 0 
1 13 45.53 0.304 54.15 4991 0 
 
 
